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General illtroducl ion 
Introduction 
Atopic dennatitis (AD) is a conUllon chronically relapsing skin disorder affecting 9-20% of 
those born after 1970 [Schultz Larsen 1993]. TI,e aetiology is still not entirely elucidated and 
research is complicated by the multifactorial nature of the disease. Both genetical and 
environmental factors are involved in the pathogenesis of AD. The prevalence of atopic 
dennatitis seems to have increased along with astluna and allergic rhinitis during the past three 
decades [Williams 1992, Schultz Larsen 1996]. Several studies from different countries 
reported a two- to three-fold increase of the prevalence of AD over the past three decades. 
However, the reasons for this evolution of atopic diseases still remain to be elucidated. 
Furthennore, large, unexplained variations in prevalence have been reported between countries 
and within countries [ISAAC 1998], suggesting a critical role for environmental thctors in 
disease expression. Although some risk factors such as gender, parental smoking, and early 
exposure to allergens Olouse dust mite, pets, cow's milk and solid food) have becn identified, 
the role of other risk factors like socio-economic status, outdoor and indoor pollution and 
infections in early life are still a matter of discussion. 
Studies on the genetical and immunological background have provided new insights into the 
mechanisms involved in atopic diseases. However, therapeutical practice has not yet changed. 
Recently guidelines based on consensus have been established for the management of AD [Me 
Henry 1995]. Emphasis is put on educating and infonning the patients. Although these and 
other guidelines provide a good franlework for managing AD, the unpredictable course of the 
disease with exacerbations and remissions may fiustrate both patients and physicians [przybilla 
1994]. 
Patients with AD account for about 30% of demlatological consultations in general practice, 
and dennatological consultations account for about 20% of all consultations in general practice 
[Rook 1986]. However, little attention has been paid to AD in tenns of research. A Medline 
literature search (title, abstract, and subject heading) from 1996 to May 1999 showed 8,986 
publications related to astlUlla, but only 942 related to AD. This is surprising when the impact 
of the two diseases is compared. In tenns of prevalence, AD is more conunon than asthma in 
Y01Ulg children [Peat 1994, Burr 1989]; in tenns of economic resources, the direct fimUlcial cost 
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in the care of a child with moderate to severe AD is substantially higher than for the average 
child with asthma [Su 1997]; and in tenns of family impact - taking into account fmaneial 
burden, familial/social impact, personal strain and mastery - even in mild AD, the impact on 
fanlilies was found to be equivalent to that for children with insulin dependent diabetes mellitus 
[Su 1997]. Consequently AD should not be perceived as a minor skin disorder, but it should be 
recognised as a disease with considerable social, personal and fInancial burden. 
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His body is said to have been marred 
by .... a nllmber of hard, dly palches 
suggesling ringworm, caused by an 
itching of his skill and a 100 vigorous 
lise oflhe scraper allhe balhs ... in early 
spring a lighllless of Ihe diaphragm; 
and when the scirocco blew, catarrh. 
(SlIelonills A.D. 69-/40 on Ihe roman 
emperor Allgllsills Caesm~ [Mier 1975J 
To our knowledge this is the first description of atopic dermatitis. Mier [1975] concludes that 
the combination of lichenified itching skin lesions, seasonal dyspnoea and rhinitis clearly 
indicates atopic diseases and must be the earliest recorded description of the atopic 
syndrome. Except for anecdotal evidence, we know nothing about the incidence of AD in the 
remote past. Ferdinand von Hebra gave the first detailed description of AD in 1884. He 
described an itchy papular eruption that began in early childhood, located in the flexures and 
persisted throughout life with interspersed exacerbations and remissions. Sulzberger and 
Wise first proposed the term atopic dennatitis in 1933 [Wise 1933]. A prerequisite was the 
work of Coca and Cooke who introduced the tenn atopy in 1923 [Coca 1923]. Atopy is 
derived from the Greek words a (no) tapas (place). Initially atopy was meant to described the 
inherited tendency to develop immediate-type hypersensitivity reactions to connnon antigens. 
Atopy was found to be associated with an increased ability to form "reagins" (lgE 
antibodies). In the course of time many names have been given to the itching disease we now 
know as atopic dennatitis (Table I) and other definitions of atopy followed. Another 
important term, allergy, was introduced by Clemens von Pirquet in 1906 as a deviation from 
the expected immunological reaction. Today, allergy is often used synonymously with 
hypersensitivity and atopy. Initially, von Pirquet meant to describe a condition of changed 
reactivity, irrespective of whether it was hamlful (hypersensitivity) or protective (immunity). 
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In 1980, Hanifin and Raijka established the classical diagnostic criteria which enabled the 
comparison of studies on AD. In contrast, the terms allergy and atopy were defined and 
redefined several times, resulting in a Babylonian confusion of languages that still persists. 
Table 1. Nomenclature of atopic dermatitis 
Synonym Author 
Mycoses flexurarum Hans von Hebra 
Pnuigo Ferdinand von 
Hebra 
Prurigo diathesique Ernest Besnier 
Dennatitis lichenoides Albert Neisser 
pruriens 
Prurigo Besnier Carl Rasch 
Le prurigo de Besnier H.R. Haxthausen 
Konstitutionelles ekzern A.G. Kochs 
Neurodennatitis v.w. Schnyder 
constitutionalis 
Le prurigo-astbme Raymond Sabouraud 
Spatexsudatives Eczematoid Geory A. Rost 
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Clinical mallifestations 
Atopic dennatitis (AD) starts in infancy in 60% of the patients and before the age of 5 years in 
90% of the children [Su et al 1997]. The course of the disease is chronically relapsing with 
unpredictable exacerbations [Przybilla et aIl994]. AD is characterised by a large number of 
clinical features. None of these feahlres is pathognomic for the disease. Therefore, a 
combination of different symptoms is necessary for the diagnosis of AD. In 1980, Hanifin and 
Raijka established major and minor criteria for the diagnosis of AD (Table 2). These criteria are 
regarded as classical and have been used in nearly all the clinical trials on AD. However, 
sensitivity and specificity of the criteria and of their combination were not satisfactorily 
investigated. Some of the criteria turned out to have very low specificity. Therefore, the value 
of these criteria has been questioned and new, more practical ones have been developed. 
Sanlpson [Sampson 1990] compiled criteria for children younger than 2 years, whereas the 
criteria by Willianls et al [Williams et al 1994] are used for individuals older than 2 years 
(Table 3 A&B). The criteria by Williams et al are similar in sensitivity to those by Hanifin and 
Raijka, but have a higher specificity. The diagnosis of AD is thus based on clinical criteria 
while the new knowledge on the pathophysiology has not been considered. Recently, there is 
discussion on including a parameter of atopy into the diagnostic criteria. Bos et al suggested 
that the presence of specific IgE should be a mandatory criterion for the diagnosis of AD (Table 
4). Indeed about 80% of the patients with AD have increased levels of total or specific 19E. As 
a consequence, the remaining group of patients with nonnallevels oflgE needs to be addressed 
separately. Bos et al [1998] suggested to use the teml atopic demlatitis when specific IgE is 
detectable and to use the ternl intrinsic atopic dennatitis or constitutional eczema for those with 
nomlal IgE. However, the classification of AD into atopic and non-atopic remains 
controversial, as there is no difference between those groups in tenns of clinical symptoms or 
treatment. 
The morphological lesions in AD Cover a wide spectmm and change continually over time 
(Table 5). Usually, tile lesions are symmetrical and not sharply demarcated. A selection ofthese 
cutaneous manifestations is used to score the intensity of AD. 
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Assessing the severity of AD should be considered as separate from establishing the diagnosis. 
Skin diseases offer the opportunity to score the severity of disease just by observation. 
However, standardisation and validation of the scoring system and training of the observer are 
necessary for this purpose. Such a scoring system for the severity of AD is crucial for 
investigating the efficacy of therapy. For clinical trials the SCORAD index has been 
established [European Task Force on AD 1993, Kunz et al 1997, OraJue et aI1997]. It is the 
only system based on aJl international consensus and validation. Like most of the other scoring 
systems, the SCORAD index is rather time-consuming and therefore not suited for daily 
practice. However, in a fluctuating disease such as AD, daily practice may be improved by 
using a more objective way of recording disease than by stating in the dossier "the eczema is 
better or worse". For daily routine the Three Item Severity (TIS) score has been developed 
[Wolkerstorfer et al 1999]. 
In conclusion, the skin lesions of AD allow both diagnosis and scoring of the severity of the 
disease which is important not only in basic research, but also in clinical practice. 
The course of the disease is unpredictable with exacerbations and remissions. AD often starts 
during the first six months of life on the exposed areas of the body, whereas the diaper area is 
typically spared. 111e lesions become more distally located in the following years. Typical 
flexural involvement usually appears after the age of one year and lichenification may appear 
after the age of2 years. 
Complications and related diseases: Patients with AD have increased susceptibility for specific 
bacterial infections (Staphylococcus aureus) aJld specific viral infections (Herpes simplex). 111e 
course of these infections is usually more severe in individuals with AD, as compared to 
individuals without AD. Asthma develops in about 40% of the children with AD, whereas in 
about 30% allergic rhinitis develops [Bergmann 1998]. 
Prognosis: Spontaneous resolution may occur at any age, but carnlot be predicted in individual 
patients. Reliable data on tile evolution of AD from infancy into adulthood are hardly available. 
In a prospective study, resolution of AD was reported to occur in almost 90% of the patients 
during the subsequent 15 years [Vickers 1980]. However, most investigators reported a higher 
percentage of persistence (50 to 60%). In a retrospective study of individuals who were 
diagnosed as having AD at the age of 2 years, 72% still had signs of AD after 20 years 
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[Kissling et al]. Generally AD tends to improve with age. Patients with severe AD seem to 
have less chance to outgrow the disease [Guillet et al 1992]. 
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Table 2. Diagnostic criteria for atopic demlatitis by Hanifin and Raijka 
Major criteria Minor criteria 
Pruritus Xerosis 
Typical morphology and distribution Ichthyosislkeratosis piJaris/palmar hyperlinearity 
Adults:Flexurallichenification and linearity Type I skin test reactivity 
Children: Facial, extensor Elevated serum IgE 
Chronic or relapsing dennatitis Early age of onset 
Personal or family history of atopy Tendency to skin infection (Staph. aureus, 
Herpes simplex) I impaired cell-mediated 
immunity 
Tendency to hand/foot dennatitis 
Nipple eczema 
Cheilitis 
Recurrent conjunctivitis 
Dennie-Morgan fold 
Keratoconus 
Anterior subcapsular cataracts 
Orbital darkening 
Facial pallor/el)1hema 
Pityriasis alba 
Anterior neck folds 
Hch when sweating 
Intolerance to wool and lipid solvents 
Perifollicular accentuation 
Food intolerance 
Course influenced by environmentaVemotioIlal 
Factors 
White dennographism/delayed blanch 
For the diagnosIs of AD;::.: 3 major and;::': 3 mmor cntena are necessary 
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Must have 
Diagnostic criteria for atopic demmtitis 
(>2 years) by Williams et al (I994J 
o An itchy skin condition (or report of scratching or rubbing 
in a child) 
Pills three or more of/hefol/owing 
o History of itchiness in skin creases stich as folds of the 
elbows, behind the knees, fronts of ankles, or around neck 
(or the cheeks in children under 4 years) 
o History of asthma or hay fever ( or history of atopic disease 
in a fIrst degree relative in children under 4 years) 
a General dry skin in the past year 
o Visible flexural eczema (or eczema affecting the cheeks or 
forehead and outer limbs in children under 4 years) 
o Onset in the first two years ofHfe (not always diagnostic in 
children Wlder 4 years) 
Table 38. 
Major features 
Diagnostic criteria for atopic dennatitis 
(<2 years) by Sampson [1990] 
o Family history of atopic dennatitis 
a Evidence of pruritic dennatitis 
o Typical facial or extensor eczematous or lichenificd 
demlatilis 
Minor features 
o Xerosislichthyosislhyperlinear pahns 
o Peri-auricular fissures 
o Chronic scalp scaling . 
o Perifollicular accentuation 
General introduction 
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Table 4. Millennium criteria for the diagnosis of atopic dcnnatitis [Bos 1998] 
Mandatory criterion Principal criteria (2 of3 present) 
0 Presence of allergen~specific IgE 0 Typical distribution and morphology of 
eczema lesions: infant, childhood, or adult type 
0 Historical, actual, or expected (in very young 0 If distribution is not typical, exclude other 
children) entity (dyshidrotic eczema, contact dcnnatitis, 
0 In peripheral blood (RAST, ELISA) or in skin contact urticaria 
( intracutaneous challenge) 0 Pmritus 
0 Chronic or chronically relapsing course 
Table 5. Morphological elements in atopic dcmmtitis 
Acute <-> Subacute <-> Chronic 
0 Erythema 0 Cmsts 0 Dryness I Scaling 
0 Oozing 0 Oedema 0 Hyper-hypopigmentation 
0 Vesicles 0 Papulation 0 Lichenification 
0 Excoriations 0 Fissures 
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Epidemiology 
Atopic demlatitis is a COlJ11non skin disease alIecting 9-20% of those born after 1970 [Schultz 
Larsen 1993]. TIle prevalence in Northern Europe was found to be 16% among 7-year-old 
children born in 1985 in Germany, Swedcn and Denmark [Schultz Larsen 1996]. TIus is 
confirmed by another study reporting a prevalence of20% for children born in the 1980s in the 
U.K. 
A systematic, world-wide comparison of the prevalence of atopic diseases has recently 
become available [Lancet 1998, Williams et al 1999)). The International Study of Asthma 
and AlIergies in Childhood (ISAAC) provided a core questionnaire to assess the prevalence 
of astIuna, allergic rhinitits and AD (Table 6) [ERS 1995). Although there may be some 
objections on diagnosing AD via questionnaire, it docs provide large scale data on the 
prevalence of AD. 
Table 6. ISAAC questionnaire for the diagnosis of AD in children 
The following questions were asked to the parents of6 to 7-year-old children and to 13 to 14-
year-old children: 
I. Have YOli (Has your child) ever had an itchy rash that was coming and going for at least 6 
months? 
2. Have you (Has your child) had this itchy rash at any time in the last 12 months? 
3. Has this itchy rash at any time affected any of the following places: the folds of the 
elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, 
ears, or the eyes? 
If yes to question 3: 
In the last 12 months, how often, on average, have YOll (Has your child) been kept awake 
at night by this itchy rash? (- never in the last 12 months, - less than one night per week, -
I or more nights per week) 
All respondents were asked: 
Have you (Has your child) ever had eczema? 
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Recently, the analysis of the immense database conceming 715,033 children in 56 countries has 
been published. As expected, tltis global survey revealed higher prevalences in Northem 
Europe, Australia, New Zealand and Japan, and lower prevalences in Eastern Europe, China 
and Central Asia. Surprisingly, data from some African countries suggested high prevalences. 
FurthemlOre variations within countries were found. Interestingly, countries with the highest 
prevalence rates were shown to have the highest IgE levels in a recent standardised 
intemational comparison [Bumey 1997]. 
However, it must be added that a questionnaire validated in one country may have different 
sensitivity and specificity in another country. Such as arthropod infections that rarely occur in 
developed cowltries may be confused with AD in developing countries. 
There is general agreement that the prevalence of atopic demmtitis has increased 
dramatically during the past decades [Schutz Larsen 1996] (Table 7). Tltis trend goes along 
with an increase in other atopic disorders, asthma and allergic rhinitis [Sears et al 1997, Burr 
et al 1989, Ninan et al 1992] (Fig I). 
However, comparative epidemiological studies over time may be biased due to the following 
reasons (Williams 1992): 
• different definitions of the disease 
• changes in diagnostic procedures 
• changes in the acceptability of eczema as a diagnosis (in earlier years eczema used to be 
associated with uncleanliness and arthropod infestation) 
• increased awareness of both patients and physicians 
• recall bias 
Further evidence for an increase of the prevalence of atopic diseases comes from studies that 
investigated the change in the expression of biological markers using the same methodology 
over time [Burr et al 1989, Peat et al 1994, Sibbald et al 1990, Barbee et al 1987, Nakagomi 
et al 1994]. 
In two surveys to years apart, Peat et al [1994], reported in cltildren an increase in airway 
hyperresponsiveness of2-fold in Belmont and lA-fold in Wagga Wagga. Burr et al [1998], 
reported that the number of children with an impaired exercise provocation test was higher in 
1988 than in 1973. They concluded that if the response to exercise indicates severity of 
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asthma, both mild and severe asthma had become more common. Sibbald et al [1990], 
investigated skin prick test reactions using the same methodology and allergens in 1974 and 
1988. They reported an increase in the proportion of subjects with at least one positive skin 
prick test reaction from 23% in 1974 to 46% in 1988. Similar results were published for an 
increase of specific 19B levels to common allergens [Nakagomi et al 1994]. 
The conclusion of these studies was that the increase in prevalence may partly be due to 
methodological bias, but also reflected a tme increase of atopic diseases and sensitisation. 
Table 7. Evidence for increasing prevalence of AD 
Country and Age Prevalence 
Time span 
Peat et ai, Australia 8-10 years 22.5%-->31.9% 
1994 1982-->1992 From 2 towns (Wagga Wagga) 
20.3%-)24.4% 
(Belmont) 
Taylor et ai, U.K. 1946--> 5-7 years 5.1%-) 
1984 1958-->1970 7.3%-)12.2% 
Burr et ai, U.K. 12 years 4.8%-) 15.9% 
1989 1973-->1988 
Schultz Larsen et ai, 1964-69--> 7 years 3%-)10% 
1986 1970-74 
Ninan et ai, U.K. 8-13 years 5.3%-)12% 
1992 1964-->1989 
The reasons for the increased prevalence of atopic diseases are still a matter of discussion. 
According to the current understanding the genetic background has not changed. Thus 
environmental factors must be responsible. 
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Alalernai smoking during pregnancy has presumably increased. It was documented that 
smoking among women of childbearing age has increased considerably during the past three 
decades and there is evidence to show an increased risk for asthma and AD when the mother 
smokes during pregnancy [ Romnark et al 1998, Gergen et al 1998, Hu et al 1997]. 
Another theory concentrates on a change in indoor environment. Some of the major allergens 
like house dust mite and pets are found in the houses. Recently, other relevant indoor 
allergens (cockroaches and fungi) have been identified. Because young infants spend most of 
the time indoors, the exposure to these allergens is high. A change in housing conditions 
such as central heating, better isolation, less ventilation, and wall-to-wall carpeting resulted 
in higher concentrations of house dust mite. Peat et al [1994] found that the increase of AD, 
wheeze and airway hyperresponsiveness was paralleled by an increase in house dust mite 
concentrations. In the course of 10 years the concentrations of house dust mite increased 5.5-
fold in Belmont and 4.5-fold in Wagga Wagga [Peat et al 1994]. Similarly, in New Guinea 
the increase of asthma was paralleled by an increase in the concetration of house dust mite 
(Dowse 1985). On the one hand, these studies point to a pathogenic role for house dust mite 
allergens in the increase of asthma. On the other hand, high increases in the prevalence of 
AD and asthma have been observed in regions where the levels of house dust mite are still 
low (e.g. in the northern parts of Sweden). Furthennore, it was observed that in regions with 
very low humidity and low house dust mite concentrations other allergens dominated. Thus, 
it may be that an allergy-prone immune system will anyway get sensitised to any available 
allergen. 
Although there is no definite proof, some authors suggested that a change of nutrition in 
early life may partly be responsible for the increasing prevalence of AD. Foods have been 
implicated in the development of atopic disease through the following mechanisms. I) Early 
introduction of food allergens may be the first trigger in the development of atopy. 2) A 
specific deficiency of polyunsaturated essential fatty acids (PUFAs) has been found in the 
blood of patients with AD. Moreover, the composition of the breast milk with regard to 
essential fatty acids differed between atopic and non-atopic infants. PUFAs may be involved 
in the regulation of the Thl/Th2 balance. It was suggested that an increase in the 
consumption of omega-6 PUF As like linoleic acid (found in margarine and vegetable oils) 
and a decrease in consumption of omega-3 PUFAs like eicosapentaenoic acid (found in fish) 
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is the reason for the increased prevalence, social class differences, and regional differences of 
atopic diseases [Black et al 1997]. The pathogenic background of titis hypothesis is that 
linoleic acid is a precursor of prostaglandin E2 (PGE2) which inhibits the formation of 
interferon ganmla (IFN-y), while eicosapentaenoic acid inhibits the fonnation of PGE2 
[Black 1999]. 3) Food additives in proccssed foods may be one of the unidcntified risk 
factors linked to the modern Western lifestyle. 
Outdoor pol/ution was thought to play a dominant role. Different experimental studies 
demonstrated that pollutants have a promoting effect on sensitisation. However, the 
East/West Gernlan comparison studies by von Mutius et al [1992,1994,1998] have changed 
our view. Surprisingly they noted lower prevalences of astlmm, hay fever, airway-
hyperresponsiveness, and atopic sensitisation (prick test) in the polluted cities of East 
Germany (Leipzig, Halle) as compared with a less polluted West German city (Munich) (von 
Mutius et al 1994, von Mutius et al 1992). The strikingly high frequency of sensitisation to 
house dust mite, cat and pollen in West Germany could explain a large part of the difference 
in astiuna and hay fever between East and West Germany (von Mutius et al 1994). In a 
logistic regression model, \Vest Gennan origin was no longer an independent risk factor 
when sensitisation was taken into account (von Mutius et al 1994). They hypothesised that 
II\Vestem lifestyle" was a major risk filCtor for atopic diseases, whereas outdoor pollution 
was not. Interestingly, in another study, they observed an increase in the prevalence of hay 
fever and atopic sensitisation in East Germany since the reunification. This may be explained 
by the exposure to risk factors associated with the \1\Vestern lifestyle" (von Mutius et al 
1998). 
Still, certain phenomena like the dramatic increase of cedar pollinosis in Japan carmot be 
explained by any of the abovc mentioned factors. \Vltile the exposure to pollen of the 
Japanese cedar tree has remained stable, the sensitisation has increased from 8.7% to 36.7% 
in 1985. The only conclusion from this observation - except methodological bias - is that the 
popUlation has become more susceptible. A hypothesis that may explain this increase in 
susceptibility is based on the balance between Th 1 and Th2 type cytokines. 
The reduced number of illfectiolls ill earll' childhood may have skewed the balance towards 
Th2 type cytokines resulting in an allergy-prone immune system. This hypothesis is 
supported by epidemiological studies that demonstrated that the number of older siblings was 
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negatively correlated to the risk for atopic diseases. Further support comes from the 
observation that certain infections (measles, tuberculosis) seemed to decrease the risk for 
atopic diseases (Shaheen et al 1997, Shirakawa et al 1997). Established atopic disease was 
demonstrated to improve by helminth infections (Turton et al 1976). The increased use of 
antibiotics, vaccinations and the higher socio-economic standard has led to a decline in 
infections which may favour a Th2 type cytokine pattent associated with atopic diseases. 
Despite the existing evidence in favour of this hypothsis, proof has still to be fumished. 
In conclusion, AD is a world-wide problem that is still increasing without any evident 
satisfactory reason reasons for this increase. 
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Risk/aclors - Prevelliioll 
The increase in atopic diseases during the past three decades underlines the import~Ulce of 
environmental factors. Some of these risk factors may be subject of preventive measures. In 
course of time there have been many claims, but few proofs of risk factors for the 
development of AD. Caution with the interpretation is necessary as epidemiological shldies 
can only detect associations, and not causal relations. Associations found in one population 
may not be present in other populations. Only a few risk factors like smoking have bcen 
found consistently in different popUlations, which implies that they must be genuine. 
1. Risk/actors with potential/or primmy prevention 
1.1 Allergells: Early exposure to allergens in predisposed individuals is generally perceived 
as a major contributor in the development of atopic diseases [Hide et a11996]. Conscquently, 
most of the preventive efforts are directed at the reduction of exposure to allergens in early 
life. 
• Food allergens: Food allergy occurs in about 8% of the general population of children 
and in about 20% of the children with AD [Pcarl 1997, Bock 1987]. Food allergy seems 
to be more prevalent in children with scvcre AD [Sampson 1992, Guillet et a11992] than 
in mild AD. Eigenmann et al [1998] reported that 37% of the children with moderate 
severe AD had clinically significant food allergy. The early introduction of cow's milk 
and solid food has bcen implicated in the development of food allergy and subscquent 
atopic disease. Food allcrgens may be one of the initial triggering factors for AD in 
infancy [Sigurs et aI1994]. This is supported by studies in both unselected cohorts and in 
high-risk children that demonstratc the predictive value of sensitisation to food allergens 
for the development of atopic diseases (Zeiger et al 1995, Hattevig et al 1987, Kulig et al 
1998). Zeiger et al found that food allergy by 4 years almost doubled the period 
prevalence between 4 and 7 years of allergic rhinitis and asthma. Food allergy is often 
regarded as the first manifestation of thc atopic syndrome [Kjellman 1998]. Therefore, 
many studies aimcd at reducing the prevalence of atopic diseases through dietary 
measurcs in early life: 
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Different preventive measures have been investigated: 
I} Diet during the last trimester of pregnancy 
2} Diet during lactation 
3} Encouraging breast-feeding or a hypoallergenic fonnula if breast-feeding is not 
possible or both 
4} Delayed introduction of solid food until 5-6 months of age 
5} Avoidance of potent dietary antigens during the first year of life 
Although prenatal sensitisation to foods may occur [Jacobsen et al 1995], a diet during 
pregnancy, can not be advised based on efficacy and possible nutritional hazards to the 
mother [Faith-Magnusson et al 1992, Lilja et al 1988]. A diet during lactation may have 
some effect on AD, but must still be regarded an experimental approach (Zeiger et al 
1995). The possible hazards of dietary exclusion to mothers and infants must be 
prevented by appropriate medical and dietetic support. The other three approaches, 3 to 5, 
are often combined and are, despite a large number of clinical trials, still controversial. 
One of the earliest studies in this field dates back to 1936 and investigated the protective 
influence of breast-feeding [Gruele et al 1936]. In a study of 20,061 infants, a marked 
difference in the prevalence of eczema was found between exclusively breast-fed infants, 
partially breast-fed infants (twice the prevalence compared to exclusively breast-fed 
children) and never breast-fed children (seven times the prevalence). Since then, such a 
such a pronounced protective effect has not been confirmed [Golding 1997]. Fergusson et 
al [1990] studied 1265 infants in a prospective study and demonstrated that the number 
of different foods introduced in the first 4 months of life predicted the development of 
AD. Saarinen et al [1995] reported a long-lasting preventive effect of breast-feeding on 
the manifestation of atopic diseases (AD, aslinna, allergic rhinitis) up to the age of 17 
years. However, their study, such as many others may have been biased by the absence of 
a randomisation. This is relevant, because mothers who tend to give breastfeeding may 
differ in many confounding factors from mothers who do not. 
Zeiger et al [1995] claim to have conducted the study with the largest cohort of high risk 
infants in a randomised, controlled setting to evaluate the effect of combined maternal 
and infant food allergen avoidance. In the prophylactic group, mothers avoided cow's 
milk, egg and peanut during the last trimester of pregnancy and lactation, and infants 
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avoided cow's milk «I year), egg (<2 years) and peanut and fish « 3 years). Results 
were evaluated after a follow-up of I-year [Zeiger et al 1989], 4 years [Zeiger et al 1992] 
and 7 years [Zeiger et al 1995]. They observed a temporary reduction in food allergy and 
sensitisation to cow's milk at the age of 1 year, with a diminution of the benefit by 2 
years and an absence of any benefit at the ages of 4 and 7 years. In a recent review of the 
literature, Golding et al [1997] found little consistent evidence to support a persisting 
protective effect of breast-feeding on atopic diseases. 
Many investigators now think that dietary prevention is temporarily effective with regard 
to food allergy and atopic dermatitis during the first years of life, while there seems to be 
no effect on the prevention of respiratory allergy [Wood et a11996, Hide et a11996]. This 
is in line with the phenomenon that most of the children outgrow food allergy to cow's 
milk and egg by the age of 2 to 4 years. 
However, breast-feeding has such major benefits by preventing infections and promoting 
the mother-child-tie that no further justification is needed to advise breast-feeding. 
• House dust mite: While food allergens playa role in young infants with AD, house dust 
mite allergens may be implicated in older children and adults with AD [Kapp 1995]. 
Atopy patch tests with house dust mite give rise to eczematous lesions in some of the 
patients with AD. It has been documented that house dust mite is an important trigger for 
AD [Cameron 1997], but we do not know whether the exposure to house dust mite 
promotes the development of AD. A double-blind controlled study demonstrated the 
benefit of avoidance measures (mattress covers) on adults with AD [Tan et al 1996]. 
Sporik et al [1990] have shown that the house dust mite concentration at the age of one 
predicts the development of wheezing at the age of II years. We have no information 
whether this is true for AD as well. In the ETAC study, it was shown that carpets in 
bedrooms were associated with a higher risk for sensitisatian to house dust mite. 
Furthermore, the ETAC study demonstrated an increased risk for asthma in children 
sensitised to house dust mite. Indirect evidence in favour of a preventive effect comes 
from combined avoidance protocols for both food and inhalant allergens, which were 
associated with a long-lasting reduction of both sensitisation to foods and prevalence of 
AD [Hide et al 1996, Marini 1996]. Furthennore it was shown that the severity of AD 
increases with the sensitisation to house dust mite [Guillet ae aI1992]. However, to date 
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there is no direct proof that reducing the house dust mite exposure prevents any atopic 
disease. 
• Pets: The increased risk for AD in the families with pets has been documented in several 
studies. Kalyoncu et al [1994] found that thc cumulative prevalences of childhood AD 
was significantly associated with the presence of pets at home. The ETAC study 
demonstrated that a sensitisation to cat allergens at the age of I to 2 years predicted the 
development of asthma in children with AD and a family history of atopy during the 
subsequent 18 months [ETAC 1998]. 
1.2 Indoor environment 
• Passive smoking: There is overwhelming evidence that passive smoking increases the 
risk for all atopic diseases [Kalyoncu et al 1994, Schafer et al 1997, Gergen et al 1998, 
ROIllmk et al 1998, Hu et al 1997]. The relationship is consistent in different studies. 
Smoking during pregnancy, lactation and in infancy has been demonstrated to be 
independent risk factors for the development of AD. Schafer et al [1997] reported that 
the risk for AD in pre-school-age children doubled when the mother smoked during 
pregnancy and/or lactation. Consequently, this should be a focus of preventive measures. 
• Gas cooking: Indoor use of gas without hood has been associated with a higher 
prevalence of AD [Schafer et al 1996]. This is in line with asthma where exposure to gas 
stoves was shown to increase the risk for respiratory symptoms [Garrett et al 1998,] 
Jarvis et al 1996]. 
1.3 Ouldoor environment 
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Although air pollution seems not to have a major role in the development of AD, it may 
aggravate the condition by acting as non-specific irritant and immunomodulator [Schafer 
et al 1997]. From animal and human studies it is known that sensitisation to allergens is 
enhanced by several pollutants, in particular, diesel particles (Suzuki et al 1989), S02 
(Riedel et al 1988), N02, and Ozone (Biagini et al 1986). These studies suggest that air 
pollution may promote the development of atopic diseases. However, in a series of 
studies comparing the prevalence of atopic diseases between East and West Germany, 
von Mutius et al [1992, 1994, 1998] reported a higher prevalence of sensitisation, 
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airway-hyperresponsiveness, asthma, and hay fever in the less polluted cities of West 
Germany. Regarding the prevalence of AD, these studies failed to show a significant 
difference between East and West Germany [von Mutius et al 1992, von Mutius et al 
1998]. 
Schafer et al [1996] specifically addressed the prevalence of AD and compared various 
direct and indirect parameters of air pollution in an East-West German study. The highest 
association with AD was found in the usc of gas stoves without hood and close proximity 
to roads with heavy traffic. Although sensitisation was more prevalent in West Germany, 
AD was more common in East Germany. This is in contrast to the shldies reported by 
von Mutius et al [1992, 1994]. Schafer et al [1996] concluded that AD followed a course 
different from that of respiratory allergy and sensitisation. Furthermore, similar to that in 
other epidemiological studies, they failed to show a direct relationship between any 
measured pollutant (SO" suspended particles, NOx, dust fall) and AD. Thus, outdoor 
pollution as a risk factor is still a controversial issue. \Vhilc experimental studies in 
animals and humans point to a pathogenic role for pollution in the development of atopic 
diseases, epidemiological studies fail to prove that association. 
2. Other risk/actors 
• Positive family history 
Atopy often mns in families suggesting the importance of genetic factors. A positive 
family history for atopy seems to be the single most important predictor of AD [Arshad 
et al 1992, Selcnk et al 1997, Schafer ct al 1997, Berth-lanes et al 1997, Tariq et al 
1998]. 
Dold et al [1992] calculated the relative risk for having a child with AD, allergic rhinitis 
or asthma: 
Relative risk (odds ratio='OR) for having a child with 
AD Asthma Allergic rhinitis 
One parent with AD 3.4 1 1.7 
One parent with allergic 1.4 1 3.6 
rhinitis 
One parent with asthma 1.5 2.6 2.5 
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In a comparable study, Uehara et al [1993] reported the prevalence for having a child 
with AD: 
• Both parents with AD 
• One parent with AD 
81 % prevalence 
56% prevalence 
• One parent with AD + one with respiratory atopy 59% prevalence 
From these studies [Dold et aI1992, Uehara et al 1993] it may be concluded that the risk 
for AD increases with the number of affected first degree family members and that an 
organ-specific transmission occurs. This means that the risk for AD is particularly high if 
one or both of the parents have AD. Furthennore a maternal history of atopy has a higher 
predictive value than a paternal history [Dotterud et al 1995, Ruiz et al 1992]. This seems 
to be explained by influences in utero that may be related to a skewing in the T helper 
cell population of the foetoplacental unit. 
• Socio-economic standard 
AD has been termed a disease of the advantaged. Indeed, AD is more connnon in 
developed countries and to date the prevalence seems to be rising also in the developing 
countries. Furthennore, various studies from developed countries show an increased 
prevalence in higher socio-economic classes [Golding et al 1987]. Strachan et al [1997] 
reported an increased prevalence of positive skin tests in those with a higher socio-
economic status in childhood. In a study of 8,279 British schoolchildren the prevalence 
of AD increased along with socio-economic class [Williams et al 1994]. The highest 
social class had almost twice the prevalence compared with the two lowest social classes. 
Importantly, the diagnosis of AD was not only based on self-reporting but also on 
medical examination, which excludes parental overreporting and better access to health 
services in higher classes as confounding factor. The reasons for this social class trend 
are unknown. Possible explanations are differences in housing conditions (presence of 
carpets, central heating), use of showers or soaps, contacts with pets, higher maternal age 
as well as differences in nutrition. 
• Family size and birth order 
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A higher prevalence of atopic diseases has been described in first-boms and children 
from small families. Olesen et al ]1997] calculated that the adjusted relative risk for a 
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specialist diagnosis of AD was 0.86, 0.69 and 0.26 when the mother had 2, 3 or 4 
children, respectively. In another study, it was demonstrated that the prevalence of 
positive skin test results was independently correlated to a lower number of older 
siblings, but not younger siblings [Strachan et al 1997]. Bodner et al] 1998] reported 
that the risk for AD was inversely correlated to having had three or more older siblings 
(OR~0.3). Assuming that infections in early life are more frequent in children with older 
siblings, these studies support the impact of infections in early life in protecting against 
subsequent atopic diseases. The underlying hypothesis is that infections promote a Thl 
type cytokine pattern that inhibits or prevents allergic reactions. 
• Attendance to day care nursery 
Recently, it was suggested that the attending day care nurseries at an early age may be 
associated with a protective effect on the development of allergy in later childhood 
[Kramer et al 1999]. This finding may also be explained by a protective effect of early 
infections. Kramer et al [1999] reported that the prevalence of a positive skin prick test 
was significantly lower in children who attended the day nurseries at an earlier age. 
Children who attend day care nurseries are known to have a higher risk for infections 
than those who do not. Kramer et al [1999] noted a reduction in the prevalence of atopy 
only in small families (up to 3 people), but not in large families. Tlus may be explained 
because the effect of day nurseries on the frequency of respiratory illness is most 
pronounced if a child has no older siblings [Hurwitz et al 1991] 
• Migration 
Studies in migrant groups have shown large increases in the prevalence of AD compared 
with migrants country of origin, indicating the importance of socio~economic and 
environmental changes such as those associated with industrialisation [Mc Nally et al 
1998]. Williams et al [1995] found that the prevalence of AD, diagnosed by a 
dernlatologist on clinical aspects and criteria, was 16.3% in black Caribbean children and 
8.7% in wlute children. 
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• Gender 
The female to male ratio of AD has recently been reportcd to be 1.3:1 in a global survey 
of 715,033 children. [Williams 1999]. The same preponderance of female gender was 
found in a survey in Northern Europe. However, some studies found a higher risk for AD 
in males (Raijka 1975). In contrast, asthma is consistently more common in boys, which 
is assumed to be due to relatively smaller airways in boys than in girls. 
• High birth weight 
Olesen et al [1997] observed that a birth weight of <: 500g above expected could predict 
AD (relative risk ~ 1.59). However, this finding was not confirmed in other studies .. 
• Gestational age 
A Danish study in 7,862 children showed a statistically significant relationship betwecn 
gestational age and a diagnosis of AD by a dennatologist (adjusted relative risk for 
gestation age <: 41 weeks ~ 1.32) [Olesen et aI1997]. 
• High maternal age 
Olesen et al [1996] observed an increased prevalence of AD when the mothers were 
older and suggested a dysmaturation of the immune system in children of older mothers. 
Tllis risk factor could not be confinned in a second study from the same investigators 
[Olesen et al 1997]. 
The increase of AD in the national British birth cohort (1974-1986) seems to have occurred 
in the context of a general increase in atopic disease and was largely unexplained by changes 
in the distribution of maternal age, birth order, birth weight, infant feeding, maternal 
smoking, active smoking by the child, or father's social class [Lewis et aI1996]. In that study 
the known risk factors did not explain the increase of atopic diseases noticed during the past 
dccades. The challenge for fhture cpidemiological research will be to combine 
epidemiological data from standardised questionnaires with immunological data concerning 
the underlying mechanisms. 
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Pathophysiology 
Atopic diseases have a complex pathophysiology with a variety of both genetic and 
environmental factors being involved. Research on the pathophysiology of atopic dennatitis 
(AD) is complicated due to the many pathogenetic factors involved, the large number of 
described immunological changes and the various manifestations of the atopic syndrome. 
A major concept on the pathophysiology of atopic diseases has evolved from the discovery 
that allergen-specific T cells generally belong to the T-helper type 2 (Th2) subset of 
lymphocytes, producing relatively high levels of IL-4, IL-5 and IL-l3, but relatively low 
levels of interferon-gamma (IFN-y) after stimulation [Wierenga et al 1990, Romagnani 
1994]. Although there has been objections on the strict classification into discrete subsets, 
this model has profoundly stimulated the evolution of important principles in immune 
regulation [Kelso 1995]. One of the results of this concept was the unravelling of the 
mechanism and regulation of IgE synthesis. 
Another important discovery relates to the function of adhesion molecules on leucocytes and 
endothelial cells in allergic inflammation. Skin lesions from patients with AD are 
characterised by an infiltrate of T cells, eosinophils and mast cells. The upregulation of 
endothelial adhesion molecules is crucial for the selective migration of leucocytes from the 
blood into peripheral tissues. In addition to adhesion molecules, chemokines promote the 
accumulation of leucocytes in inflammatory tissues. Chemokines mediate the extravascular 
migration of leucocytes (Rafeul 1997). 
An important component in the pathophysiology of atopic diseases is exposure to allergens 
in predisposed individuals. It is documented that AD may deteriorate or even exacerbate after 
contact with an allergen. This phenomenon is the basis of the atopy patch test, which can be 
used as an experimental model for AD [Langeveld-Wild schut et al 1999]. Furthermore, it is 
documented that exposure to allergens increases the risk of sensitisation, and sensitisation 
increases the risk of atopic diseases. 
The role of micro-organisms in the development of sensitisation and the pathophysiology of 
atopic diseases has been the focus of recent research. In particular, the colonisation of the 
skin with Staphylococcus aureus has been suggested to be responsible for a continuous 
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stimulation of T cells. Recently, research has focused on the genetic background of asthma 
and atopy, whereas little is known in AD. 
• Thl / Th2 - a working hypothesis 
The concept of T helper cell subclasses was first proposed by Mosmann and colleagues in 
1986. They reported that cloned CD4+ T cell lines from mice could be classified into two 
subclasses according to their cytokine production and their related function [Mosmrum et al 
1986] 
The key cytokines ofThl and Tb2 lymphocytes are IFN-y and IL-4, respectively. These two 
cytokines were demonstrated to have opposite effects on a variety of immune mechanisms 
including IgE isotype switching in B cells, functional status of macrophages, and the 
development of T cell cytokines [Kelso 1995]. Figure 1 shows the cytokine pattern produced 
by Thl and Th2 cells and the diseases in which a differential expression of either a Th type I 
or Th type 2 cytokine profile has been implicated. 
FIgure 1 
Th11 Th2 model 
Intracellular pathogens 
Autoimmunity 
Allograft rejection 
Unexplained recurrent abortion 
Contact dermatitis, Diabetes mellitus 
M. Crohn 
) 
Humoral immunity 
Helminths 
Pregnancy 
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IL-5 
IL-6 
IL-9 
IL-10 
IL-13 
In the absence of clear polarising signals, T cells with a less differentiated cytokine profile 
than Thl or Tb2 cells arise [Romagnani 1996]. These cells are called ThO cells and can 
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develop further into Th cells producing a more polarised cytokine profile. However, it still is 
not clear whether the switch between Th1 and Th2 is a switch in individual cells or a 
population phenomenon, with more or less cells developing along the Thl or Th2 pathway 
[Gallagher 1997]. 
However, the concept of a Thlm12 dichotomy turned out to be a simplification of the tnte 
nature of immune regulation. [Kelso 1995, Borish et al 1997, Allen et al 1997]. A rigid 
interpretation of the Thlffh2 model has been criticised because the Thlffh2 model was 
based on T cell clones cultured in vitro from mice. However, cloning is an artificial process 
and a polarised Thl or Th2 pattern is found after long-lasting culture with certain cytokines 
or in T cell clones from some hyperinmmne individuals. In contrast, T cell clones from 
nornlal individuals assayed early after culture coexpress Th I and TI12 type cytokines in 
various combinations. Furthennore the situation in human beings is different from the 
murine situation as there is no clear-cut distinction between the cytokine profile ofThl and 
Th2 cells. In human beings both "subsets" produce IL-2, IL-3, IL-IO, IL-13, and GM-CSF. 
Another limitation of the model is the diversity of the c)10kine pattern produced by Th cells. 
It often is assumed that IL-4 represents a Th2 type cytokine profile, whereas IFN-y represents 
a Thl type cytokine profile. However, the expression of each cytokine seems to be regulated 
independently and Th cells have been described that contain mRNA for only one cytokine 
[Assenmacher et al 1994]. 
Therefore, it was proposed that 1111 and Th2 cells are not discrete subsets, but extreme 
phenotypes of a continuous spectntm in-between [Kelso 1995]. Interestingly, type 1 and type 
2 cytokine patterns were not only found in CD4+ T cells, but also in the other T cell subsets 
such as CD8+ T cells and y3 T cells (Ferrick et al 1995). 
Campbell et al [1998] compared IL-4 and IFN-y production from children with AD, children 
with IgE-mediated food hypersensitivity without AD, and normal controls. As compared 
with healthy children, children with AD had increased IL-4 production and decreased IFN-y 
production, whereas children with IgE-mediated food hypersensitivity had increased JL-4 but 
nornlal IFN-y (Campbell et al 1998). They suggested that isolated IL-4 enhancement 
promotes the development of IgE-mediated hypersensitivity, whereas the combination of 
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defective INF-y and enhanced IL-4 production promotes inflammatory atopic disorders such 
as AD and asthma. 
However, in AD Thl type cytokines are important as well [Grewe et al 1994, Werfel et al 
1996, Grewe et aI1998], and a two-phase-model has been proposed, with Th2-type cytokines 
promoting the initiation of the allergic inflammation and Thl-type cytokines later on 
prolonging and aggravating the allergic inflammation [Thepen 1996, Grewe 1995]. 
Several investigators reported that house dust mite-specificT cell clones from peripheral 
blood of patients with AD produced both IL-4 and IFN-y [Werfel et al 1996]. In lesional skin 
in AD, Grewe et al [1994] reported increased levels ofIFN-y mRNA expression in 13 out of 
15 patients, whereas increased levels of IL-4 mRNA expression were found in only 4 out of 
15 patients as compared with nonnal skin. Furthennore, they observed that successful 
treatment reduced IFN-y, but not IL-4 mRNA expression, indicating that in-situ IFN-y 
expression is linked to the clinical course of AD. Thepen et al [1996] found a differential 
cytokine expression in APT tests depending on the timing of measurement. After 24 hours, 
they observed a predominance of IL-4 positive cells, whereas after 48 and 72 hours a 
predominance of IFN-y positive cells was present. Moreover, they observed a predominance 
of IFN-y positive cells over IL-4 positive cells in lesional skin of patients with AD [Thepen 
1996]. Hamid et al [1994] compared the mRNA expression for IL-4, IFN-y, and IL-5 in acute 
versus chronic lesions of AD. In acute lesions they observed a significantly higher number of 
cells positive for JL-4 and IL-5 mRNA, whereas in chronic lesions only IL-5 mRNA was 
increased [Hamid et aI1994]. 
Taken together, these studies support the concept of a sequential Th cell activation, with a 
Th2 type pattern in the initial phase and a Th I type pattern in the chronic phase of AD 
[Grewe et al 1998, Thepen et aI1996]. In line with this concept is the observation in a mouse 
model, that injection of Th2 cells induced a rapid and short inflammatory response, whereas 
injection ofThl cells into the skin induced a late onset and prolonged inflammatory response 
[Muller et al 1993]. The two-phase model is also reflected in a distinct expression of 
cytokine receptors. Taha et al [1998] reported that acute AD was associated with a high 
expression ofIL-4 receptor alpha, whereas IL-5 receptor alpha and GM-CSF receptor alpha 
mRNA were predominantly increased in chronic AD and to lesser extent in acute lesions. 
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These findings support the biphasic role of IL-4, IL-S, and GM-CSF in the pathophysiology 
of AD. 
The underlying mechanisms involved in the regulation of the sequential Th cell activation 
are not known. Recently it was speculated that !L-12 secreted by eosiniphils may be 
responsible for the switching from Thl to Th2 phenotype [Grewe et al 1998]. In the initiation 
phase, IL-4 may result in accumulation of eosinophils via upregulation of VCAM-I on 
endothelial cells [Bochner et al 1994] and by acting as chemoattractant [Dubois et al 1994]. 
Eosinophils produce IL-12, which is known to induce a Thl type cytokine pattern. The 
production of !L-12 by eosinophils is stimulated by Th2 type cytokines. Via this mechanism 
a switch from a Th2 to a Th I phenotype occurs through the attraction of eosinophils and the 
stimulation ofIL-12 production in eosinophils [Grewe et al 1998]. 
IL-12 has an outstanding role in skewing the Th cell responses, as other modulating factors 
such as IL-4, IFN-y, IL-IO, and PGE2 act by modulating either the production of IL-12 in 
antigen presenting cells (APCs) or the responsiveness to IL-12 in T cells [Kapsenberg et al 
1998]. 
The most important source ofIL-12 are the different APCs like Langerhans cells in the skin. 
They have have been implicated in the differential development of a Thl or Th2 cytokine 
pattern [Kapsenberg et al 1998]. The polarisation of Th cell responses involves signals, 
particularly, during or shortly after their activation. As activation of T cells occurs through 
antigen presentation, the balance between Thl and Th2 type responses is highly detennined 
by APCs [Kapsenberg et al 1998]. It has been documented that !L-12 enhances the 
production of IFN-y and the development of IFN-y producing Th cells. In contrast PGE2 
inhibits IFN-y production by Th cells [Snijders et al 1998]. Both !L-12 and PGE2 can be 
produced by APCs. The ratio between secreted PGE2 and IL-12 may for a large part be 
responsible for a differential Th cell cytokine pattern. In asthma, peripheral blood monocytes 
were demonstrated to have a lower production of IL-12 in response to bacterial antigen as 
compared with control monocytes [Van der Pouw Kraan et aI1997]. This was not confinned 
in AD. However, in AD an increase in PGE2 production in monocytes has been reported 
(Snijders 1998). Recently, it was shown that enhanced PGE2 production by monocytes in 
AD is not accompanied by a general rise in monocyte cytokine production indicating that AD 
is indeed associated with an increased PGE2IIL-12 production ratio by monoc)1es [Snijders 
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et al 1998]. This indicates that a primary abnormality in the APCs may in part be responsible 
for the Th2 skewing encountered in atopic diseases. Therefore, Kapsenberg et al [1998] 
proposed the existence of functionally distinct APC subsets with a high (typel) or a low 
(type 2) ability to produce lL-12 upon contact with antigen-specific T cells. Besides 
influencing the balance between Thl and Th2 type cytokine patterns, APCs have been 
implicated in the development of tolerance. Ridge et al [1996] demonstrated that the 
development of tolerance is not restricted to neonatal T cells, but also occurs in adult T cells. 
The crucial parameters influencing the development of tolerance seem to be the dose of 
antigen, the type of adjuvant, and the type of APC. Whereas professional APCs activate 
neonatal and adult T cells, APCs lacking costimulatory molecules result in tolerance [Ridge 
et al 1996]. 
The intake of polyunsaturated essential fatty acids (PUFAs) may be important as they are 
involved in the regulation of the Thlffh2 balance. Linoleic acid (found in vegetable oils) is a 
precursor of PGE2 that inhibits the fonnation of IFN-y, whereas eicosapentaenoic acid 
(found in fish) inhibits the formation ofPGE2 [Black et a11997, Black 1999]. Therefore, the 
intake of vegetable oils may promote Th2 type responses. Support for this hypothesis comes 
from an epidemiological study by von Mutius et al [1998]. They found an increase in hay 
fewer since the reunification in East Gennany that was significantly associated to a change in 
intake of margarine [von Mutius et a11998]. Other factors involved in the regulation of the 
Thlffh2 balance may be infections (by directly inducing IL-12 production in APCs), 
superantigens, the cytokine microenvironment during antigen presentation, the antigen itself 
(type, concentration, and route), and genetic factors [Romagnani 1996, Umetsu et aI1997]. 
• Effector cells 
Whereas Th subsets, by producing cytokines, have a regulating role in the allergic 
inflammation, effector cells like mast cells, basophils, and eosinophils are responsible for the 
tissue damage. An overview of the T cell cytokines controlling and activating the functional 
activity of the effector cells involved in the allergic inflannnation is presented in Figure 2. 
However, this figure is a simplification of the number of mediators secreted and the network 
of interactions between cells. 
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Figuro2 
Pathophysiology of the allergic inflammation 
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Mast cells are not only effector cells by release of a large number of mediators (histamine, 
tryptase, chymaso, platelet-activating factor, leukotriene C4, and prostaglandin D2) but also 
control inflallllllation by secreting a large number of cytokines (IL-4, IL-5, IL-6, IL-13, TNF-
a) [Church et al 1997]. Mast cells have been shown to be a major source of IL-4 themselves 
[Horsmanheimo et al 1994] and can also provide the B-cell help for IgE switching, the so-
called cognate interaction as they express CD40L [Gauchatet al 1993, Church et a11997] 
Gauchat et al [1993] reported that highly purified lung mast cells and basophils were able to 
support IgE production by B cells in the absence ofT cells. Furthennore, mast cells 
have been shown to be able to process and present antigens, though it is not known whether 
this function has any relevance in vivo [Church et al 1997]. 
Eosinophils are another involved cell type that contributes to the chronic allergic 
inflammation. They are involved in the Honnal response to parasitic infections, but are 
largely held responsible for the tissue damage occurring in allergic inflmmuation. The main 
cytotoxic proteins secreted are major basic protein (MBP), and eosinophil cationic protein 
(ECP). Like mast cells, eosinophils have been considered primarily as effector cells under 
the control of T cell cytokines. However, this turned out to be untme, as eosinophils 
themselves are the source of a number of cytokines [Desreumaux 1996]. Eosinophils were 
found to produce IL-3, IL-5, and granulocyte monocyte-colony stimulating factor (GM-CSF) 
39 
Chapter 1 
[Desremaux et al 1996]. Interestingly, these three cytokines are the main factors in the 
recruitment, activation, and degranulation of eosinophils. The in vivo relevance of this 
observation is not known, but it suggests that once allergic inflammation is established, it 
may be perpetuated by such a positive feedback mechanism. Recently, eosinophils were also 
reported to synthesisc IL-2, IL-4, IL-IO, and IFN-y [Desremaux et al 1996], which makes it 
difficult to understand the fuuction of eosinophils. Another important feature of eosinophils 
is the presence of both low-affinity and high-affinity IgE receptors (FceRiI and FceRII) on 
the surface of eosinophils [Soussi Gounni et al 1994]. The cross-linking of these IgE 
receptors has been shown to induce eosinophil degranulation. This means that IgE activates 
and induces degranulation not only in mast cells but also in eosinophils. Furthermore, the 
expression of FCER! on eosinophils has been implicated in the antigen-presenting function of 
eosinophils. Another mechanism by which eosinophils may regulate the itmnune system is 
the production ofIL-12, which induccs a type I cytokine pattern in T cells. It was speculated 
that this may be the underlying mechanism for the switching from a type 2 phenotype 
(initiation phase of AD) to a type I phenotype (chronic phase of AD) in T cells [Grewe et al 
1998]. 
In conclusion, the function of mast cells and eosinophils is more complex than initially 
proposed, and information has accumulated to suggest an active role in antigen presentation, 
regulation of a Th type I or 2 response, IgE switching, and various other proinflammatory 
processes. 
Little is known on the role of other cell types prcsent in the skin. Recently it was suggested 
that skin kcratinocytes from patients with AD and non-atopic subjects differ in their intrinsic 
ability to respond to proinflannnatory stimuli. Pastore et al [1998] reported that keratinocytes 
from uninvolved skin in AD were hyperresponsive to IFN-y in terms of production of IL-l 
alpha, GM-CSF, and TNF-alpha. 
• Regulation ofigE synthesis 
The presence of increased levels of IgE antibodies to conunon allergens is a main feature of 
atopic diseases. Actually, many investigators define atopy by the presence of specific IgE 
40 
Figure 3 
Regulation of IgE synthesis 
1L-4 1L-13 
.... '~. 
General inh'oducliolJ 
(>0.35 lUll), a positive skin test or a positive provocation test. About 80% of the patients 
with AD have increased levels of 19B. As figure 3 shows, the induction of 19B synthesis 
requires several signals, 
One signal is the presence ofIL-4, which is not only produced by T cells, but also mast cells, 
basophils and eosinophils. With regard to 19B synthesis, IL-13 has a similar function as IL-4 
[Yanagihara 1998]. The second signal is constituted by a cell to cell interaction between 
Tcells and B cells [Yanagihara 1995]. This process called cognate interaction involves cell 
surface molecules on both T cells (CD40L, T cell receptoFTCR, and CD28) and B cells 
(CD40, MHC class II, and CDSO). Both signals together induce E germline transcription and 
induce isotype switching to 19B in human B cells. The receptors for 19B can be classified into 
those with high affinity (\"CERl) and low affinity (FcERlI) and have 
primarily been localised to mast cells and basophils. However, the discovery of FCERI on 
eosinophils, Langerhans cells, and monocytes changed the traditional view of 19B as just a 
mediator of mast cell degranulation. Besides activation and degranulation of eosinophils, 19B 
- FCERIIFcERlI binding improves the antigen uptakc and thereby promotes antigen 
presentation in different cell types (APCs, B cells, and eosinophils) [Mudde et al 1995]. 
• Adhesion molecules 
Adhesion molecules are glycoproteins, which mediate the attachment of leucocytes to 
endothelial cells thereby controlling migration. Recent studies indicated that adhesion 
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molecules are enhanced in acute and chronic AD lesions, in allergic skin reactions [Kyanw 
Aung et al 1991, Takigawa et al 1995] and even in uninvolved skin of AD patients when 
compared to normal control skin [Jung et al 1996]. Distinct adhesion molecules on both 
leucocytes and endothelial cells are involved in the different phases of the extravasation of 
leucocytes (Figure 4). 
Figure 4 
Adhesion molecules direct leukocytes to the 
sites of inflammation 
c c 
E-selectin and P-selectin mediate the first a«achment of the leucocytes to the endothelial lay-
er, resulting in rolling along the endothelium. This weak binding, however, promotes 
stronger interactions between ICAM-I and VCAM-I on the endothelium and their leucocyte 
surface ligands, resulting in tight binding [Bodmer et al 1994]. The next step, diapedesis, is 
mediated by ICAM-I and VCAM-I and their receptors on leueocytes. Based on the 
biochemical structure adhesion molecules are classified into 4 families: 
• Selectins (E-selectin, P-selectin, L-seJectin) 
• Vascular addressins (GlyCAM-I, CD34 ... ) 
• Integrins (LFA-I, VLA-4 ... ) 
• Inununoglobulin superfamily (ICAMs, VCAMs ... ) 
Adhesion molecules on endothelial cells selectively bind to particular adhesion molecules on 
leucocytes [Bochner et al 1994]. VCAM-I adheres to its counter-ligand VLA-4 that is 
expressed on eosinophils, basophils and lymphocytes but not on neutrophils [Koizumi et al 
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1995]. E-selectin promotes the selective migration of both CD4+ and CD8+ T cells expres-
sing the cutaneous lymphocyte antigen (CLA) which is a skin homing factor for CD45+ RO+ 
memory-type T cells [Santamaria et al 1995]. The expression of adhesion molecules is con-
trolled by locally produced cytokines and is rapidly upregulated on both endothelial cells and 
leucocytes upon exposure to cytokines, including interleukin-l (IL-I), tumour necrosis 
factor-a (TNF-a) and interleukin-4 (IL-4) [Boclmer et al 1994]. Increased expression of 
ICAM-I, VCAM-I and E-selectin has been demonstrated in skin biopsies from chronic and 
acute AD lesions [Takigawa et al 1995, Jung et al 1996]. Six hours after intradennal allergen 
injection to sensitised individuals, enhanced expression ofICAM-l and E-selectin was found 
in affected skin [Kyan Aung et al 1991]. 
The soluble fonn of these adhesion m.olecules is present in the circulation as a result of 
shedding or proteolytic cleavage [Gearing et al 1993]. The level of soluble adhesion 
molecules in peripheral blood is an indicator of the endothelial activation [Leeuwenberg et al 
1992] and may be of value as a marker of inflammation in AD [Wuthrich et al 1994, Czech 
et al 1996, Yamashita et al 1997]. Little is known on the function of soluble adhesion 
molecules. Soluble adhesion molecules may have physiological implications such as inhi-
bition of adhesion by competitive binding. In contrast, it was also suggested that they may 
act in a pro-inflammatory manner by chemoattraction and by activating leucocytes (La 
1991). 
• Chemokines 
Chemokines are a group of struchlrally related proteins, characterised by their chemotactic 
activity [Adams et al 1997]. However, chemokines do not only induce leucocyte migration, 
but are also involved in leucocyte activation, adhesion and angiogenesis [Rafeul 1997J. The 
term chemokines is a shortening for chemoattractant cytokines. The 28 described 
chemokines are classified into 3 families based on the biochemical structure. Virtually all 
studied blood and tissue cells secrete chemokines. As chemokines attract and activate 
eosinophils, mast cells, basophils and T cells they are assumed to playa crucial role in the 
pathophysiology of atopic diseases [Rafeul 1997]. The expression of chemokines is induced 
by pro-inflammatory cytokines sllch as IL-I, IL-2, IFN-y, TNF-e<, and lipopolysccharides 
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[Adams et al 1997]. In allergic diseases, eotaxin seems to have a crncial role due to the 
selective chemoattraction and activation of eosinophils [Adams et al 1997]. 
• Genetic background of atopic diseases: 
It has long been known that atopic diseases run in families. A positive family history for 
atopy considerably increases the risk of developing atopic diseases [Dold et al 1992, Berth-
Jones et al 1997]. It is generally perceived that a variety of enviromnental factors operate in 
genetically susceptible individuals. Twin studies that compare monozygotic with dizygotic 
twins provide data on the relative importance of genetic factors. The pairwise concordance 
rate for AD was 72% in monozygotic and 23% in dizygotic twin pairs (Schultz Larsen 1993). 
In an earlier report tlus was found to be 77% and 15 % in monozygotic and dizygotic twins, 
respectively (Schultz Larsen 1986). The high concordance rate in monozygotic twins clearly 
indicates that genetic factors are decisive in the development of atopic dermatitis. 
Random genome searches investigating genetic linkage in affected families and candidate 
gene studies have established several chromosomal regions that seem to be associated with 
the following phenotypes: asthma (5q31-q33, 6p21.3, Ilq13 and 12q14-q24), bronchial 
hyperresponsiveness (5q31-33), increased totallgE (5q31-q33, Ilq13 and 12q14-q24), and 
increased specific JgE (I1q13 and 14qll-q13). The candidate genes located in the above 
mentioned chromosomal regions arc shown in Table 8. 
Table 8 [After Barnes el al1998 and Holgale 1997]: 
Linked chromosomal region Candidate genes 
5q31-q33 lL-3,IL-4,IL-5, lL-9, 1L-13, GM-CSF, p,-adrenergic receplor, 
glucocorticoid receptor 
6p21.3 Human leucocyte antigen 0, tumour necrosis factor a 
Ilql3 High affinity IgE receptor (PCsRl) • fibroblast growth factor 
3 
12q14-q24 IFN~y, stem cell factor 
14qll-ql3 T cell receplor u (TCRu), NF-KP inhibilor 
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As mcntioned in Table 8, all the proposed candidate genes code for protcins related to the 
regulation of the allergic inflammation. 
The first step in rmding a relationship between a phenotype and a gene is to determine its 
chromosomal location by genetic linkage studies. The affected sib pair analysis is 
particularly suitable for the analysis of atopic disorders, because a specification of the mode 
of inheritance is not required. In a second step, specific functional polymorphism can be 
related to the expression of the related phenotypes [Barnes et al 1998]. 
To date, more than 10 genes or chromosomal regions have been proposed to be related to 
asthma or atopy. However, a detailed description is beyond the scope of this thesis. 
Nevertheless, in AD relativcly little is known on the relationship to distinct genotypes. 
Recently, genetic variants of mast cell chymase were claimed to be associated with AD (odds 
ratio 2.17), but not with asthma or allergic rhinitis [Mao ct al 1996]. TIus association was 
confinned in a subsequcnt study [Mao et al 1998] by thc same group. 
Cox et al [1998] tested several polymorphisms within Fc epsilon Rl-beta for association with 
atopic dennatitis. They found a significant association with Fc epsilon Rl-beta gene 
polymorphisms involving allele 2 ofRsal intron 2 (P = 0.0022) and allele 1 ofRsaI exon 7 (P 
= 0.0036). Hcrshey et al [1997] reported that a specific gain-of-function mutation in the 
alpha subunit of the IL-4 receptor was significantly more common among patients with AD 
as compared with healthy non-atopic controls. 
The search for genes predisposing for atopic diseases is complex due to the variable clinical 
phenotype, variations in the genotype between different populations, the influence of non-
genetic (environmental) factors, and the involvement and interactions of presumably many 
major and minor genes [Scheffer 1996]. While the evidence for an association of astlnna 
with HLA-D (6p21.3) and atopy with FCERI (llq13) is highly suggestive, further research is 
needed to define the genes in the other regions and to ascertain their relevance in the 
expression of atopic diseases. 
• Influences in utero 
It is known from epidemiological studies that maternal atopy confers a higher risk to the 
child for developing atopic dennatitis than paternal atopy [Ruiz et al 1992]. This may be 
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explained by the cytokine profile to which the foetus is exposed in utero. Mothers with 
atopic disease during pregnancy may expose the foetus to higher concentrations of Th2 type 
cytokines. The mechanisms involved are not elucidated, but appeared to begin at 22 weeks of 
gestation [Holgate 1997]. Exposure to birch pollen after 22 weeks of gestation has been 
associated with T cell responses to birch pollen at birth. Furthennore maternal exposure to 
house dust mite during the last trimester of pregnancy was found to increase T cell responses 
to house dust mite in the neonate [Warner et al 1994]. However, a maternal diet during the 
last trim.ester of pregnancy was demonstrated to have no preventive effect on the 
development of atopic disorders [Zeiger et al 1995]. 
Pregnancy is associated with a predominance of Th2 type cytokines that protects the foetus 
from the mother's cell-mediated iIl11Jlunity [Warner et al 1996]. A Thl type cytokine profile 
has been associated with a higher rate of abortions [Wegmatm et al 1993]. TillS meatlS that 
the foetus is exposed to Th2 type cytokines in utero. The placenta plays an important role by 
transporting antigens to the foetus and by maintaining a Th2 type cytokine environment. 
However, only some of the children develop persistent Th2 type responses. It was suggested 
that the foetus counteracts the placental Th2 environment by maintaining a Thl biased 
environment and that only those children develop persistent Th2 responses whose PBMCs 
are not able to produce enough IFN-y [Warner et al 1996]. In agreement with this hypothesis 
Tang et al [1994] have shown that neonates who subsequently developed a positive skin 
prick test (cow's milk, egg, peanut, house dust mite, cat, dog) were characterised by a 
reduced IFN-y secretion at birth. Recently, it was demonstrated that low-level IgE responses 
to food and inhalant allergens in the first months of life were present in both atopic and non-
atopic children [Prescott et al 1999]. Whereas in non-atopic children a suppression of Th2 
responses occurred, in atopic children a consolidation of Th2 responses occurred [Prescott et 
al 1999]. The persistence of allergen-specific Th2 responses was shown to be associated with 
a decreased capacity for production oflFN-y in the neonate [Prescott et aI1999]. 
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• Local factors 
The chronic inflammation in AD is characterised by depositions of eosinophil cationic 
protein (ECP) and major basic protein (MBP) and a mononuclear infiltrate consisting 
predominantly ofCDl+ cells and CD4+ memory T cells. Eosinophils are present particularly 
in acute lesions of AD [Takigawa et al 1995]. The selective accumulation of these 
inflanunatory cells is mediated by adhesion molecules and chemokines [Bochner et al 1994, 
Adams et al 1997]. 
At present, basic research is strongly focused on the immunological changes in AD while 
local factors receive little attention. There is no doubt that a systemic aberration in the 
immune system is a major pathogenic factor in AD. However, some phenomena cannot be 
explained by current concepts of a systemic deviation in the immune system. 
If local factors would not be relevant, AD lesions would be present in the same intensity on 
the whole body. However, lesions of AD are normally restricted to predilection sites that 
vary with age. In infants, the diaper region is typically spared from lesions which may be the 
result of reduced exposure to irritants or allergens. Another possibility is that increased skin 
moisture has a protective effect. In line with the last hypothesis, Eberlein-Konig et al [1996] 
demonstrated that after only three hours of low air humidity (30%) a significant increase in 
skin roughness occurred in patients with AD, but not in normal controls. Such dry skin is a 
characteristic feature of AD and has a reduced barrier function. Dry skin may increase the 
risk of active lesions. The skin barrier function has been shown to be compromised even in 
clinically uninvolved skin, which may result in higher penetration rates of irritants and 
allergens. It has been suggested that an abnormality in stratum comeum lipids (ceramidase) 
or proteins is the reason for the defective skin barrier function. Seguchi et al [1996] 
demonstrated that in non-Iesional skin of patients with AD, the amount of the epidennal 
protein filaggrin was only 32% of that present in nonnal controls. As filaggrin is thought to 
be the precursor protein of the emollient factors in the stratum corneum, a decrease in 
filaggrin may be partially responsible for the dry skin in AD [Seguchi et al 1996]. 
Exposure to hard water has recently been suggested to increase the risk of AD in children. In 
a recent study involving primary and secondary schoolchildren from Nottinghamshire, both 
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one year period prevalence and lifetime prevalence of AD in primary schoolchildren were 
significantly associated with domestic water hardncss [Mc Nally et al 1998]. 
Such locally active genetic and environmental factors may determine wether the systemic 
aberration in the immune system manifests in the skin. 
• The Role of infections 
Infections have a complex role in the regulation of the immune system and there are 
indications that micro-organisms can either induce or prevent the development of atopy 
[Holgate 1997]. 
Infections in early life. Infections have been documented to influence the balance 
between Thl and Th2 type cytokines. From an immunological point of view, infections are 
associated with the production of IFN-y, IL-12 and 1L-18 [Holgate et al 1997]. Such a 
cytokine profile decreases the chance for allergen sensitisation and may therefore be 
protective [Holgate 1997, Martinez et al 1994]. The postnatal period may be crucial in 
determining the pattcrn ofT cell reactivity in adulthood (Holt et al 1997). The Th2 skewing 
observed in neonates is probably a prolongation of the phenomenon that fetal responses are 
consitutively sltifted towards a Th2 type cytokine pattcrn [Warner et al 1996, Wegmann et al 
1993]. As a result newborns have low levellgE responses to food and inhalant allergens and 
weakly primed Th2 responses wltich are modulated by environmental influences [Holt 1997, 
Prescott et al 1999]. However, it is not known why some children continue to have a Th2 
type response to allergens, while others develop tolerance or a Th1 type response to allergens 
[Holt 1997]. The abilty to produce IFNy at birth was found to be lowest in children with a 
genetic background of atopy [Liao et al 1996], and those who will develop atopy later [Tang 
et al 1994]. Infections early in life, alter the microenvirorunent of 'I' cells, at a crucial 
moment when many allergens arc first presented to T cells of mainly the ThO type. In a 
murine model oral tolerance to ovalbumine was enhanced by concomitant administration of 
bacterial lipopolysaccharide (LPS). LPS is found on most enterobacteria, and it was 
hypothesized that a rcduced colonisation by enterobacteria may lack the stimulus to support a 
switch from the physiological Th2 type response in early life to a predominantly Th I type 
response to allergens in non-atopic individuals [Wold et al 1998].lnlinc with this hypothesis 
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several studies demonstrated a delayed and different colonisation of the gastrointestinal tract 
in babies from \Vestern countries as compared to babies from developing countries [Wold et 
aI1998]. 
The increased use of antibiotics and vaccinations, the smaller family size, and the higher 
socio-economic standard has led to a decline in infections which may :f.:1vour a Th2 type 
cytokine pattern associated with atopic diseases. Epidemiological studies seem to support 
this hypothesis as the risk for atopic diseases is negatively cOlTelated with the number of 
older siblings [Olesen et al 1997, Strachan ct al 1997] and positively correlated with socio-
economic standard [Golding et al 1987, Strachan et al 1997, Williams et al 1994]. 
Established atopic disease was demonstrated to improve upon helminth infections [Turton 
1976]. Furthenllorc, certain viral and bacterial infections (measles and tuberculosis) were 
reported to decrease the risk for atopic diseases. Fujimura et al [1997] found a conversion of 
a Th2 cytokine pattern towards a Thl cytokine pattern after varicella-zoster infection in 
patients with AD. However, this conclusion was drawn from 3 patients only. Furthennore, 
AD does not always improve by varicella infection, but may exacerbate as well. 
Three studies are often cited to support the hypothesis of a protective role of infections on 
the development of atopic diseases. 
1) In Japanese children an inverse relationship between delayed hypersensitivity to 
Mycobacterium tuberculosis and several features of atopy was reported by Shirakawa et 
al [1997]. They concluded that a decline in TBC infection may increase the risk of atopic 
diseases in a population. 
2) African children who had been vaccinated with measles vims had a significantly higher 
risk for a positive skin prick test to hOllse dust mite as compared with unvaccinated 
children who had had measles infection [Shaheen et al 1997). 
3) In Italian militalY students, hepatitis-A seropositivity was less common among atopic 
than among non-atopic individuals [Matricardi et al 1997]. 
However, these studies were observational and Aim et al [1997] in a more experimental 
approach could not confirm the previous finding by Shirakawa et al [1997] on the risk of 
BCG vaccination for the development of atopy in children. The outcome of the study by 
Shirakawa et al [1997] may also be intel])feted as a result of a depressed delayed-type 
hypersensitivity that is a typical feature in atopic individuals. Matricardi et al measured 
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seropositivity for hepatitis A, whieh is a marker of poor hygiene in general. However, tills 
group may differ in many other relevant risk factors for atopic disease from the hepatitis-A 
seronegative group. 
To date, there is no direct evidence that infections in early life have been more frequent in 
those individuals who become atopic than in those who remain non-atopic. FurthemlOre, 
infections do not simply promote a Th1 type response. Often Thl type cytokines are 
produced in the early phase of infections and Th2 type cytokines later. 
Thus, the role of infections in early life remains a controversial issue. 
Staphylococcus aureus colOlllsation. Colonisation by Staphylococcus aureus (S. mucus) 
is a common feature in patients with AD and systemic or topical treatment with antimicrobial 
agents has been demonstrated to improve AD. Both observations point to a pathogenic role 
of S. aureus in AD. Colonisation has been demonstrated to be present in 93% of children 
with AD, but in only 37% of age-matched controls [Hoeger et al 1992]. Exotoxins were 
found to be produced by 40-50% of the S. aureus isolates from children with AD ]Kemp et al 
1996, Hoeger et al 1992]. hlterestingly, an improvement of AD by topical antibiotics was 
observed even in the absence of clinically evident impetiginisation [Lever et al 1988]. 
Relevance for the pathophysiology of AD has been suggested by several diITerent 
mechanisms. Leung et al [1993] found significant senlln levels of IgE to staphylococcal 
exotoxins (SEA, SEE, TSST) in 57% of the patients with AD [Leung 1993]. They concluded 
that the toxins of S. aureus may exacerbate AD via an activation of Fc epsilon-receptor 
bearing cells. 
Another possible mechanism is based on the ability of S. aureus exotoxins to stimulate a 
large proportion ofT cells via interaction with the Vp region of the T cell receptor and MHC 
class II molecules [Kemp et al 1996]. This activation of T cells is not dependent on 
recognition of a specific antigen binding site on the T cell receptor and results in a 
stimulation of about 30% of the T cell population [Kemp et al 1996]. Such an ongoing 
stimulation ofT cells may perpetuate inflammatory reactions in lesional skin. 
Furthermore, S. aureus protein A has the capacity to directly stimulate B-eell proliferation. 
Recently, fundamentally different responses to S. aureus and its toxins have been described 
between patients with AD and normal controls [Campbell et al 1997]. They observed a 
significantly decreased production of IFN-y and increased production of IL-4 in response to 
50 
General illlroductioJl 
S. aureus as compared with normal controls. They concluded that impaired IFN-y production 
to S. aureus in vivo may result in failure to eradicate S. aureus from skin [Campbell et al 
1997]. 
Taken together, these data indicate that the stimulation of the inunune system by S. aureus 
and its toxins in individuals with an "atopic aberration" in the immune system may be 
responsible for the clinically observed association between S. aureus and AD. 
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Socio-ecollomic impacl 
Atopic dermatitis (AD) is often perceived as a mild and temporary disease with minor impact 
on health status and psychosocial well being. Tills may be true in some of the children with 
mild AD, but it is certainly not tme in moderate to severe AD. A recent Australian study on 
family impact and financial cost of AD using the questionnaire of Stein et al [1980] which 
had been used to assess the impact of conditions such as spina bifida, ventilator dependence 
and post-traumatic brain injury. The authors [Su et al 1997) concluded that childhood atopic 
eczema had a profound impact on the social, personal, emotional, and financial perspectives 
of families. Remarkably, even in mild AD, the impact on the family was comparable to that 
for children with insulin-dependent diabetes mellitns [Su et al 1997). 
Several factors related to AD contribute to the impact on child and family. 
• Chrollically relapsillg disease: The unpredictable course of the disease with ups and 
downs, exacerbations and infections can frustrate both parents and physicians. 
Unfortunately, desperation is the symptom of chronic skin disease that is hardest to treat. 
Parents may loose confidence in regular medicine and end up with considerable costs for 
alternative medicine. 
• Pruritus: Itching is often reported by the parents to be the worst feature of AD. Itching 
and scratching go together. Parents, whose child scratches until bleeding wounds emerge, 
often report a feeling of helplessness. However, some parents demand the impossible -
not to scratch. In those cases scratching may become the subject of a power struggle 
between parents and child. Usually, itching is most prominent in the evening and at night. 
In infants this results in repeated awakening, crying and sleep loss by the parents, 
whereas older children may experience drowsiness and lack of concentration during the 
day. 
• Sleep disturbances: Dahl et al [1995) demonstrated that children with AD have several 
sleep disturbances compared to healthy subjects: greater difficulty in falling asleep, 
frequcnt night waking, less total sleep, and greater difficnlty in waking up for school. The 
severity of AD was moderately correlated with sleep problems and with daytime 
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behaviours. Difficulty falling asleep and night waking correlated with problems in 
daytime behaviour and discipline. 
• Behavioural disturbance: Parents often report that their children with eczema display 
hyperactive symptoms. A recent study investigating 50 children with AD and 50 children 
with diagnosed attention deficit hyperactivity disorder (ADHD) demonstrated a higher 
incidence of atopic symptoms and family history of atopy in children with diagnosed 
ADHD [Baron et al 1998]. Furthermore, they found a higher incidence of hyperactivity 
symptoms in children with atopic eczema than in the general population. The authors 
identified 24% of the children with AD as having hyperactivity scores (Connors parents 
rating scale) equivalent to those seen in ADHD. The higher prevalence of behavioural 
problems is confirmed by Hashiro et al [1998] who reported that patients with AD were 
significantly more often depressive and scored higher for state anxiety than the normal 
control group. 
• Cosmetic aspects: The skin is the outer layer of our self-image. Decreased self-esteem 
can be the consequence of disfiguring eczematous skin lesions on the face or the hands. 
In this context the attitude of parents and teachers towards these skin lesions is cmcial. 
Especially, oozing and infected lesions may prevent even parents from having regular 
skin contact with their baby. In daily life, normal undertaking, like shaking hands, can be 
painful and embarrassing. 
• Therapy: The topical therapy in AD is rather timc-consuming and can be painful due to 
mechanical irritation when applying the ointment. Some of the children refuse the 
treatment that may result in a power stmggle between child and parents. 
• Risk/or asthma: It is documented that about 40% of the children with AD will develop 
astluna, whereas about 30% will develop allergic rhinitis [ETAC 1998, Bergmann et al 
1998]. The risk for asthma is further increased in case of severe AD or additional food 
allergy (especially egg) [Guijet et al]. 
• Food al/ergy: It is estimated that about 20% of the young children with AD have food 
allergy. Since it is a general belief that food allergy is responsible for AD, food allergy 
may be assumed unjustified, and subsequently treated with a diet. In this way the child 
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may be put on a strict elimination diet without indication, which imposes an extra burden 
and, in extreme cases, a danger to the child's health and well-being. 
• Financial costs: Financial implications of AD have been largely neglected, with only a 
few relevant publications in recent years [Herd et al 1996, Lapidus et al 1993, Su et al 
1997]. Recent data from Australia suggest that direct fmaneial costs in moderate to 
severe AD are substantially higher than those for the average child with asthma [Su et al 
1997]. The amlUal cost to the conmlUnity in mild, moderate and severe AD was estimated 
to be Aus$ 453 (f1634,-), 1523 (f12132,-), and 2912 (f14076,-) per child, respectively. In 
the same study the annual personal cost of managing mild, moderate and severe AD was 
estimated to be Aus$ 330 (f1 462,-), 818 (f1 1145,-) and 1255 (f1 1757,-) per child, 
respectively. In another recent study from the U.K., the mean cost of AD over a 2-month 
period was found be £25.90 (f1 85.5,-) to the patient and £ 16.20 (f1 53.5,-) to the health 
selvice. The corresponding data for patients with severe AD were £325 (f11073,-) to the 
patient and £415 (f1 1370,-) to the health service. Although these data cannot easily be 
extrapolated to other countries, it can be concluded that AD imposes a considerable 
financial burden to the family and the conununity. 
Recently, standardised questioIUlaires have been developed to measure the psychosocial 
impact of AD on the child and the family. The impainnent of the child's quality of life can 
be assessed by using the Children's Demlatology Life Quality index (CDLQI), while the 
impact of childhood AD on the family can be assessed by using the Dermatitis Family 
Impact questioIUlairc. These questionnaires will help to elucidate the impact of the disease 
and the efficacy of treatment in terms of psychosocial well-being. In conclusion there is 
considerable impact on the child and the family. 
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The impact of this disease is best illustrated by the experience of a patient with AD: 
"for me, having AD is like having to weal' a coat that Jeels rough, is the wrong color, is 
stiff where it should bend, and is unattractive to evelJ1body. AileI' several years oj wearing 
this thing, you grow to hale it, yourself, and anybody who h·ies 10 make you like it. " 
Cited from: Sometimes the skin is only the top layer of the problem (Irene A. Crosby) 
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Atopic syl/drome - otller mal/ifestatlol/ 
The atopic syndrome includes AD, allergic rhinitis and asthma. The link between these three 
atopic diseases is evident in epidemiology and pathophysiology. Food allergy has been 
suggested as one other manifestation of the atopic syndrome. The presence of one atopic 
disease indicates an increased risk for the other atopic diseases. Usually, food allergy and AD 
are the first manifestation of the atopic syndrome, while asthma and allergic rhinitis develop 
later. Children with atopic dermatitis have 40 % risk to develop asthma and about 30 % risk 
to develop allergic rhinitis. Epidemiological studies of the past decades have demonstrated 
an increase in the prevalence of all atopic diseases [Ninan et al 1992, Wllincup et al 1993, 
Burr et al 1989]. The underlying pathophysiological mechanisms arc similar in AD, asthma, 
and allergic rhinitis as is evidenced by the inflammatory cells involved (Th cells, mast cells, 
and eosinophils), the inflammatory mediators involved (lL-3, lL-4, IL-5, IL-13, GM-CSF, 
and RANTES), tissue hyperreactivity, elevatcd polyclonal IgE, and the allergen-specific IgE 
responses. From a pharmacological point of view the link is apparent, as in all atopic 
diseases emphasis is put on an anti-inflammatory approach using corticosteroids. The clinical 
manifestations of atopy - the atopic diseases - are very variable and depend on a 
combination and interaction of genetic and environmental factors. 
Asthma 
Recent definitions of the disease concentrate on a combination of airway obstmction, airway 
inflammation, and ainvay reactivity to various stimuli. The diagnosis of asthma usually relies 
on a combination of a history of suggestive symptoms (wheeze, cough, dyspnoea, chest 
tightness), airway liability (variable airflow obstmction with> 15% change in flow rate), and 
increased bronchoconstrictor response to histamine or methacholine [Sears 1997]. Wheezing 
is a typical symptom of asthma. However, particularly in young children it is evident that not 
all children with asthma wheeze, and not all wheeze is astluna. Among children younger than 
3 years of age there seem to he two forms of wheezing. Those with transient wheezing were 
shown to have constitutionally smaller airways, whereas those with persistent attacks of 
wheezing were charactcrised by manifestations of atopy [Martinez et al 1995]. The 
prevalence of asthma has increased during the past 3 decades and is estimated to be 5-15% in 
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westem countries [Annesi et al 1995, Anderson et al 1994, Strachan et al 1994, Luyt et al 
1993, Semlhauser et al 1995, Dold et al 1992). 
Allergic rhinitis 
Criteria based on consensus, for the definition or diagnosis of allergic rhinitis are lacking. 
Allergic rhinitis is characterised by sneezing, rhinorrhoea, and nasal blockade. Seasonal 
allergic rhinitis is frequently accompanied by conjunctivitis and can easily be identified, 
while allergic perennial rhinitis is difficult to differentiate from non-allergic rhinitis 
(vasomotor rhinitis). The prevalence of allergic rhinitis is low in children under the age of 5 
years, but increases rapidly thereafter and reaches a peak in adolescence [Sibbald el al 1991). 
From various studies it was estimated that the prevalence of allergic rhinitis approaches 20% 
in the general population [Dold el al 1992, Ninan et al 1992). 
Atopy 
The conunon denominator of atopic diseases is atopy. However, what exactly is atopy? 
Allready several decades ago Ingram complained thaI "Atopy means exactly nothing except 
in the mind of Coca and Cooke". In the literature there is a striking variety of different 
meanings and definitions associated with the tenn "atopy". The question arises on the sense 
of a term that causes confusion and uncertainty. 
Coca and Cooke introduced the tenn atopy in 1923 [Coca 1923). Atopy is derived from the 
Greek words a(no) topos(place). Initially atopy was meant to describe the inherited tendency 
to develop immediate-type hypersensitivity reactions to common antigens. Furthermore they 
found an association with an increased liability to fonn "reagins" (later named IgE 
antibodies). However, atopic diseases are not just immediate-type hypersensitivity reactions, 
and some of the individuals with AD or asthma have no evidence of underlying IgE mediated 
mechanisms (20 % in AD). Should those be given another name like intrinsic AD in analogy 
to intrinsic asthma? Is such a classification useful, since there is no difference in terms of 
clinical symptoms? On the other hand, the pathophysiology of AD may be different in those 
with and without evidence of IgE mediated mechanisms. Therefore, studies on the 
pathophysiology of AD should consider this different pathogenetic constellation. In 1973 
Pepys defined atopy as "that fonu of immunological reactivity of the subject in which 
reaginic antibody is readily produced in response to ordinary exposure to conunOll allergens 
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of the subject's envirollluent" [Pepys 1975]. A similar definition is given in the European 
Allergy White Paper [Aas et al 1997], describing atopy as the hereditary predisposition to 
produce elevated concentrations of IgE specific to common allergens. Both definitions do not 
require the presence of a clinical expression of atopy and differ from the definition used by 
many physicians describing atopy as the hereditary predisposition to develop allergic 
diseases including asthma, allergic rhinitis and AD. Moreover, there are individuals with 
posiHve skin prick tests and/or specific IgE to common allergens, without having had any 
atopic disease. We do not know how these patients differ from the ones with clinical 
manifestation of atopy. Advances in the understanding of relevant genes in atopic diseases 
may show a specific atopic genotype associated with the regulation of IgE synthesis, and 
distinct organ-specific genes, associated with the target organ affected. Patients with specific 
IgE to common allergcns without clinical symptoms may lack the distinct organ-specific 
genes. 
Thus, the definition of atopy is controversial, and so is the diagnosis of atopy. One limitation 
of the diagnosis of atopy is that it does not correspond to the definition of atopy. Since most 
definitions of atopy describe a predisposition, strictly speaking, only genetic screening can 
detect atopy while the presence of total IgE, specific IgE, or a positive skin test is the net 
result of both genetic predisposition and enviroruucntal influences. Most authors diagnose 
atopy as the presence of one or more of the following features: - elevated total IgE - specific 
IgE - positive skin prick test - positive provocation test. The agreement between these tests 
is not very high and therefore a study in which atopy is diagnosed by the presence of total 
IgE will have a different study popUlation than that diagnosed by skin prick test or 
provocation test. These differences in study population may influence the outcomes of 
studies. 
The ongoing discussion on the definition of atopy [Rocken et al 1998, Lilja et 81 1998] 
underscores the need for unitary criteria for definition and diagnosis of atopy. 
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Alms of the study 

Aims of the study 
Aims of tlte study 
The studies described in tIus thesis were performed in order to improve the evaluation and 
therapy of atopic dennatitis (AD) in childhood. 
In order to study AD, a reproducible and validated scoring system for the clinical 
evaluation of the severity of AD is necessary. At present, the SCOring Atopic Dennatitis 
(SCORAD) index is the best validated clinically based system. We used the objective 
SCORAD which is based on the SCORAD index without subjective scoring. However, the 
objective SCORAD is too time-consuming for daily practice. Therefore, in chapter 3 we 
evaluate a simplified scoring system, the Tree Item Severity (TIS) score, for measuring the 
severity of disease. Furthennore, the objective SCORAD is validated regarding its inter-
observer variability in physicians working in the same institute. 
Another possibility to measure the severity of disease and the outcome of therapy is 
the assessment of biological markers. Candidates for such markers are the soluble forms of 
adhesion molecules. Adhesion molecules arc up-regulated in inflammatory tissues and have 
a cmcial role in controlling the migration of leucocytes into target organs. The concentration 
of soluble adhesion molecules in vitro was shown to reflect the expression of adhesion 
molecules on the endothelial cells. Therefore, soluble adhesion molecules such as E-selectin 
may be used as an indicator of inflammation in the skin. In chapter 4 we investigate this 
option by studying the relationship between the severity of AD as assessed by objective 
SCORAD and the levels of markers of inflammation (soluble adhesion molecules, 
eosinophil cationic protein), markers of sensitisation (to~al IgE, specific IgE) and the 
production of IL-4 and interferon-y by peripheral blood mononuclear cells. 
Studies aimed to evaluate the efficacy of treatment in moderate to severe AD by 
using a clinieally based scoring system are described in chapter 6. Different aspects of 
therapy in children with AD are summarized in a state of the art article. A topical 
corticosteroid of the so-called 4th generation (fluticasone propionate 0.05% cream) is 
investigated to assess its suggested improved benefit / risk ratio. In children with AD, who 
would especially benefit from such a treatment, published studies were lacking. Therefore, 
we investigate the efficacy and safety of flutieasone propionate 0.05% cream in children 
with moderate active atopic dermatitis as assessed by objective SCORAD. However, in 
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severe refractory disease other approaches are required. For tlus purpose we propose and 
study a modified protocol for the "wet wrap" therapy in children with severe AD. Basically, 
the wet wrap therapy is an occlusive treatment with corticosteroids. Such a therapy was 
associated with major side~effects in the past. Therefore, the use of a corticosteroid with 
improved benefit I risk ratio may be a major improvement for the wet wrap therapy. \Vhereas 
in the literature a high rate of systemic side-effects is reported, our initial results with the wet 
wrap therapy using dilutions of fluticasone propionate 0.05% cream were promising and 
prompted us to investigate the efficicacy and the safety of our modified wet wrap protocol. 
To further evaluate and increase the safety of the wet wrap treatment, we study daily serum 
cortisol using different concentrations of the corticosteroid. The aim of tllls study is to 
extend our knowledge on optimal corticosteroid concentration and the optimal duration of 
daily Wet Wrap treatment with f1uticasone propionate. 
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Chapter 3 
Scoring the severity of atopIc dermatitis 
Scoring the severity of atopic dermatitis: Three item severity (TIS) score as a rough sytem for daily 
practice and as a prescreening tool for studies. 
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Scorillg the Severity of Atopic Dermatitis: Three Item Severity Score as a 
Rough System for Daily Practice alld as a Prescreellillg Tool for Studies 
I I 2 3 d . API Wolkerstorfer A ,de Waard van der Spek FB ,Glazenburg EJ ,Mulder PGH an Oran]e . 
I Deparlmenl of Dermalo-Venereology, University Hospital, Rotterdam, 2Medical Department, 
Glaw We/lcome EV; Zeist and 3 Department of Epidemiology and Biostatistics, Erasmus 
University, Rotterdam, The Netherlands. 
Abstract 
Different scoring systems have been developed to determine the severity of atopic dennatitis. 
The SeORAD (SCORing Atopic Dennatitis), one of the best validated systems, is suited for 
clinical trials, but is too complicated and time consuming for routine clinical use. The TIS score 
(TIlI'ee Item Severity score), a simplified system, is based on the evaluation of erythema, oede-
ma/papulation and excoriation on a scale from 0 to 3. In order to detennine the value of the TIS 
score we conducted a prospective study in 126 children with mild to severe atopic dennatitis. 
Both the TIS score and the seORAD were assessed by trained investigators. Interobserver 
agreement was investigated in 20 children by comparing the independently perfonned scores of 
three investigators. A positive correlation was found between the TIS score and the seORAD 
(Rank Speannan r,~0.86; p<0.0005). TIle item which correlated best with the SeORAD was 
excoriation (r,~O.72; p<0.0005) followed by oedema/papulations (r,~O.66; p<0.0005). 
Interobserver agreement which was calculated by Cohen's kappa (K) was 'excellent' for 
SeORAD (K~0.82; p<O.OOI) and 'fair' for TIS score (K~0.58; p<O.OI). We conclude that the 
TIS score is a rough, though reliablc and simple system for scoring atopic dermatitis. It is 
particularly suitable in general practice, for routine clinical use and for screening purposes in 
clinical trials. For research purposes, the objective seORAD offers a more detailed and 
comprehensive assessment. 
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Introduction 
Atopic dennatitis is a common chronically relapsing skin disease affecting 8.9-20.4% of those 
bom after 1970 (I). Patients with atopic demJatitis (AD) account for about 30% of 
dennatological consultations in general practice (2). Although guidelines give a good 
framework in managing AD (3), the chronically relapsing course may disappoint not only the 
patient, but also the physician (4). In the follow-up of such a fluctuating disease a more 
informative way of recording than "the patient seems better or worse" is necessary. Therefore 
assessing the severity of AD as objectively and reproducible as possible is extremely importaot 
not only for research purposes but also in clinical practice. However, a best scoring system for 
all purposes is not available (5). TI,e choice of the system will depend on whether it is used for 
clinical trials, clinical routine assessment or at busy general practice. A system which is 
intended for research should be sufficiently discriminating and comprehensive to cover the 
various clinical manifestations of AD. As a result, such a scoring system will be complicated 
and rather timeMconsuming. By way of contrast, simplicity and time spent for scoring are 
cmcial issues in a scoring system for daily routine use. 
Many different scoring systems have been proposed for assessing the severity of AD (I). These 
systems are based on the evaluation of one or more of the following items: 1) extent, 2) a 
selection ofintensity items, 3) subjective signs (pmritus, sleep loss) aod 4) history of eczema. 
For research purposes in atopic dennatitis, systems have been described by Hanifin (6), Bahmer 
et al. (ADASI) (7), Sowden et al. (Leicester score) (8) and Harper et al. (9). The lack of 
standardization prompted work groups to achieve a consensus on how to score AD. In the 
U.K., the Joint Workshop on Management of Atopic Eczema has recommended the Leicester 
system (8) for research purposes willie in the the Ulllted States the 'Eczema area aod severity 
index' (EASI) has been proposed (Clullcal Dennatology 2000, Singapore). Both systems rely 
on the recording of different signs at different defined body sites. 
[n Europe, the European Task Force on Atopic Demlatitis has developed and evaluated a 
composite severity index based on a broad consensus by dennatologists. The resulting 
SCORAD index (10) consisted of ullomlatioll on the extent, the intensity and subjective 
symptoms. The SCORAD uldex has been used in several immunological and clWcal trials 
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since then. The objective part of the SCORAD (extent, intensity) has been f"rther validated 
with regards to the inter-observer variability in two studies with patients (II) and with the aid 
ofa pictorial atlas (12). The subjective part (pmritus, sleep loss), which appeared to be a cause 
of large variations, has been scraped by the work group except for the follow-up of individual 
patients. The objective SCORAD is an excellent system for trials, but is too complicated and 
time~conslUning for a routine clinical setting. Therefore, we have developed a simple scoring 
system called "nITee Item Severity (TIS) score', which is based on only three intensity items 
(erythema, oedema/papulation and excoriations). The aim of the study was to evaluate the TIS 
score in routine clinical practice and to investigate the correlation with the SeDRAD. 
Material and methods 
Patients 
One hundred and twenty-six children (mean age 3.9 years; range 4 months to 16 years) with 
atopic dennalilis according to Sampson (13) (younger than 2 years) and Williams et al. (14) 
(older than 2 years) were recmited from the outpatient unit of the Paediatric Dennatology 
Department at the University Hospital Rotterdam. All children with atopic dennalitis visiting 
our outpatient unit between July 1997 and March 1998 entered the study. 111e severity of the 
disease was evaluated using the SCORAD and the 11S score in all children. To assess inter-
observer variation, twenty of these children were scored simultaneously by three different 
physicians: an expert dennatologist involved in the development of the SCORAD, another 
trained dennatologist and a trained non-demlatologist . 
SCORAD 
'The objective SeDRAD is a scoring system based on the assessment of extent and intensity in 
a standardized manner. The complete system is called SCORAD index (10) and also includes 
the assessment of subjective symptoms (pmritus, sleep loss) on a visual analogue scale. The ex-
tent of lesions is scored by applying the mle of nine after drawing the lesions on an evaluation 
fonn. The intensity is detennined by grading each of the six items on a scale from 0 to 3 (e1)1-
hema, oedema/papulation, oozing/cmsts, excoriation, lichenification and dryness). Each item 
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should be scored on the most representative area for a given intensity item. Finally the total 
score is the sum of extentJ5+ 7xintensityl2. Owing to tlus formule extent accounts for about 
25% and intensity for about 75% of the total score. TI,e range of the objective SCORAD lies 
between 0 and 83. Based on the objective SCORAD, the severity of AD can be classified into 
mild «15), moderate (between 15 and 40) and severe (:2:40) AD. The objective SCORAD re-
flects the modified consensus of the European Task Force on Atopic Dermatitis. Unlike the 
initial version of the SCORAD index (10), subjective symptoms are not included in the scoring 
of AD (II). 
TIS score 
The TIS score is the sum of three intensity items scored on a scale from 0 to 3 (erythema, 
oedema/papulation, excoriations). Similar to the objective SCORAD, each item should be 
scored on the most representative lesion. 11tis means that different items may be scored on 
different sites. TIle range of the TIS score lies between 0 and 9. 
Statistical analysis 
Correlation between objective SCORAD and TIS score and between objective SCORAD and 
the different intensity items was calculated using the Rank Spearman's correlation. lnter-
observer agreement for both objective SCORAD and TIS score was calculated as the intraclass 
correlation coefficient using kappa (K). Agreement between observers was also calculated for 
each scoring item separately. A KSO.4 represents poor agreement; O.75>K>0.4 represents fair 
agreement and QO.75 represents excellent agreement (15). 
Results 
The investigated study population (n~ 126) consisted of children with mild (n~34), moderate 
(n~78) and severe (IFI4) AD according to the objective SCORAD. A positive correlation was 
observed between TIS score and objective SCORAD (Rank Speannan's r,~0.86 p<0.0005) 
(Fig. I). The intensity item which correlated best with the objective SCORAD was excoriation 
(r,~O.72 p<0.0005) followed by oedema/papulation (r,~0.66 p<0.0005), oozing/enlsts (r,~O.6 
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Fig. 1. Correlation between objective seORAD and TIS score in 126 children with AD. Rank 
Speannan correlation f5=0.86, P<O.OOOS. 
Fig. 2. Objective SCORAD in 20 children by three different physicians (+ expert dermatologist, A 
dermatologist, 0 l1on·dennatologist), Inter-observer agreement was excellent K=O.82. 
p<0.0005), erythema (r,~0.56 p<0.0005), lichenification (r,~O.56 p<0.0005) and dryness 
(r,~0.32 p<0.0005). Extent, according to the mle of nine, also correlated well with the objective 
SCORAD (r,~0.82 p<0.0005). Inter-observer agreement was assessed in 20 patients and was 
'excellent' for objective SCORAD (K~0.82; p<O.OOI) and 'fair' for TIS score (K~O.58; p<O.OI) 
(Figs. 2 and 3). 
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Fig. 3. TIS in 20 children by three different physicians (+ expert dennatologist, A dennatologist, 0 
non-dennatologist). Inter-observer agreement was fair K=0.58. 
Furthemlore, Figs. 2 and 3 show that a trained physician (non-dennatologist) scores AD as 
good as a trained dermatologist. 
When each scored item was calculated separately (Table I), we observed that the inter-observer 
agreement was the highest for extent and the lowest for oedema/papulation. Table I shows 
the between-patient variance, the total variance and the interobserver agreement (K) for each 
of the scored items. Generally, a higher intensity of AD did not increase the variation 
between observers. An exception was the scoring of lichenification where the interobserver 
variation increased with the objective SCORAD (Rank Speannan's r,~0.56 p<0.05). 
Discussion 
The TIS score is a simple scoring system for AD which is quick and easy to perform. 
In the present study we observed a high correlation of the TIS score with the objective 
SCORAD and a fair inter-observer agreement between physicians in the TIS score. 
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Table I. Inter-observer agreement (kappa) in 20 children by three different physicians. 
CJ PATIENT* 
} I Kapp (TWTAI, 
Objective seORAD 115.88 141.32 0.82 
TIS 1.22 2.11 0.58 
Extcnt 627.64 679.72 0.92 
Lichenification 0.9 1.19 0.76 
Dryness 0.51 0.73 0.7 
Oozing I crust 0.39 0.69 0.57 
Excoriation 0.23 0.42 0.56 
Erythema 0.24 0.45 0.52 
Oedema I papulation 0.25 0.6 0.41 
* (i PATIENT stands for the between~patient variance. 
I O\OTAL stands for the total variance, 
t kappa represents inter~obscrver agrecment. A kappa ~ 0.4 represents poor agreement, kappa between 
0.4 and 0.75 represents represents fair agreement and kappa> 0.75 represents excellent agreement. 
Of the six intensity items scored in the objective SCORAD, excoriation was the one that clearly 
correlated best with the objective SeORAD. Tltis reflects the clinical observation regarding 
pmritus as a prominent symptom of AD. Next to excoriation, oedema/papulation also showed a 
good correlation with the objective SeOlV\D. Tltis supports our choice of including these two 
items in the TIS score. Dryness was the only item that showed poor correlation with the 
objective SeORAD. While we found a high correlation between the TIS score and the 
objective SeORAD, it is clear from Fig. 1 that there is still so much variation left that the TIS 
score cannot accurately predict the objective SeORAD for all individual patients. This illeans 
that the TIS score and the objective SeORAD cannot be used interchangeably in individual 
patients. 
In contrast to earlier studies in which considerable inter-observer variation was reported 
(11,16), we demonstrate excellent inter-observer agreement between the three physicians using 
the objective SeORAD. We believe that tltis is a result of both a training in scoring AD and the 
fact that the physicians involved already used the objective SeORAD for scoring AD in 
clinical routine. 
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A scoring system which is used in daily clinical routine should be as simple as possible which 
may result in a less sensitive and accurate system. During the course of time, a few systems 
have been developed with this in mind (16,17). Of these scoring systems, only the Basic 
Clinical Scoring System (BCSS) (16) is as simple and quick to perform as the TIS score. In the 
BCSS, the extent of AD is scored by evaluating the number of sites involved (5 sites are 
scored). Each site is scored 0 (no lesion) or I (lesion). Tllis system was demonstrated to have 
an excellent inter~observer agreement, but showed poor agreement with the SCORAD index. 
The drawback of this system is that it presumably provides a poor reflection of therapeutic 
interventions. In fact, when patients with AD are treated, the involved sites will not clear 
completely but improve in extent and intensity without a change of the BCSS. Therefore the 
BCSS is probably not suited for the follow-up of patients and for evaluating the efficacy of 
therapy. Although sensitivity to change in individual patients has never been addressed in any 
study it is known from clinical practice that the items represented in the TIS score are among 
the first to improve under treatment. The choice of the items used in the TIS score was based 
on the following criteria: 
I) TI,e items should be relevant for all age groups. 
2) If two items are highly correlated only one is scored. 
3) TIle items should reflect disease severity and should be independent of other interfering 
factors. 
4) The items should be subject to change and improve when AD improves. 
5) No combination of objective signs with subjective symptoms. 
Dryness, xerosis or scaling are a very characteristic feahlre of AD. TIley are used in many 
scoring systems but were not included in the TIS score as they largely depend on when the 
emollient was last applied. Lichenification which is also used in many scoring systems is not 
relevant in the very young children as it does not occur before the age of two years in 
Caucasians. FUl1hennore, lichenification responds rather slowly to therapy and is therefore not 
suited when evaluating the short-tenn effects of therapy. Oozing is very typical in infants, but is 
rare in older children. Moreover, oozing is closely linked to erythema. and is therefore already 
represented by erythema in the TIS score. 
Subjective symptoms like pnrritus or sleep-loss are strongly influenced by psychological 
factors and can cause large variations. Therefore, these symptoms were not included in the TIS 
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score. However, these symptoms remain important as an indicator of the quality ofHfe and may 
serve as a separate measurement tool for follow~up (II). For a complete measurement of the 
quality of life, DLQI (/8) for adults and CDLQI (/9) for children are appropriate techniques. 
Results of earlier studies indicate that the objective SCORAD can also be used by non-
dennatologists if they are trained to score AD (I2). Tills is also true for the TIS score as in our 
study we did not find a difference between the scores by a dennatalogist and a non-
dennatologist as compared with those by an expert dennatologist. 
In conclusion, we demonstrate that the TIS score is a reliable and simple scoring system for 
atopic demlatitis with a fair inter-observer agreement. It is particularly suitable for general 
practice, for routine clinical use and for screening purposes in clinical trials. However, for 
research purposes, when a sensitive method is required, the objective seORAD offers a more 
detailed and comprehensive assessment of AD with an excellent inter-observer agreement. 
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Evaluation of Immunological markers in atopic dermatWs 
4.1 Disease severity and soluble E-selectin and other markers of inflammation in children with 
atopic dermatitis. 
Brit J Dennetof 1998; 138: 431-5. 
4.2 Soluble E-selectin and soluble ICAM-1 as markers of the activity of atopic 
dermatitis. 
Submilled 
4.3 Cytokine production by peripheral blood cells from children with atopic dermatitis. 
$ubmrtled 

Soluble adhesion molecules in children with atopic denl1atitis 
Disease severity amI soluble E-selectill a/ld other markers of inflammatio/l 
ill children with atopic dermatitis. 
Albert Wolkerstorfer", Marika P. Laanb, Huub F.J. Savelkoulb, Hennan J. Neijens', Paul 
G.H. Mulder', Anne M. Oudesluys-Murphy', Ram N. Sukhai', Arnold P. Oranje'. 
a Department of Dermatology and Venereology, University Hospital Rotterdam, b 
Department of Immullology, Erasmus University, Rotterdam, C Department of Pediatrics, 
Sophia Children's Hospital, Rotterdam, d Department o.f Biostatistics, Erasmus University, C 
Department o.f Pediatrics, Zuiderziekenhuis, Rotterdam, The Netherlands. 
Abstract 
E-seleetin, P-selectin, interstitial cell adhesion molecule-l (lCAM-I) and vascular cell 
adhesion molecule-l (VCAM-I) are membrane bound adhesion molecules which mediate 
the attachment of leucocytes to endothelial cells. These molecules are preferentially 
expressed on activated endotheliulll. The soluble form of these molecules will be present in 
the circulation as a result of shedding. Some of the soluble adhesion molecules have been 
thought to reflect disease activity in atopic dennatitis (AD). To evaluate their potential to 
reflect disease activity in AD, we correlated their plasma concentration with clinical severity 
measured by objective SCORAD (SCORing Atopic Dermatitis). Furthermore, levels of total 
IgE, specific IgE, and eosinophil cationic protein (ECP) were determined. SCORAD and sE-
selectin levels were significantly increased in children with specific IgE for both food and 
inhalation allergens (p<O.05). ECP consistently showed an increase with the scores of 
SCORAD, but no statistical significance was reached. Disease activity was significantly COf-
related with the plasma levels of sE-selectin (r,~O.6, p<O.0005) but not with sP-selectin, 
sICAM-I and sVCAM-l. This agrees with recent studies perfoffiled in adults with AD, and 
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supports the potential of sE-selectin as a parameter for monitoring disease activity in young 
children with AD. 
Introduction 
Although the precise pathogenesis of atopic demlUtitis (AD) is still not entirely elucidated, a 
number of immunological features have been proposed, as markers of inflanunation in AD. 
Total semm IgE is increased in 80% of the patients and elevated values are loosely 
associated with more severe disease'. Activated eosinophils which are increased in blood and 
affected skin are widely held responsible for the tissue damage in AD. One of the most im-
portant toxic proteins released from these cells, eosinophil cationic protein (ECP), has been 
shown to reflect disease activit/. Recently soluble adhesion molecules were proposed as 
markers of disease activity9.14. Membrane bound adhesion molecules are glycoproteins 
which mediate the attachment of leucocytes , including eosinophils, to endothelial cells the-
reby controlling migration. E-selectin and P-selectin mediate the first attachment of the 
leucocytes to the endothelial layer, resulting in rolling along the endothelium. This weak bin-
ding, however, promotes stronger interactions between ICAM-! and VCAM-l on the endot-
helium and their leucocyte surface ligands, lymphoc)1e function associated antigen-I (LFA-
I) and very late antigen-4 (VLA-4 ), respectively', Adhesion molecules are rapidly upre-
gulated on both endothelial cells and leUcoc)1es upon exposure to c}1okines, including 
interleukin-I (lL-I), tumor necrosis factor-a (TNF-a) and interleukin-4 (IL-4i, Increased 
expression of ICAM-I, VCAM-I and E-selectin have been demonstrated in skin biopsies 
from chronic and acute AD lesions4. Six hours after intradermal allergen injection to sensiti-
zed individuals, enhanced expression ofICAM-1 and E-selectin was found in affected skit{ 
The soluble form of the adhesion molecules, sE-selectin, sP-selectin, sICAM-1 and sVCAM-
I originates from membrane bound molecules due to shedding or proteolytic cleavage'. The 
amount of soluble sE-selectin and sICAM-1 released, was found to correlate directly with the 
cell surface expression in vitro'. Thus, the levels of sIC AM-I and sE-selectin may reflect the 
intensity as well as the extent of the inflammation in AD. In vivo semm levels of sICAM-I 
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and sE-selectin have been shown to be increased in asthma' lUld AD". Recently several 
studies reported a correlation between disease severity and the soluble adhesion molecules 
sICAM-l and sE-selectin in AD IO-14 . However, such data are not yet available from children_ 
Moreover no comparison was made between sE-selectin and ECP, the most extensively stu-
died marker of severity in AD so far. In a pilot study we compared the levels of soluble 
adhesion molecules (sICAM-l, sE-selectin) in small groups of children with allergic astimla, 
non-allergic astiuna, atopic dennatitis and healthy controls". In the group with atopic 
demlatitis (n~lO) we found a correlation between the levels of sE-selectin and severity of 
disease. In the present study we investigated whether and to what extent ECP, total JgE, 
specific JgE, sE-selectin, sP-selectin, sICAM-l and sVCAM-l are correlated to disease seve-
rity in children with AD. 
Methods 
Patients and methods 
Forty children (21 boys and 19 girls; mean age: 22,3 months; range: 13 to 36 months) mainly 
with mild to moderate AD" (one child had severe AD) participated in the present study. All 
of the children had a positive fanlily history for atopy and no diagnosis of asthma. Children 
. with AD were treated with emollients, and as required with topical glucocorticosteroids, tar 
ointments and systemic antihistamines_ None of the children was treated with systemic 
corticosteroids. The study including blood sampling was approved by the Medical Ethical 
Connnittee of the University Hospital Rotterdam and the Zuiderziekenhuis, and informed 
consent was obtained from the parents prior to participation. 
Clinical scoring system 
The severity of disease was detemlined by the modified SCORAD system 17. accepted for pu-
blication Dermatology), which is a composite index including the assessment of two items in 
a standardized way: a) extent (applying the rule of nine) and b) intensity (erythema, ede-
ma/papulation, oozing/crust, excoriation, lichenification, dryness). This scoring system, 
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called SCORAD, reflects the modified consensus of the European Task Force on Atopic 
Dennatitis. Unlike the initial version of the seDRAD index l8, subjective symptoms are not 
included in the scoring of AD. 
Determination of soluble adhesion molecules 
sE-selectin and sICAM-l were measured in plasma by ELISA as described previously'9. 
Briefly, 96-wells microtitre plates were coated with monoclonal antibodies to slCAM-l 
(HM.2,3 Ilg/ml) or sE-selectin (ENAl, 10 Ilg/ml) in phosphate-buffered saline (PBS) fol-
lowed by saturation with 1 % bovine serum albumine. Standard or diluted samples were 
added in 100 Ill/well. After two hours at room temperature, the plates were washed and 
incubated for one hour with biotin labeled anti-ICAM-l or anti-E-selectin monoclonal 
antibodies. All antibodies were a kind gift of dr WA Buunnan (University of Maastricht, The 
Netherlands). After washing streptavidin-eonjugated peroxidase was added. Peroxidase acti-
vity was determined by addition of 2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid) 
(ABTS). The reaction was stopped with H2S04 and read at 414 nm. The concentration of 
sICAM-l and sE-selectin were determined by interpolation from the standard curve. The 
detection limits of these ELISA assays were 400pg/ml for slCAM-l and 200 pg/ml for sE-
selectin. Both spRselectin and sVCAM-l were measured by commercial ELISA's in plasma, 
based on a similar procedure using a commercially available test kit (R&D Systems Europe, 
Abbigdon, UK). 
Determination of total and specific immllnogloblliin E (JgE) 
Total IgE was detennined in the sera by chemiluminescence (Ciba Coming ACS). Specific 
IgE for food allergens (cow's milk, egg) and inhalation allergens (house dust mite, grass pol-
len, cat dander) was detennined by CAP Farmacia Upjohn (Uppsala Sweden). 
Data analysis 
Statistical analysis was performed with SPSS/PC+, using the Mann-Whitney U test to assess 
differences between groups (total IgE, specific IgE for food and inhalation allergens) in 
SCORAD and soluble adhesion molecules. The Speamlan rank correlation was used to test 
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monotonic relationships between SeDRAD, soluble adhesion molecules, specific IgE, ECP, 
myeloperoxidase (MPO) and eosinophils. Statistical significance was defined as p<0.05. 
Results 
IgE, specific IgE, peripheral eosinophils and eosinophil calionic proleill (Eep) 
Total IgE levels in the sera of the children were increased above the age specific limit (<2 
years: 0-29 kU/l; >2 years: 0-69 kU/l) in 23(of39) children. These children had significantly 
more severe disease, as reflected in increased SeORAD, than children with normal total JgE 
(p<O.OI). Specific IgE for food and inhalation allergens were found in 21(of 38) and 20(of 
39) children, respectively. In those children with increased specific IgE to both food and 
inhalation allergens increased disease activity was also observed (p<0.05) (fig. I). 
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Figure 2. (a) The relation between serum ECP and clinical severity as measured by SCORAD. Rank 
Spearman r$==0.254, p=0.15 (n.s.). (b) The relation between plasma levels of E~selectin and 
SeORAD. Rank Speanuan r,~ 0.6013, p<O.OOOS. 
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Similarly a positive correlation was found between the severity of disease and the RAST 
class for both food allergens (r,~0.39, p<0.05) and inhalation allergens (r,~0.33, p<0.05). 
Peripheral eosinophil concentrations were found to be increased (>5%) in 7(of 37) children 
and correlated with disease activity (r,~0.34, p<0.05). Serum levels of eosinophil cationic 
protein were increased in only 4 (of 34) children. These children had significantly more 
severe disease than children with nonnal levels of eosiuophil cationic protein (p<O.O I). 
However, when IDlalyzing the group as a whole, no significant correlation was found 
between eosinophil cationic protein and disease severity (r,~0.25, p>0.05) (fig.2a). 
sE-seleclin in plasma 
The mean plasma concentration of sE-selectin was 10.9 ± 14.3 nglml (mean ± SO). A 
significant correlation was found betwccn plasma Icvcls of sE-selectin and the SCORAO 
(r,~0.6, p<0.0005) (fig. 2b). Those children who had specific IgE for both food allergens and 
inhalation allergens had significantly higher levels of sE-selectin than those who had not 
(p<O.05) (fig. 3). Moreover sE-sclcctin levels correlated with the RAST class for food aller-
gens (r,~0.44, p<O.OI) and inhalation allergens (r,~0.33, p<0.05) respectively, but not with 
totallgE. 
When the levels of soluble E-selectin werc corrccted for SCORAO, a significant (p<0.05) 
positive correlation was observed between levels of sE-selectin and age. 
sICAM-I, sVCAM-I and sP-seleclin ill plasma 
The mean plasma concentrations of sICAM-I, sVCAM-I and sP-selectin were respectively 
253.7 ± 178.6 nglml, 870.5 ± 292.4 nglml and 109.6 ± 34.8 nglml (mean ± SO). A positive 
correlation was found between the levels of sP-selectin and sVCAM-l (,~0.45, p<0.005). 
However no significant correlations between these soluble adhesion molecules and 
SCORAD (sICAM-l r,~0.02, p>0.05; sVCAM-l r,~0.02, p>0.05; sP-selectill r,~0.14, 
p>0.05) were detected. 
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Figure 1. SeDRAD in children without specific IgE (RAST negative), with specific 19E for food 
allergens (RAST food), inhalation allergens (RAST inhalation) and for both food and inhalation 
allergens (RAST food, inhalation). Specific IgE was tested for cow's milk, egg, cat dander, house 
dust mite and grass pollen). For statistical analysis the Mann Whitney U test was used. 
Discussion 
The present study shows a significant correlation between the plasma levels of sE-selectin 
and the clinical severity of AD (SCORAD) in children. Such a correlation could not be 
demonstrated between SCORAD and the other adhesion molecules sICAM-I, sVCAM-I and 
sP-selectin. 
This finding agrees with a recent study in adults with AD, in which disease severity was 
found to correlate with sE-selectin but not with sICAM_I'o. In the same study clinical 
improvement was associated with a significant drop in sE-selectin levels. Other shldies 
involving adults found a similar correlation between disease severity and sE-selectinIO•14 • 
Contradicting reports have been published conceming the correlation between sICAM-I and 
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disease severity. Several studies reported a positive correlation of sICAM-1 with disease 
activityIO,ll,13 ,wllile others did not find such a correiation20 and one study even reported a 
negative correlation21 • Our data do not confirm a clear correlation between eosinophil 
E 
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Figure 3. Soluble EMselectin in children without specific IgE (RAST negative), with specific IgE for 
food allergens (RAST food), inhalation allergens (RAST inhalation) and for both food and 
inhalation allergens (RAST food, inhalation). Specific IgE was tested for cow's milk, egg, cat 
dander, hOllse dust mite and grass pollen). For statistical analysis the Mann Whitney U test was 
used. 
cationic protein (ECP) and disease severity as was reported by others. Although those 
children with increased levels of ECP had significantly more severe disease, there was no 
correlation between levels ofECP and disease severity in the whole group of patients. 
The observed discrepancies to other studies with respect to ECP and soluble ICAM-l may be 
explained by different study populations and different scoring systellls which were used to 
assess disease severity of AD. We included young children with mainly mild to moderate 
AD. This Illay be important because in acute AD exacerbations other adhesion molecules 
may be expressed than in mild to moderate chronic AD". Furthennore weak correlations 
betwcen disease severity and biological markers may only be detected when comparing mild 
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to severe AD. 
In addition the choice of the scoring system may influence the outcomes as well. The scoring 
system we used (SCORAD) is based on the consensus of the European Task Force on Atopic 
Dermatitis. TIlis system reflects acute and chronic components of disease activity, but shows 
a variability of more than 20%. 
Adhesion molecules are essential not only for the adhesion of leucocytes to endothelium but 
also for diapedesis and chemotaxis. They selectively bind particular leucocyte types. VCAM-
I adheres to its counterligand VLA-4 which is expresscd on eosinophils, basophils and 
lymphocytes but not on neutrophils". E-selectin promotes the selective migration of both 
CD4+ and CDS+ T cells expressing the cutancous lymphocyte antigen (CLA) which is a skin 
homing factor for CD4S+ RO+ memory-type T celll3. Furthennore E-selectin is involved in 
the recruitment of neutrophils and monocytes. The expression of adhesion molecules is con-
trolled by locally produced cytokines. 
Little is known of the function of soluble adhesion molecules. It has been suggested that rele-
ase 
of soluble adhesion molecules in the circulation, Illay have physiological implications, such 
as inhibition of adhesion by competition. Furthenuore they may act in a proinflammatory 
manner by chemoattraction and by activating leukocytes. 
Increased levels of soluble adhesion molecules (sICAM-I, sE-selectin) have been reported in 
. f d' 24 hr' . 25 I h t 25 a vanety 0 Iseases including asthma , rheumatoid art lhs , upus eryt ema osus , 
• • 14 d . C f I 26 psonasls an certallliorms 0 me anoma . 
Kinetics of the expression of soluble adhesion molecules may well be of relevance in the 
chance to be detectable as a marker of disease. The rates of release and clearance, as well as 
binding, reflected by blood concentration-time curves, will partly detennine the applicability 
of these levels to reflect a localised disease process. While no in vivo data are available, 
interesting differences were described in vitro between the kinetics of sICAM-l and sE-
selectin'. After stimulation of endothelial cells with IL-I and TNF, sE-selectin levels were 
maximal after 6 to 12 hours and dropped below detection limit after 24 hours. In contrast 
sICAM-I gradually increased over a period of24 hours and remained stable for 3 days. 
In vivo the expression ofVCAM-I and ICAM-l was found to be significantly increased in 
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nonlesional atopic skin in comparison to the skin of nonnal individuals27• Thus, VCAM-l 
and ICAM-l were upregulated even in nonaffected skin of patients with AD while E-selectin 
was detected exclusively in affected skin. Tlus indicates a lugher specificity of E-selectin for 
affected skin and may explain why soluble E-selectin is a better indicator of disease severity. 
In conclusion this is the first report to show that in cluldren with mainly mild to moderate 
AD, sE-selectin correlates best with the SCORAD, as an indicator of the severity of disease. 
Although sE-selectin is not specific for AD, it reflects disease activity aud may be a reliable 
laboratory marker. 
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Abstract 
Background: TIle expression of adhesion molecules is upregulated in the skin of atopic 
dennatitis (AD) patients, and the levels of the soluble adhesion molecules sE-selectin and 
sICAM-I have been reported to reflect the endothelial activation in the skin of AD patients. 
Objective: To investigate the relationship between symptom score and levels of sE-selectin, 
sICAM-I and sVCAM-I before and after two weeks oftreatment. 
Methods: Eighteen children with an exacerbation of AD were admitted and treated with 
corticosteroid dilutions under occlusive wet dressings (wet wrap treatment). Symptom score 
(objective SCORAD) and levels ofsE-selectin, sICAM-I, and sVCAM-I were assessed before 
and after two weeks of treatment. 
Results: A significant correlation between the objective SCORAD before treatment and the 
level of sE-selectin (p<0.05), but not the level of sICAM-I (p~0.7) or sVCAM-I (p~O.5) 
were observed. The treatment resulted in a high degree of remission, which was reflected by 
a significant decrease in the level of sICAM-l (p<O.OI), whereas there was a trend in the 
level of sE-selectin to decrease (p~0.08). Most importantly, the level of sE-selectin after 2 
weeks of treatment still correlated significantly with the SCORAD at the beginning (p 
<0.005). 
Conclusion: Soluble E-selectin is a good marker for the severity of AD. However, it does not 
reflect acute changes in the symptom scores, but may be useful as a marker for the IOllg-tenn 
activity of AD. 
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Introduction 
Atopic dermatitis is a common chronically relapsing inflammatory skin disease affecting 8.9-
20.4% of those born after 1970. 1 Research on the underlying mechanism of AD requires a 
reproducible system to score the activity of AD. The limitations of a clinical scoring system 
based on evaluation ofsymptom.s are the need for dermatological training of the investigator, 
and the intra- and interobserver variability, which may account for variations of up to 60% 
depending on the investigator and the scoring system.2 Another drawback of such a system is 
that it represents a snapshot of the activity of AD. The typical fluctuations in the severity of 
symptoms with spontaneous exacerbations and remissions during a short period of time may 
make it difficult to find the relation between symptom scores and underlying stable immune 
deviations. Therefore, an objective marker, which reflects a prolonged period of disease 
activity, may improve investigations into the pathogenic mechanisms in AD. 
Different semm parameters have been reported to reflect the inflanullation in AD. Total senun 
IgE is increased in about 80% of the patients with AD, but is only loosely associated with the 
severity of AD3. Eosinophil cationic protein (ECP - a marker for eosinophil activation), soluble 
IL-2 receptor and soluble CDI4 (a marker for monocytes) reflect distinct components of the 
inflammation in AD and have been reported to correlate with the clinical severity of AD.4"; 
Recently, soluble adhesion molecules were proposed as markers of disease activity in AD.7. 
13 The adhesion molecules E-selectin, intercellular adhesion molecule-I (ICAM-I) and 
vascular cell adhesion molecule-l (VCAM-l) are increased in acute and chronic skin lesions 
in ADI'. The serum levels ofsE-seleetin and sICAM-I released from endothelial cells were 
observed to correlate directly with the cell surface expression in vitro. IS Thus, the levels of 
sICAM-I and sE-selectin may reflect the intensity of the inflammation as well as the extent 
of skin involvement in AD. \Ve have previously reported a correlation between the level of 
sE-selectin and the severity of disease as measured by objective SCORAD. 16-17 Whereas a 
large number of studies have established the relation between symptom score and the level 
of sE-selectin, conflicting results have been reported on the applicability of sE-selectin for 
monitoring the effect oftreatment. 11 . 13 WillIe Kagi et al" reported a significant decrease in 
sE-selectin levels after 16 weeks of treatment with cyclosporin A (4-4.5 mglkg) 
Halmerbauer et al 18 reported no significant decrcase of sE-selectin after 4 days of treatment 
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with systemic corticosteroids. The aim of the present study was to investigate whether the 
levels of sE-selectin, sICAM-1 and sVCAM-1 reflect the severity of AD and the clinical 
improvement of AD after 2 weeks of treatment in children with severe AD. 
Methods 
Patients and design 
Eighteen children aged 4 months to 9 years with AD'9.20 were included. All patients had AD 
resistant to conventional therapy as outlined in guidelines21 . At the moment of inclusion, 
disease severity was severe in 16 of the patients and moderate in 2 of the patients as judged 
by objective SCORAD22. Patients were treated according to the modified wet-wrap protocol 
as previously described23 . The initial wet-wrap protocol was described by Goodyear et af4 as 
a treatment that results in remissions after only 3 to 5 days in severe generalized AD. Briefly, 
patients were admitted to the hospital for at least I week and treated once daily with a 
diluted corticosteroid (fluticasone propionate cream 0.05%) on the whole body under 
occlusive wet dressings (tubifast). All patients were treated according to the described 
protocol for 2 weeks. Other treatments for AD except antihistamines were stopped. The 
severity of AD was assessed by SCORAD at the beginning and at the end of the treatment. 
Clinical scoring system 
The severity of disease lVas scored using the objective SCORAD22 which includes the 
assessment of two items in a standardised manner: a) extent (applying the rule of nine) and 
b) intensity (erythema, oedema/papulation, oozing/cmst, excoriation, lichenification and 
dryness on a scale from 0 to 3). This scoring system reflects the modified consensus of the 
European Task Force on Atopic Dermatitis. Unlike the initial version called SCORAD 
index,25 SUbjective symptoms were not included in the scoring of AD.22,26 
Delel'lI/illalion olsE-seleclin, sICAM-! and sVCAM-1 
Sennn was harvested from venous blood and stored at -20'C. Levels of sE-selectin (HBT, 
Uden, The Netherlands), sICAM-1 and sVCAM-1 were determined in the sera using a 
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commercially available ELlSA kit (Bio Source Fleurus, Belgium). ELlSA procedures were 
performed according to the manufacturees instructions. The levels ofsE-selectin, sICAM-l 
and sVCAM-I were expressed in nglm!. The detection limits of these ELlSA assays were 
l.0 pglml for sICAM-I, 2.0 pglml for sVCAM-I and 2.0 pglml for sE-seleetin. 
Safety analysis 
To determine the systemic load of the topical medication, we assessed the hypothalamie-
pituitary-adrenal (HPA) axis suppression. Levels of9 a.m. serum cortisol were detennined at 
the beginning (baseline) and at the end of the treatment period. Local side effects were 
assessed by visual inspection. 
Statistical analysis 
Statistical analysis was performed with SPSS 7.5 using the Wilcoxon rank sum test to assess 
differences in the levels ofsE-selectin, sICAM-I and sVCAM-I at the begimling and at the 
end of the treatment. The Speanllan rank correlation was used to test monotonic 
relationships between the SCORAD and the levels ofsE-seleetin, sICAM-I and sVCAM-l. 
Statistical significance was defined as p<O.OS. 
Figure 1. 
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Graph showing the objective SCORAD at the beginning and after 2 weeks of treatment. 
The change in objective SCORAD was assessed by Wilcoxon rank sum test (p<O.OOO I). 
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Results 
First, we examined the efficacy and safety of the wet wrap treatment. For evaluation of the 
efficacy, the objective SCORAD at the begilming and after 2 weeks of the treatment were 
compared and are shown in Figure 1. There was a significant decrease in both the intensity 
and the extent of AD as reflected in the objective SCORAD after 2 weeks of treatment 
(p<O.OOO I). The severity of AD classified into mild, moderate and severe according to the 
objective SCORAD decreased in all of the children after 2 wceks of treatment (Fable J). One 
child was lost to follow-up due to personal reasons. The improvement in AD was most 
prominent in children with the highest objective SCORAD before treatment. For the 
evaluation of the safety, we assessed the levels of9 a.m. serum cortisol at the beginning and 
after 2 weeks of the treatment. Serum cortisol levels were temporarily below the Bonnal 
range (0.2-0.8 VII) in 3 out of 18 children aftcr 2 weeks, indicating a suppression ofthc HPA 
axis. These results demonstrated that in our study population the wet wrap was highly 
effective in reducing the severity of AD. 
Table I 
Classification of children according to diseases severity 
before and after wet wrap treatment 
B~rol'e A/tel' treatment 
treatment 11= 18 N~17 
Mild AD 0 II 
Moderate AD 2 6 
Severe AD 16 0 
Mild AD: objective SCORAD n 15 
Moderate AD: objective SCORAD 15-40 
Severe AD: objective SCORAD U40 
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To investigate whether the serum levels of soluble adhesion molecules reflected the 
improvement of AD, we compared the levels ofsE-selectin, sICAM-I and sVCAM-1 at the 
beginning and after 2 weeks of the treatment. Although there was a trend for the levels of sE-
selectin to decrease after treatment, statistical significance was not reached in this period 
(p~O.08) (Figure 2A). The serum levels of siC AM-I (Figure 2E) were significantly reduced 
after treatment (p<O.OI), whereas the levels of sVCAM-1 (Figure 2e) did not change 
significantly after treatment (p~O.5). These results indicated that the marked improvement in 
AD was only reflected by the decreased level of sICAM-I, but not by the levels of sE-
select in or sVCAM-1. 
Next, we investigated whether the serum level of soluble adhesion molecules reflected the 
severity of AD at the time of blood sampling. The levels of sE-selectin, sICAM-I, and 
sVCAM-1 were compared with the objective SCORAD. A significant correlation between 
the objective SCORAD and the level of sE-selectin was noted (pO.54; p<O.05) (Figure 3A), 
while no correlation was observed with the levels ofsICAM-\ (r~-O.\2; p~O.7) or sVCAM-l 
(p-O.17; p~O.5). After 2 weeks of treatment, a negative relationship between the level of sE-
selectin and objective SCORAD was noted (Figure 3E). This resulted from the observed 
higher efficacy of the treatment in children with more severe AD and higher levels of sE-
selectin at the begiIming as compared to the children with less severe AD at the begiIming 
(Rank Spearman correlation between objective SCORAD at the beginning and the decrease 
in SCORAD during treatment: pO.79; p<O.0005). 
Figure 2. 
Graph showing the levels of soluble adhesion molecules at the beginning and after 2 weeks of 
treatment. A) sE-selectin did not change significantly (p=O.08). B) sICAM-I decreased significantly 
(p<O.OI). C) sVCAM-l did not change significantly (p~O.s). 
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Figure 3. 
A) Relationship between objective SCORAD and levels of sE-selectin at the beginning of the 
treatment (Rank Speannan's correlation: r=0.54, p<0.05). B) Relationship between objective 
SCORAD and levels of sE-selectin after 2 weeks of treatment (Rank Spearman's correlation: r=-
0.52. p<0.05). 
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Figure 4. 
Relationship between objective SCORAD at the beginning and levels of sE·selectin after 2 weeks of 
treatment (Rank Spearman' correlation: r-0.53, p<0.05) 
Most importantly, the level of sE-seleetin after 2 weeks of treatment still correlated 
significantly with the SCORAD at the beginning (1""'0.53; p<0.05) (Figure 4). Thus, while 
the severity of AD had dramatically decreased, the initial severity of disease was still 
reflected by the level of sE-seleetin after 2 weeks. Furthermore, we noticed that children 
with high levels 
of sE-selectin at the beginning tended to have high levels of sE-selectin after treatment as 
well (1""'0.45; (p0.09) (figure 5). 
Six children had asthma diagnosed by a physician of whom three children had current 
asthma medication with inhalation corticosteroids, but none of the children had current 
wheezing. There was no significant difference in the levels of sE-selectin, sICAM-l and 
sVCAM-l between the children with and without a diagnosis of asthma (p>0.05). 
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Figure 5. 
Relationship between the levels of sE-selectin at the beginning and after 2 weeks of treatment (Rank 
Spearman's correlation: r=0.45, p=O.09). 
Discussion 
The results of the present study indicate that sE-selectin is a marker of long-term activity of 
atopic dermatitis (AD), whereas sICAM-I reflects short-tenn changes in the activity of AD. 
In contrast, sVCAM-l was not related with the severity of AD. In agreement with the results 
of previous studies from our groupl6,17 and others7,11-13,27 we observed a clear correlation 
between the objective SCORAD and the levels of sE-selectin at the beginning of the 
treatment. We hypothesized that the treatment, which caused a dramatic improvement in the 
symptoms of up to 90%, would result in a profound decrease in the levels of sE-selectin. 
However, we failed to notice a significant decrease in the levels of sE-selectin. This was 
unexpected because the change in symptom score caused by the treatment was much higher 
than the variation in the symptom score at the begiIming. 
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Table II 
Longitudinal studies on the change in the levels of 
sE-selectin by treatment of AD 
intel'venliOJI 
Cyclosporin A 
4-4.5mg/kg 
Topical 
corticosteroidsl2 
Topical 
corticostcroidsI3 
Systemic 
corticosteroids's 
Not s ecified27 
Period 
between 
measurements 
of sE-selectill 
16 weeks 
2-5 weeks 
4 weeks 
4 days 
Not s ecified 
Change in level 
of sE-selectill 
1'<0.0001 
1'<0.05 
1'<0.01 
Not significant 
1'<0.01 
Most importantly, we observed that the levels of sE-selectin after 2 weeks of sllccessfbl 
treatment still correlated with the objective SCOI{AD at the start of the treatment. Taken 
together, these results indicated that the serum levels of sE-selectin reflect the severity of AD 
during periods of longer than 2 weeks and arc not influenced by acute fluctuations in the 
severity of disease. According to this finding, the seemingly conflicting results from 
previous longihldinal studies on sE-selectin can be explained (Table JJ). Kagi et al,II Czech 
et al,I2 and Furue et all) reported a significant decrease ofsEMselectin levels after 16 weeks, 
2-5 weeks, and 4 weeks of treatment, respectively. In contrast, there was no signiticant 
decrease in sE-sclectin after 2 weeks of treatment in our study or 4 days of treatmcnt in the 
study by Halmerhauer et a1. 18 Noteworthy, conventional treatment with topical steroids 
significantly decreased sEMselectin levels if measured after more than 2 weeks,ll-13 whereas 
even highly effective therapies associated with a major improvement in AD (systemic 
corticosteroids,18 potent corticosteroids under occlusion). did not significantly decrease sE-
selectin levels during the first 2 weeks oftreatment. 
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Thus we propose sE-sclectin as a marker of long-term activity of AD and demonstrate that 
the levels of sE-selectin after 2 weeks of successful treatment still reflect the original 
symptom score, despite major clinical improvement. \Ve can only speculate on the 
underlying mechanisms of this finding, since little is known on the mechanisms of clearance 
and half-life of soluble adhesion molecules. Kinetics of the expression of soluble adhesion 
molecules may well be of relevance for detection as a marker of disease. The rates of release, 
binding and clearance reflected by blood concentration-time curves will partly detennine the 
applicability of such levels in reflecting a localized disease process. After stimulation of 
endothelial cells with IL-I and TNF-u in vitro, the levels ofsE-selectin reached a maximum 
after 6 to 12 hours and dropped below detection limit after 24 hours. IS In contrast, sICAM-\ 
gradually increased over a period of 24 hours and remained stable for 3 days. Thus, the 
production and release rate of sE-selectin does not explain our finding of sE-selcctin as a 
marker oflong-tenn activity of AD. However, differences in binding and clearance between 
sICAM-l and sE-selectin may explain our observations. 
In agreement with previous studies,7,s we noted a significant decrease in the levels of 
sICAM-1 after treatment, whereas we failed to show any correlation between the severity of 
AD before treatment and the levels ofsICAM-\ before treatment. We do not know why the 
severity of disease at the beginning was only reflected by the levels of sE-selectin, because 
sVCAM-\ and sICAM-\ expression is also increased in lesional skin. One possible 
explanation is that ICAM-I and VCAM-l are constitutively expressed in normal skin and 
healthy appearing skin in patients with AD, whereas sE-selectin was only found in lesional 
skin. 14 Furthermore, sE-selectin expression is restricted to endothelial cells, whereas sleAM-
I and sVCAM-I are expressed on other cell types as well. This indicates a higher specificity 
of E-selectin for affected skin and may explain why soluble E-selectin is a better indicator of 
disease severity in AD. However, E-sclectin is not specific for AD and increased expression 
has been reported in psoriasis as well. 12 
Adhesion molecules have a cmcial role in the migration of leukocytes. Membrane-bound ad-
hesion molecules are glycoproteins, which mediate the attachment of leukocytes to 
endothelial cells thereby controlling migration. E-selectin and P-selectin mediate the first at-
tachment of the leukocytes to the endothelial layer resulting in rolling along the endothelium. 
This weak binding, however, promotes stronger interactions between ICAM-I and VCAM-\ 
124 
Soluble adhesion molecules as markers in atopic dermatitis 
on the endothelium and their leukocyte surface ligands; lymphocyte function associated 
antigen-l (LFA-I) and very late antigen-4 (VLA-4), respectively." 
E-selectin seems to have a critical role in allergic inflammation as it promotes the selective 
migration of both CD4+ and CD8+ T cells expressing the cutaneous lymphocyte antigen 
(CLA), which is a skin homing factor for CD45+ RO+ memory-type T cells.'9~o 
Adhesion molecules are rapidly upregulated on both endothelial cells and leukocytes upon 
exposure to cytokines such as interleukin-l (IL-I), tumor necrosis factor-a (TNF-a) and 
interleukin-4 (lL-4)." Increased expression ofiCAM-I, VCAM-I and E-selectin have been 
demonstrated in skin biopsies from chronic and acute AD lesions. 14,31 Six hours after intra-
dermal allergen injection to sensitised individuals, enhanced expression ofiCAM-I and E-
selectin was found in affected skin.32 The soluble foon of the adhesion molecules, sE-selec-
tin, sP-selectin, sICAM-I and sVCAM-I originates from membrane bound molecules due to 
shedding or proteolytic cleavage.33 
Little is known on the function of soluble adhesion molecules. It has been suggested that so-
luble adhesion molecules may have physiological implications, such as inhibition of adhe-
sion by competitive binding. In contrast, it was also suggested that they may act in a 
proinfiammatory maimer by chemoattraction and by activating leukocytes.34 
In conclusion, we advocate to use both a clinically based scoring system, such as the 
objective SCORAD and soluble E-selectin as an objective marker of the long-teml activity 
of AD in studies on the pathogenic mechanisms of AD. Furtheonore, the kinetics of soluble 
E-selectin has to be considered in the interpretation of the results. 
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Abstract 
Assessment of the capacity of inullunocompetent cells to produce IL-4 and IFN-y requires a 
multistep procedure consisting of cell isolation (PBMC), stimulation culure and analysis of 
cytokine levels in supernatauts, The DynaMIX DIA kit uses whole blood and combines cell 
stimulation and cytokine trapping by catching antibodies in a simple one-well fonnat, In the 
present study lL-4 and IFN-y production were investigated in both stimulated peripheral 
blood mononuclear cells (by Medgenix Screening Line ELISA) and in whole blood cell 
cultures (by DynaMIX DIA kit) in 12 children with atopic dennatitis (AD), Optimal culture 
conditions were established and the IL-4 and IFN-y production were correlated to the 
severity of AD and the levels of soluble E-selectin and ICAM-l. No significant correlation 
was found in the cytokine production between the assessment using Screening Line ELISA 
and DynaMIX DIA kit. 
IL-4 production by PBMC was correlated to the severity of AD (Rank Spearman's 
correlation: [='0,93; p<0,0005) while IFN-y production was not. IL-4 and IFN-y production 
in whole blood were not correlated to the severity of AD, which may be due to suboptimal 
culture conditions. Our data show that stimulation with Ca-ionophore and PMA in Yssel's 
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medium resulted in production levels of IL-4 and IFN-y which were higher than stimulation 
with PHA in RPMI, while retaining a similar sensitivity and specificity compared to 
stimulation ofPBMC using the Medgenix Screening Line ELISA. 
Soluble E-selectin was correlated to the severity of disease (FO.96; p<O.OOS) and to the IL-4 
production in PBMC (FO.99; p<O.OS) . 
We conclude that when incorporating the culture and stimulation conditions we present here 
(Ca-ionophore and PMA in Yssel's medium) the DynaMIX D1A kit can be used effectively 
for cytokine analysis in children suffering from AD. 
Introduction 
Atopic diseases are general1y considered to be the resultant of an aberrant cytokine synthesis 
in genetically predisposed individuals in response to exposure to common allergens. 
Importantly, the Thl-Th2 paradigm has been used to explain this cytokine dysbalanee [I, 2] 
as a direct consequence of an excessive number and/or activation state of Th2 type cells, 
mainly characterized by the predominant production ofIL-4, IL-S, IL-IO and IL-13 [3,4, S]. 
Thl type cells, producing IFN-y, are suggested to restore this balance due to crossregulation 
on the Th2 activity [6]. IL-4- and IL-13-dependent serum IgE levels are increased in 80 to 
8S% of all patients with AD [7, 8] with the highest concentrations when allergic asthma and 
rhinitis coexist [9]. The skin lesions of AD are characterized by a chronic inflammation 
involving mast cells, eosinophils and T lymphocytes. The accumulation of these 
inflanunatory cells is a consequence of the upregulation of endothelial adhesion molecules 
[10], Increased expression of endothelial adhesion molecules, like intercellular adhesion 
molecule-I (ICAM-I) and E-selectin have been demonstrated in skin biopsies from chronic 
and acute AD lesions [II, 12]. As a result of shedding or proteol)1ic cleavage soluble 
adhesion molecules are present in the circulation. We have found a positive correlation 
between the serum levels of soluble E-selectin and the severity of AD in children [13, 14]. 
The severity of AD can be measured by using the SCORing Atopic Dermatitis (SCORAD) 
system, which reflects the consensus of the European Task Force on Atopic Dermatitis [IS-
17]. Various studies have tried to correlate the severity of AD to the activity of Th2 type 
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cells or Thl type cells by measuring IL-4, IFN-y or lL-13 mR1~A expression and protein 
production levels by peripheral blood mononuclear cells (PBMC) [I8, 19, 20]. Generally 
such a simple correlation does not exist, probably due to the very low production rate and 
low precursor frequency of IL-4 (or IL-13) producing cells. Furthermore the Thl/Th2 
paradigm has been questioned [21,22] and Thl type cells and related cytokines too have 
been shown to be important in atopic dennatitis. In lesional skin of atopic dermatitis 
increased expression of lFN-y has been demonstrated [23-25]. Several studies support a 
biphasic model with IL-4 being responsible for the initiation of allergic skin reactions 
whereas IL-5 and IFN-y predominate in chronic AD lesions and in late phase allergic skin 
reactions [23-26]. 
In order to further investigate the ThlfTh2 balance in children suffering from AD, we 
analysed the production of lL-4 and lFN-y in stimulated peripheral blood mononuclear cells 
and compared this with whole blood cell cultures. Furthermore optimal culture conditions 
were established and the lL-4 and lFN-y production was correlated to the severity of AD, the 
levels oftotallgE, and the levels of soluble E-selectin and lCAM-l. 
Materials and methods 
Patients 
Twelve children (age 15 to 32 months) with AD according to the criteria of Hanifin and 
Raijka [27] were included. After informed consent peripheral blood was obtained. Severity 
of AD was severe (SCORAD>40) in I child, moderate (SCORAD 15-40) in 2 and mild 
(SCORAD<15) in 9 children according to the objective SCORAD [16]. Eight children used 
topical corticosteroids and I or systemic antihistamines as treatment of AD. None of the 
children had asthma or any other chronic disease. The local Ethical Conmlittee approved this 
study. 
Clinical scoring system 
The severity of disease was scored using the objective SCORAD [16, 17] which includes lhe 
assessment of two items in a standardised manner: a) extent (applying the rule of nine) and 
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b) intensity (erythema, edema/papulation, oozing/crust, excoriation, lichenification and 
dryness on a scale from 0 to 3), Tills scoring system reflects the consensus of the European 
Task Force on Atopic Dermatitis [IS]. 
Determination of soluble adhesion molecules 
sE-selectin and sICAM-I were measured in plasma by ELISA as described previously [13]. 
Briefly, 96-wells microtitre plates were coated with monoclonal antibodies to sICAM-I 
(HM.2, 3 Ilg/ml) or sE-selectin (ENA I, 10 Ilg/ml) in phosphate-buffered saline (PBS) fol-
lowed by saturation with I % bovine semm albumin. Standard or diluted samples were added 
in 100 IlVwell. After two hours at room temperature, the plates were washed and incubated 
for one hour with biotin labelled anti-ICAM-I or anti-E-selectin monoclonal antibodies. All 
antibodies were a kind gift of dr. W.A. Buurman (University of Maastricht, The 
Netherlands). After washing streptavidin-conjugated peroxidase was added. Peroxidase acti-
vity was detemlined by addition of 2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid) 
(ABTS). The reaction was stopped with H2S04 and read at 414 IUn. The concentration of 
sICAM-I and sE-selectin were detemlined by interpolation from the standard curve. The 
detection limits of these ELISA assays were 4.0 pg/ml for sICAM-I and 2.0 pg/ml for sE-
selectin. sVCAM-l was measured in plasma by a similar procedure using a commercially 
available test kit (R&D Systems Europe, Abbigdon, UK) 
Total IgE was determined by CAP system (Phannacia Upjohn, Uppsala, Sweden). 
Culture conditions 
Whole blood cells were cultured using the DynaMIX DIA kit according to the 
manufacturer's instmctions (Medgenix Diagnostics, Fleums, Belgium). Briefly, 25 !II of 
whole blood was diluted in 200 III of RPMI medium supplemented with 
phytohemagglutinine (PHA, 10 Ilglml) and incubated for 24 hours (both for IL-4 and IFNy) 
at 37"C. Alternatively, peripheral blood mononuclear cells (PBMC) were isolated from 
heparinised venous blood by density gradient centrifugation on Ficol-Hypaque (pharmacia) 
[3]. 
Staining whole blood and isolated PBMC with anti-CD3 (Leu4) monoclonal antibodies and 
subsequent FACscan analysis permitted detennination of the relative amount of T cells. 
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Equal concentrations of T cells were cultured for 24 hours by stimulation with Ca-ionophore 
(1 llglml; a23187, Sigma, St. Louis MO, USA) and phorbol-12-myristate-I3 acetate (PMA, 
2nglml; Sigma) in Yssel's medium (YM) [3,4]. Moreover, reciprocal stimulation conditions 
were also investigated by using Ca-ionophore and PMA in Yssel's medium in the DynaMIX 
DIA kit and by stimulating PBMC with RPMI supplemented with PHA. Furthennore, the 
cytokine production of PBMC with or without stimulation by PHA was analysed in cultures 
with RPMI-1640 (used in our laboratory), RPM! supplied in the DynaMIX DIA kit, or 
Yssel's medium. 
Assay for lL-4 and IFN-y 
In the conventional ELISA assay levels of ILA and IFN-y were determined in the 
supernatants by Screening Line ELISA kits (Medgenix Diagnostics SA) according to the 
manufacturer's instrnctions. The lower detection limit was 30 pglml for IFN-y and 3 pglml 
for IL-4. 
In the DynaMIX DIA kit IL-4 and IFN-y are captured on the surface of microtiter plates that 
are coated with specific monoclonal antibodies directed against the cytokine [28, 29]. 
Subsequent to the removal of the supernatant, the captured cytokine can be detected by a 
specific anti-cytokine peroxidase-labeled monoclonal antibody and tetramethylbenzidine 
(TMB), quantified by a spectrophotometer at 450 and 490 run. The lower detection limit was 
2 pglml for IL-4 and I pglml for IFN-y. 
Statistics 
Statistical analyses were perfonned with SPSS 6.1. Non-parametric data were tested using 
the Mann-Whitney test. SCORAD, sE-selectin, sICAM-I, IL-4 and lNF-y production were 
correlated by using the Rank Speannan's cOlTelation coefficient. In either test, P values less 
than 0.05 were considered significant. 
135 
Chapter 4.3 
Results 
Cullure conditions 
Stimulation experiments were performed under several different culture conditions. 
Stimulation was perfonned on whole blood cells (WBC) diluted in RPMI medium 
supplemented with PHA and on PBMC diluted in Yssel's medium and supplemented with 
PMA and Ca-ionophore. Moreover, reciprocal stimulation conditions were also assayed by 
using Ca-ionophore and PMA in Yssel's medium in the D1A kit and by stimulating PBMC 
with RPMI supplemented with PHA. 
Table I Cytokine production in stimulated whole blood cells (WBC) and PBMC 
WBC(DlA) PBMC(DIA) PBMC(ELISA 
IFN-y 
(pg/ml) 
RPMI <I <I <I 
RPMI+PHA 1l±2.4 <I <I 
YM <I 1.4±O.6 <I 
YM+CalPM 2.7±1.2 13±3.4 97.5±12.9 
A 
IL-4 (pg/ml) 
RPMI <2 <2 <2 
RPMI+PHA 21.5±4.9 <2 <2 
YM 16±3.8 <2 15.5±2.8 
YM+CalPM 90.5±14.1 50±12.3 95±16.7 
A 
Cultures were perfonned with whole blood cells (WBC) and isolated peripheral blood mononuclear 
cells (PBMC) cultured for 24 hours in RPMI-1640 and YM culture media. Stimulation was 
performed either with PHA or with Ca-ionophore plus PMA. DIA refers to stimulation and ELISA in 
DynaMIX kits, while ELISA refers to stimulation in culture plates and assaying of culture 
slipematants in separate ELISA plates. Representative results of one out of 4 experiments are shown. 
Cytokine production was measured in screening line ELISA and levels of 1L-4 and IFN-y are 
expressed in pglml (11=4; mean ± I SD). 
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The results (table I) suggested that in both assay fonnats using WBC or PBMC stimulation 
with Ca~ionophore and PMA in combination with Yssels's medium were superior in the 
production ofIL-4 and IFN-y as compared with stimulation by PHA in RPM!. Stimulation of 
whole blood by Ca-ionophore and PMA in Yssel's medium revealed similar levels of 
cytokines as compared to stimulation of WBC in RPMI supplemented with PHA as provided 
in the DIA kit. Cultures of PBMC stimulated by PHA in RPMI appeared to be less viable 
when compared to cultures in Yssel's medium (data not shown). 
The effect of different culture conditions on PHA-induced cytokine production of PBMC 
cultured for 24 hours is shown in table 2. Thcse results demonstrated that stimulation by 
PHA induced higher production levels of IL-4 and IFN-y when used in combination with 
Yssel's medium. The use of RPM I from either source did not result in detectable increases in 
cytokine production after stimulation. 
Table 2 Influence of PHA stimulation and culture medium on cytokine production. 
IL-4 IFN-
RPMI 
RPMI'+PHA 
67 81 
91.4 100 
RPMI' <3 
Rl'MI*+PHA <3 
YM <3 
YM+PHA 19.9 
71 
85 
17 
1242 
All cultures were performed with isolated PBMC cultured for 24 hours. Representative results of one 
out of 4 experiments are shown. Cytokine production was measured in Screening Line ELISA and 
levels of IL-4 and IFN-y are expressed in pglml (11=4; mean ±ISD). RPMI# refers to RPMI~1640 
while RPMI*' refers to the RPMI supplied in the DynaMIX DIA kit. The source of PHA is identical 
and is used at 1O~g!ml. 
Comparison of assays 
For comparison of the quantitative determinations ofIL-4 and IFN-y by DymaMIX DIA kit 
and by Screening Line ELISA the supplied cytokine standards were used. In the 
conventional ELISA assay two-fold dilutions of Yssel's medium starting at 500, 250, 125, 
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63.5,31.25 and 16 pg/ ml IFN-y and the DynaMIX DIA kit standard of 160,80,40,20 and 0 
pg/ml IFN-y from Medgenix were tested. The sensitivity of this ELISA for both IFN-y 
standards was identical both in detection limit of the assay (l pg/ml) and in fitting 
parameters of the standard curve according to the 4-parameter log/Iogit transformation 
(Figure I, upper panel). Based on the two standard curves the specific activity of the IFN-y 
standard was calculated to be 8.25 x 10 8 U/mg. 
Similar experiments were performed for IL-4 using the Medgenix Screening Line ELISA 
standard. (Figure I, lower panel). In the conventional ELISA assay two-fold dilutions of 
Yssel's medium starting at 1125,500,250,125,63.5,31.25,15.63 and 0 pg/ml of the of the 
IL-4 standard from Medgenix were tested. In this ELISA also the DynaMIX DIA kit IL-4 
standard of 1125, 500, 425, 375, 90, 80, 60, 40 and 0 pg/ml was applied in Yssel's medium. 
The sensitivity of this ELISA for both IL-4 standards was identical both in detection limit of 
thc assay (2 pg/ml) and in fitting parameters of the standard curve according to the 4-
parameter log/Iogit transformation (Figure I, lower panel). 
The use of the DIA kit permits the storing at -20°C of the sanlples afier stimulation and 
before further analysis. Direct analysis offreshly diluted standards for IL-4 and IFN-y versus 
analysis of frozen samples revealed similar standard curves (Figure 2). 
Cy/okille allalysis o[bloodji'Olli al/ergic chi/drell 
Whole blood and purified PBMC obtained from children suffering from AD and healthy 
control children were analysed using the various culture conditions for the levels of IL-4 and 
IFN-y production after stimulation (Figure 3). The cytokine production levels in 
unstimulated cultures were below detection level except in one patient who had high 
spontaneous production of both IL-4 and IFN-y in unstimulated conditions. This was the 
only patient with severe and widespread AD and an objective SCORAD of 49. The IL-4 
levels produced by PBMC stimulated by Ca-ionophore and PMA in YM in the DIA kit 
fonna! correlated significantly with the total IgE levels in the sera of these children (Figure 
4), while the IL-4 levels as determined by analysing whole blood in the DIA kit (stimulated 
with PHA in RPM!) did not correlate with the total IgE levels (data not shown). 
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ELISA results perfonned on IL-4 (upper panel) and IFN~y (lower panel) standards lIsed in ELISA 
and DyllaMIX DIA kits. Dilutions of available IL~4 and IFN-y standard preparations present in the 
ELISA kit (Medgenix Screening Line) and in the D)'naMIX IL-4 and IFN-y DIA kit (Medgcnix) 
were made in YM and tested in a routine ELISA resulting in ODmnm readings after 90 min. 
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after frozen storage. Various dilutions of standards were freshly tested (fresh), or after freezing and 
immediate thawing (frozen I), or freezing and subsequent storage of two weeks before thawing and 
testing (frozen 2). All samples were tested in ELSIA and results are presented as OD4SOnm versus 
dilutions. 
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Figure 3 
Cytokine production (JL~4 and IFN~y) after polyclonal stimulation of isolated PBMC stimulated with 
Ca~ionophore and PlvlA in YM in DynaMIX DIA kit (PMA), stimulation of whole blood with PHA 
in RPMI in the DynaMIX DIA kit (PHA), or stimulation ofPBMC with Ca~ionophore and PMA and 
analysing the culture supernatant by regular ELISA (PMAIELISA). Blood was obtained from all 12 
allergic children suffering from AD that were included in this study. The results are expressed in 
nglml and represent the mean and SD of 4 independent experiments. 
When comparing the cytokine production between the Screening Line ELISA and the 
DynaMIX DlA kit no significant correlation was found (IL-4: FO.046 p~0.8; IFN-y: FO.34 
~0.3) (data not shown). 
IL-4 production by PBMC (Screening Line ELISA) was correlated to the severity of AD 
(Rank Spearman's correlation: FO.93; p<0.05) (Figure 5), while IFN-y production was 1I0t 
(data not shown). IL-4 and IFN-y production in whole blood (DynaMIX D1A kit) were not 
correlated to the objective SCORAD (IL-4: FOAl; IFN-y: FO.81, p~0.55; Figure 6). 
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Relationship between total IgE levels in the scnllll (in IU/ml) of the allergic children included in this 
study (11=12) and the IL-4 production. IL-4 production in PBMe stimulated with Ca-ionophorc and 
PMA in YM lIsing the DynaMIX DIA kit and expressed in pg/ml. 
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Figure 5 
Relation between IL-4 production and severity of AD as measured by SCORAD. IL-4 production in 
PBMC stimulated with Ca-ionophore and PMA in YM using the DynaMIX DIA kit. The figure 
shows the relation between JL-4 production and objective SCORAD in 12 children with AD (Rank 
Speannan's correlation: FO.95; p<0.05). 
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Relation between IL-4 production (upper panel) and IFN-y production (lower panel) with the severity 
of AD as measured by SCORAD, IL-4 and IFN-y production in PBMC stimulated with Ca-
ionophore and PMA in YM using the DynaMIX DIA kit. The figure shows the relation between 
eytokine production and objective SCORAD in 12 children with AD. 
Levels of sE-seleclin and s[CAM-J 
Figure 7 shows the relation between the levels of sE-selectin and the severity of AD (Rank 
Speanllan'correlation: t=0.96; p<0.05). The levels of sICAM-I were not significantly 
correlated to the objective SCORAD. Furthermore we found a significant correlation 
between levels of sE-selectin and IL-4 production in stimulated PBMC (data not shown). 
Even when the patient with the high SCORAD value (49) was omitted from the analysis, the 
correlation between IL-4 and sE-selectin was still significant (p<0.05). 
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Figure 7 
Relation between senlln levels of sE-selectin (upper panel) and sICAM-1 (lower panel) (in pg/ml) 
and the severity of AD as measured by SCORAD (n~8). 
Discussion 
In the present study we found a significant positive correlation between the severity of AD 
(SCORAD) and the IL-4 production of stimulated PBMC. The dominance of Th2-like cells 
in the affected skin tissue of patients with AD was also demonstrated. Thus, these Th2 cells 
appear to be essential for the development of AD. Several studies have demonstrated 
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increased IL-4 and decreased IFN-y mRNA expression and protein production in AD as 
compared to non-atopic controls. The most pronounced changes in cytokine pattern are 
found in severe AD wlule in patients with mild AD normal [19,20] or milumally deviating 
[5] cytokine patterns were found. This points to a relation between the severity of disease 
and the underlying immune devatio11. However, a correlation with the severity of AD using a 
validated clinical scoring system has rarely been established yet [5,22]. Contrary to asthma 
and allergic rhinitis, the extent and intensity of the inflallllnation can be assessed by a 
scoring system in AD. For tlus purpose we used the objective SCORAD which is based on a 
broad consensus of dennatologists. 
As IL-4 and IFN-y are usually undetectable in serum, the secretion ability of 
immunocompetent cells after stimulation is analysed. For this purpose usually a multistep 
procedure is applied consisting of cell isolation, stimulation, culture and analysis of cytokine 
levels in supernatants. The DynaMIX DIA kit combines cell stimulation and cytokine 
trapping by catching antibodies in a simple one-well format (28). A reliable quantification 
method can thus be employed without the need of an isolation procedure that may lead to 
uncontrolled cell activation and deprive cells of important interactions present in whole 
blood (29). While we found a significant correlation between the IL-4 production in PBMC 
(by Screening Line ELISA) and the objective SCOI{AD, there was no correlation between 
the IL-4 production in whole blood (by DynaMIX D1A kit) and the objective SCORAD. We 
consider this a consequence of suboptimal culture conditions used in the DynaMIX DIA kit. 
Both IL-4 and IFN-y production in unstimulated blood was below detection limit except in 
the patient with the highest SCORAD. This was the only patient with severe AD. 
Interestingly, both IL-4 and IFN-y production were increased suggesting also a role for IFN-
y in severe AD. This finding is in agreement with an earlier report of spontaneous IL-4 
production in unstimulated cultures of PBMC from patients with high IgE levels and severe 
atopic dermatitis [30]. In other studies spontaneous production of intracellular IFN-y has 
been reported in AD [31,32]. It can be assumed that in those patients with severe AD 
previous in vivo activatio11, presumably ofT cells, has occurred. 
The present study shows a significant correlation between sE-selectin and the severity of 
disease, which is in line with earlier rep0I1s [13, 14, 33-35]. E-selectin seems to have a 
critical role in allergic inflammation as it promotes the selective migration of both CD4+ and 
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CD8+ T cells expressing the cutaneous lymphocyte antigen (CLA) which is a skin homing 
factor for CD45+ RO+ memory-type T cells [36, 37]. Furthermore we demonstrate a highly 
significant correlation between the levels of sE-selcctin and the production of IL-4 in 
stimulated PBMC of children with AD. This has not been reported previously, as far as we 
arc aware. Although the expression of adhesion molecules is controlled by locally produced 
cytokines, it is unlikely that there is a direct causal relation between the increased IL-4 
production and the increased sE-selectin levels. IL-4 has been shown to inhibit the induction 
ofE-selectin expression by both IL-I and tumor necrosis factor ff. (TNF-ff.) [38]. Therefore 
other cytokines than IL4 that are increased in atopic dermatitis must be responsible for the 
increased expression ofE-selectin. Candidates are IL-l[39, 40], TNF-ff. [38, 39, 40] and IL-3 
[41]. 
When using polyclonal stimulation by Ca-ionophore and PMA, all different culture media 
employed will facilitate cytokine production equally well. However, mitogenic stimuli, like 
PHA, stimulate most, but not all T-cell subsets, in an antigen-presenting cell-dependent 
fashion. Optimal stimulation conditions are then dependent on the presence of multiple 
cellular subsets and are therefore best arranged by testing whole blood samples, mimicking 
the in vivo situation. These stimulation conditions ensure the detection of possible intrinsic 
differences among the T cells in the various patient groups that would reveal changes due to 
environmental stimuli or the expression of the atopic disease. Only when such intrinsic 
differences arc not apparent among the T cell subsets it is useful to interpret differences 
under allergen-specific stimulation conditions. As in all experimental test systems identical 
antibody populations were used, and the tests were all perfonned in microtiterpiates, and 
therefore the specificity of the assays is identical. All ELISA procedures display similar 
sensitivities enabling the detection of cytokine levels after polyclonal stimulation of PBMC 
in vitro. 
Our data show that when using different culture conditions than advised by the manufacturer 
(Yssel's medium with CalTPA instead of RPMI with PHA) the sensitivity and specifity of 
the DynaMIX DIA kit were rendered comparable to the olles in stimulated PBMC using the 
Medgenix Screening Line ELISA. The very fact that the DynaMIX DIA kit permits storage 
of the samples after stimulation before further analysis increases its practical use. The 
comparison between freshly diluted standards and frozen ones revealed similar standard 
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curves. Moreover, since both the stimulation and the assay are perfonned in the same plate 
makes the system well suited for a high sample throughput as compared to the conventional 
way of analysis. Furthermore, the omission of of cell separation presents further time saving. 
\Vhen incorporating the culture and stimulation conditions we present here (Ca-ionophore 
and PMA in Yssel's medium) this system presents similar specificity, sensitivity and 
secretion levels as compared to our conventional analysis. Based on its better practical 
performance the presented DynaMIX DIA kit can be used effectively in cytokine analysis in 
clinical immunology. However, though both systems perform rather similar, it is advised not 
to intenningie the use of both systems. 
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Introduction 
Current therapy of atopic derruatitis (AD) is directed at suppressing the inflammation and 
reducing triggering factors. The goals of current standard therapy arc improvement of the 
skin-barrier, blocking of receptors and reduction of the inflammatory infiltrate [I, 2]. 
Advanced treatment of severe AD in children inclndes: (I) general aspects; (2) preventive 
measures; (3) an individualized therapeutic regimen and use of emollients; (4) topical 
application of corticosteroids; (5) topical or systemic antibiotics and topical antiseptics; (6) 
elimination diets; (7) systemic treatment in recalcitrant disease (cyclosporin); (8) other 
therapies, and (9) experimental therapy. 
II is important to score the severity of AD to evaluate the effects of therapy. Different 
systems are available for scoring the severity of AD. The European Task Force on Atopic 
Dermatitis developed a scoring system based on consensus [3]. This system was called the 
SeDRAD-index and contained objective and subjective criteria. Subjective criteria are 
difticuIt to evaluate, especially in young children. Therefore we use the objective SCORAD. 
This scoring-system is an excellent instrument for use in trials and studies. Because the 
SeDRAD is time-consuming, for routine use we devised a simpler scoring system from this 
and called it TIS: three-items severity score, involving the representative erythema, oedema 
and excoriations [Wolkerstorfer et aI., submitted]. Each item can be graded on a scale from 
0-3. Maximum TIS-score is 9. 
Tn a validation retrospective study we detennined the TIS-score of 152 children [van Meurs, 
internal report]. Objective SCORAD scores of all these children were already known. The 
t55 
Chapter 5.1 
con-elation between the TIS scores and the SCORAD scores was calculated. This correlation 
was very good. (0.8746 p ~ 0.001). In a prospective study we obtained the same results 
[Wo1kerstorfer et a1.. submitted]. The TIS-score is a good assessment method for routine 
use. This may be a satisfactory solution to the problem of assessing the severity of AD, 
especially in the general practice. 
General aspects of current therapy 
After daily bathing (for a maximum of 10 min). the use of emollients and soap 
substitutes are recommended. Prevention of triggering factors is important and will be dealt 
with in more detail later. The mainstays of topical treatment of AD are the use of emollients 
and corticosteroids, although adjunctive measures are important. Tars have been used for 
many years in the treatment of AD [4]. Tars are antipruritic and antiproliferative and 
eftTective in subacute and chronic AD. Major drawbacks of tar are that it is messy, odorous, 
photo toxic and may induce folliculitis. A lot of concern has arisen due to possible 
carcinogenicity, but the incidence of skin cancer in tar-treated patients is very low [5]. Vle 
still often use coal tar at low concentrations, for example solutio carbonis detergens 10% in 
a zinc oxide-containing ointment. 
Day care with education for the parents and the children and psychosocial support 
will improve the care of children and parents. Minor behavioral problems and distress in the 
parents are important features in severe AD in early childhood [6]. Children and their 
families need education and the support of health care professionals [7]. Long hospitalization 
is stressful for the well-being of the children, is extremely expensive for society, and should 
be limited as much as possible. 
Preventive measures 
One should avoid irritanls such as delergents and wool. Early exposure 10 allergens 
may result into sensibilisation. Therefore preventive sanitization procedures (for house dust 
mite, animals and other allergens) should be undertaken from early infancy onwards. 
Emotional slress should be avoided [7]. Psychological faclors such as fmslration and anxiety 
will complicate AD and trigger worsening of the disease. 
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Interventions to prevent the switch from AD to asthma are difficult to evaluate. Two 
candidates to prevent the switch are cetirizine and loratidine. Studies are currently in 
progress to evaluate these. The Early Treatment of Atopic Child trial concems a unique long-
term study in 817 children with atopic dermatitis [AD] to determine the risk of developing 
asthma as well as the preventive efficacy of cetirizine. During the three years-study, a part of 
those children is likely to develop asthma and it will be of special interest to assess whether 
this can be predicted by clinical or laboratory variables. Blood and urine samples were taken 
at several visits and stored for additional research to study the allergic march from AD to 
astlmla. Several markers were investigated to evaluate the inflammation in order to obtain a 
more detailed insight into the process of allergic inflammation in the skin or the lungs. The 
first results of tllls trial have only recently become available and have just been published. 
There are indications that cetirizc reduces the chances for developing astlmm in some 
subgroups of young children with AD [8]. In a double-blind placebo-controlled study, 
cetirizine halved the number of patients developing astlmm in the subgroups sensitised to 
grass pollen or house dust mite, that included 20% of the study popUlation [8]. Asthma 
preventing capacities are also claimed for loratadine, but a study is still in progress on. 
Corticosteroids 
Topical corticosteroids are the primary mainstay of the topical treatment of childhood 
AD [4]. Depending upon the age mild to moderate potent corticosteroids are used in 
children. Most dermatologists prefer in children to use hydrocortisone acetate and 
triamcinolone acetonide in children. Stronger preparations usually carry higher risks of 
systemic side-effects. 
New preparations such as tluticasone propionate, mometasone fuorate 
methylprednisolone aceponate and prednicarbate are interesting because of their effectivity 
and inereased benefit-risk ratios. Mometasone furoate 0.1% is already registered in the USA 
for pediatric age. Local and systemic side effects are negligible except for slight skin 
thilllllng and hair growth (own observations) [9,10]. Incidentally striae were observed in 
(pre)puberal children (own observations). These fonnulas are suitable for application with 
the wet wrap technique because of their increased bencfit-to- risk ratio. 
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Adrenal suppression is a potential complication of topical corticosteroid treatment 
in AD [II]. Fasting cortisol levels, body weight, urinary excretion of cortisol and ACTH 
test are used to check adrenal suppression. The ACTH test is the most reliable test, but is 
patient unfriendly and stressful. Patel et al [II] studied 14 prepnbertal children with 
moderate to severe AD using the ACTH test to detect subtle changes in adrenal 
glucocorticoid function. All children nsed hydrocortisone acetate ointment and moderately 
potent preparations intennittently. No suppression of adrenal glucocorticoid function was 
observed [II]. In a comparative study by Vernon et al. [10] of 0.1 % mometasone furoate 
cream and 1.0% hydrocortisone cream in 48 children with AD, only 1 child showed 
transiently suppressed cortisol levels. This child was treated with 1.0% hydrocortisone 
acetate cream. Wolkerstorfer et al. [12] studied 21 children who were treated double-blind 
with either 0.05% fluticasone propionate or 0.05% elobetasone butyrate. Once daily 
application of 0.05% flutieasone propionate was eqnal to twice daily application of 0.05%) 
clobetasone butyrate. No influence on the levels of excreted cortisol in the urine was 
observed [12]. 
Wet Wrap Technique 
In 1991 Goodyear et al. [13] described the wet wrap technique for the treatment of 
AD. \Vet wrap treatment plays an important role in the management of childhood AD 
which does not respond to first-line treatment. \Vet wrap treatment is also effective in adult 
erythrodermic AD. Different variations of this technique may be used (bandages soaked 
with emollients or diluted corticosteroids. or bandages soaked with warm water or re-
wetting or not re-wetting the bandages every hour). However, controlled studies are 
lacking. 
The wet wrap teclmique is a kind of occlusive treatment. The absorption of the topical 
corticosteroid is increased under occlusion, while hydration of the skin leads to a 4- to 5-
fold increase in absorption [4]. Wet tubular dressings are used over emollients and diluted 
corticosteroids. Although rapid improvement in AD occurred, adrenal pituitary suppression 
limited its long-term use [13]. Betamethasone and even 1.0% hydrocortisone acetate 
application resnlted in HPA-axis suppression. Fluticasone propionate (0.05%) is a 
corticosteroid which seems to have an improved benefit-to-risk ratio. Therefore it appears 
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to be suitable for the wet wrap technique for long-term treatment. This therapy with a 
potent diluted corticosteroid cream with minor systemic side effects is an interesting and 
promising option not only in children. but also in adults. The concentration of the 0.05% 
fluticasone propionate cream-emollient I: 1 dilution may be lowered to 10% diluted steroid 
cream. This lower concentration will further improve the safety of the treatment 
[Wolkerstorfer ct aI., in preparation]. 
Antihistamines 
Oral antihistamines are often included in the therapy for AD. However, the exact 
role in the treatment is conflicting. At least oral antihistamines will reduce urticarial flare-
ups [8]. Most antihistamines are probably inefiective, but in young children they are at least 
useful because of sedation. The newer generation cetirizine and loratidine are thought to be 
effective in AD and were recently investigated in clinical trials [14,15]. Cetirizine inhibited 
the in vivo and in vitro chemotactic response ofT lymphocytes and monocytes [16]. 
There is also a lot of debate concerning the safety of antihistamines. We use dimetindene in 
the first year of life (afler the age of 6 months) and, considering the low number of reported 
seriolls adverse advents. \Ve have never observed seriolls side effects. 
An Ii hi 0 lies! An I isep lies 
Topical or oral antibiotics or topical antiseptics are often used, although there are 
doubts on their usefulness. Therefore the role of antibiotics is conflicting. Some investigators 
believe in its use, but others do not. 
Systemic treatment in recalcitrant disease 
Oral cyclosporin can be considered in recalcitrant cases of childhood AD. The initial 
dose is 5-6 mg/kg daily and in some patients the dose can be reduced according to the 
response. Therapy should be continued for a maximum of 3 months. Therapy is well 
tolcrated and has no side-effects in most patients [17], except the very rare increases in 
alkaline phosphatase [18]. Cyciosporin is safe and effective in short-term treatment for 
severe childhood AD [17]. Short-term treatment with eyciosporin may improve the long-
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term outcome of AD, although most patients relapsed within 1-2 months after cyclosporin 
was stopped [19]. 
Elimination diets 
Elimination diets are probably beneficial in some young children with AD. Many 
different opinions exist on food allergy and it may be considered a controversial issue. In our 
opinion it plays an role in 10-20% of the young children with AD with direct effects on 
eczema in about 4 of 10 cases [20]. Contact urticaria syndrome is one of the major 
manifestations of food allergy in small children with AD and food allergy [21,22]. Most 
commen allergens are eggs, cow's milk, peanuts, wheat and fish, but it also depends on 
consumption customs. Probably direct cutaneous contacts are important in inducing food and 
aero allergy. Not only immune-mediated reactions occur, also pseudo-anergic reactions such 
as with chocolate and oranges may occur. Oral food challenge should be performed 
cautiously in a hospital setting and is considered to be the gold standard for diagnosis. 
However. the criteria for oral food challenges need a defined cutoff point and 
standardization. 
Other Therapies 
Chinese herbs have been reported to be useful in therapy-resistant cases, however, 
side effects stich as liver function disturbances have been reported [23, 24]. Besides, Chinese 
herbal physicians have combined this therapy with old-fashioned topical corticosteroids 
leading to plasma cortisol suppression. 
Phototherapy is helpful in cases nonresponsive to local and systemic therapy; however, in 
general terms I would not advise giving it to children under the age of 18 years. In extremely 
recalcitrant cases combination therapy with UV A and UVB is indicated. Appropriate doses 
are 3-5 J UV A and 30-50 111J UVB. Oral PUV A is used in older children with severe 
disabling AD with good reslllts. Sheehan et al. [25] state that lise of oral PUV A is justified in 
these serious cases, despite anxieties about possible long-tenn hazards. Highdose UV Al 
(340-400 nm) is extremely useful, but the long-term effects are not known, and the treatment 
should not be used in children [21. 
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Experimental Therapy 
Promising experimental treatment results with tacrolimus ointment and ascomycine 
ointment, drugs completely different from corticosteroids, have been reported. l\1ost 
experience has been obtained with tacrolimus ointment. The therapeutic effect is seen within 
2 days, and moderately severe AD can be controiJed by twice weekly applications (personal 
communications). These drugs will become available in the future. These products are more 
effective than placebo and at least equal to moderately potent corticosteroids (Symposia 
Clinical Dermatology 2000 Congress, Singapore 1998). 
Recombinant human interferon-y therapy may be effective in the longterm treatment of 
patients with AD [26]. The results are, however, conflicting. 
High-dose intravenous immunoglobulin therapy in AD and hyper-lgE syndrome may be a 
potent, but very expensive alternative in the treatment of severe, steroid-dependent allergic 
disorders such as AD and allergic asthma [27, 28]. However, others have found it not to be 
effective in eczema [291. 
In the distant future, new approaches for therapy of AD may involve the use of adhesion 
molecules or monoclonal antibodies directed against them and T-cell inhibitors [30]. 
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Abstract 
Background: Fluticasone propionate is a novel and potent corticosteroid. It seems to have an 
improved therapeutic index according to studies on skin thinning and suppression of 
hypothalamic-piluitary-adrenal axis. 
Objective: To assess efficacy and safety offluticasone propionate (FP) 0.05% cream once daily 
as compared with clobetasone butyrate (CB) 0.05% cream twice daily in children with atopic 
dcnnatitis (AD). 
Methods: Twenty-two children (3 to 8 years old) with moderately active AD received either FP 
once daily or CB twice daily. Severity of AD was scored weekly using the modified scoring of 
atopic dennatitis (SCORAD) and treatment was either stopped when skin lesions were almost 
cleared (SCORAD <9) or after 4 weeks. Cortisol excretion was detennined in 24 hours urine 
before and after treatment. 
Results: Twenty-one children completed the study. After I week of treatment, meml SCORAD 
significantly decreased in both treatment groups. After 2,3 and 4 weeks cumulatively 8, 12 and 
16 children were clinically healed (SCORAD <9). No significant differences in the efficacy 
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were observed between the two treatments. Urinary cortisol excretion was not altered by either 
of the treatments (compared between groups and in time). Two weeks after discontinuation of 
active treatment, mean SCORAD had increased to 22, but still was significantly lower than that 
at the begilming of the study. 
Conclusion: Once daily treatment with FP is as safe and effective as twice daily treatment with 
CB in children with AD. All of the children experienced an exacerbation of AD within two 
weeks, after treatment was withdrawn, indicating the need for long term tlintennittentU 
treatment. 
Introduction 
Topical corticosteroids are the mainstay of therapy in atopic dennatitis (AD). Based on the 
vasoconstrictor assay', they may be divided into the following four groups: mildly potent, 
moderately potent, potent and very potent'. Usually, children with AD can be managed using 
emollients and mild to moderately potent topical corticosteroids. However, some children 
require further anti-inflammatory treatment. For this purpose, potent and safe topical corticoste-
roids are necessary. Until recently, it was generally assumed that the adverse effects of topical 
corticosteroids were directly related to their potencl. However, new corticosteroids have been 
developed with the promise of potent local efficacy and relatively little or no suppression of the 
hypothalamic-pituitary-adrenocortical (HPA) axis"'. Fluticasone propionate (FP) is a potent 
corticosteroid with sllch an improved topical/systemic activity ratios. TIus is of particular sig-
nificance in children who have a high ratio of body surface to body weight. In these patients 
systemic absorption is of major concern when potent corticosteroids are used. 
Despite the widespread use of topical corticosteroids in children with AD there are surprisingly 
few clinical studies available on the efficacy and safety of topical corticosteroids in ch.ildren. 
With respect to the use of potent topical corticosteroids in young children with AD, clinical 
studies are almost totally lacking. The scarcity of clinieal trials in tills field may be a result from 
the justified caution on the use of potent corticosteroids in young children. Another reason may 
be the opiIuon that the vasoconstrictor testt, a ranking system for the potency of topical 
corticosteroids, would make clitucal trials unnecessary. 111is opinion has been challenged 
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recently by the demonstration of a rather weak correlation between vasoconstrictor assay and 
clinical outcome6, and by the development oftopicai corticosteroids with an improved benefit-
risk ratio. Taken together, there is still a need for clinical trials. 
Twice daily use of Clobetasone butyrate (CB) 0.05% cream, a moderately potent corticosteroid, 
is a well evaluated therapeutic regim.en which was shown to be safe and effective in the acute 
phase treatment of atopic dennatitis in children7.8. ll1erefore we used CB 0.05% cream twice 
daily as the reference for comparing and evaluating the efficacy and the safety of FP 0.05% 
cream applied once daily in children with atopic dennatitis. 
Methods 
Patients and design 
Twenty-two children (12 males and 10 females) with AIl, aged 3 to 8 years were included. 
Disease severity was moderate severe according to the SCORAD IO (SCORAD between 20 and 
40). TIle patients had received no systemic treatment for AD in the month preceding the study. 
At the begilUling a one week wash-out period with restricted medication (emollient, hydrocor-
tisone acetate 1% and/or antihistamines when needed) was implemented. Thereafter, the chil-
dren were randomized to receive either 0.05% FP cream once daily or 0.05% CB cream twice 
daily in a double-blind setting. To keep the study blinded, patients in the once daily group 
received vehicle crean} in the morning and FP cream in the evening. During the trial all of the 
children used the same kind of basic skin care (emollient. bath oil). Visits to the center were 
plarmed once a week to assess the severity of AD (SCOI0\]) and the occurrence of side-
efrects. Treatment was stopped when SCOI0\]) was below 9 (clinically healed) or ultimately 
aner 4 weeks. A two- week follo- up period with basic skin care only (no anti-inflammatory 
treatment) served to evaluate the decline of AD and whether a rebound occurred. The study 
was approved by the local Medical Ethical Conunittee and written infonlled consent was 
obtained from the parents of all participating children. 
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Clinical scoring system 
The severity of disease activity was scored using the modified Scoring atopic dermatitis (SCO-
RAD) system 10 which is a composite index including the assessment of two items in a 
standardized manner: a) extent (applying the rule of ninc) and b) intensity (erythema, ede-
ma/papulation, oozing/cmsts, excoriation, lichenification and dryness). TIlls scoring system re-
flects the modified consensus of the European Task Force on Atopic Dermatitis. Unlike the 
initial version of the SCORAD indexll, subjective symptoms were not included for the scoring 
of ADIO. 
Fluticasone Clobe/asolle 
propionate cream butyrate cream 
Age (yr) 4.9±1.7 4.1 ±I.I 
Weight (kg) 19.3±4.8 17.5 ±3.8 
Sex (male/fcmale) 4/8 7/2 
Initial SCORAD 29±6.2 32±5.6 
Table I. Characteristics of the patients in the two groups. 
Fluticasone Clobe/asolle 
propionate cream butyrate cream 
Week I 0 0 
Week 2 4 4 
Week 3 2 2 
Week 4 3 
Table II. Number of patients scored as clinically healed (SCORAD <9) in the course 
of the study. 
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Safety analysis 
To assess the systemic load we measured the excretion of cortisol in 24-hours urine at the 
beginning (baseline) and the last day of the treatment period and at the end of the follow up. 
After following 5 patients, it was discovered, that the amount of collected 24-hours urine 
differed considerably between the visits. It was then decided to use creatinine levels as marker 
for estinlating the reliability of the amount of collected mine. In 2 paticnts, the creatinine 
excretion for a particular visit was significantly lower than the average creatinine excretion 
measured over the other two visils. It may be assumed that at those particular visits not all the 
urine that was produced was collected. Correction for creatinine was perfonned in these two 
patients by increasing the measured cortisol excretion according to the extent of missing 
creatinine. 
In six patients, the reliability of the amount of collected urine was not tested because data for 
creatinine excretion were not available. 
Statistical analysis 
The mean downward linear trend in time for the objective SCORAD and its difference between 
the two treatment groups was estimated and tested lIsing a random coefficient model. The mean 
intercept was assumed to be the same for both treatment groups. 
Cortisol excretion between the two treatmcnt groups was compared using the MalUl-Whitney 
tcst, and compared in time within each of the two treatment groups using the paired Wilcoxon 
test. 
Results 
Twenty-two children (12 males, 10 females; mean age 4.6 years, range 3 to 8 years) were 
randomly allocated to receive either 0.05% fluticasone propionate (FP) creanl or 0.05% 
elobetasol butyrate (CB) cream. Twenty-one children completed the study (one drop out in the 
CB group due to varicella). 
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Figure I. SeDRAD (mean and standard deviation) for the groups treated either with 0.05% fluticasone 
propionate (FP) cream or 0.05% clobetasone butyrate (CB) cream. Note that patients scored as 
clinically healed (SeDRAD <9) in weeks 2 and 3 are not included in the subsequent weeks. This 
results in a selection ofpaorly responding patients in weeks 3 and 4. 
Objective 
SCORAD -FP 
24 -x- CD 
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16 
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Figure 2. Mean downward linear trend in time of SCORAD in the goups treated either with 0.05% 
fluticasone propionate (FP) cream or 0.05% clobetasone butyrate (CB) cream. The difference in the 
slopes between FP and CB is not significant (p=o.8), 
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There were 12 patients in the FP group and 9 patients in the CB group. The two groups were 
well matched for age, weight and severity of AD. There was marked difference between the 
gender in the two groups (Table I). The initial SCORAD (mean ±SD) was 31 ±6 (FP: 32 ±6, 
CB: 29 ±6). As shown in Figure I, after one week of treatment, the SCORAD (mean ±SD) 
significantly decreased in both of the treatment groups (FP: 17 ±6, CB: 18 ±6). In spite of the 
marked improvement after one week, none of the children was scored as clinically healed 
(SCORAD <9) (Table 11). After 2,3 and 4 weeks respectively 8,4 and 4 children were scored as 
clinically healed (Table II) and active treatment was stopped. 
At the end of the treatment period, the mean SCORAD had dropped to 10 ±to (FP group) and 
to ±6 (CB group). Although the improvement of AD was more pronounced in the FP group, 
there was no significant difference in the mean downward linear trend of SCORAD between 
the FP- and CB-treated groups (Figure 2). After 4 weeks of treatment there were still 5 children 
with a SCORAD:;,9 (3 children in the FP group and 2 in the CB group). Two weeks after the 
discontinuation of active treatment, the mean SCORAD had increased to 23 ±9 (FP group) and 
21 ±7 (C13 group) 
Urinary cortisol excretion was not significantly diflerent between the two treatment groups at 
the beginning (p~0.8), at the end of the treatment (P~0.8) and at the end of the follow up 
(p~0.9). When comparing the 24 hours urinary cortisol excretion at the beginning with the 
excretion at the end of treatment (FP group: Z~-I.I, ~0.3; CB group: Z~-O.4, P~0.7) and at 
the end of follow up (FP group: Z~-O.4, P~O. 7; CB group: Z~-1.2, P~0.2) there were no 
significant changes. However, there was one child in the CB group with an evident suppression 
of the urinary cortisol excretion after 4 weeks of treatment (Urinary cortisol excretion before 
treatment: 162.8 nmol/24hours; end of treatment: 67 nmoIl24hours). At the follow up visit the 
urinary cortisol excretion had retumed to the pre treatment value in tills child. 
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Discussion 
In the present study, a similar improvement was observed in two groups of children with atopic 
dennatitis who were either treated with 0.05% f1uticasone propionate (FP) cream once daily or 
with 0.05% clobetasol butyrate (CB) cream twice daily. After one week of treatment all of the 
children experienced a significant improvement and at the end of the treatment period ordy one 
child out of the 21 children had not improved markedly. 
As far as the literature is concerned, this is the first study on the topical treatment with FP in 
young children with atopic dernlatitis. In adults and older children several double-blind studies, 
in which treatment with FP was compared with other topical corticosteroids have been pub lis-
hed I2.J3 • In one study involving adults and children above the age of 12 years with eczema, 
0.05% FP cream applied twice daily was observed to have a similar efficacy to that of 
treatment with hydrocortisone-17-butyrate cream applied twice dail/2. 
FP CB FP CB FP CB 
Baseline End of treatment End of follow up 
Figure 3. 24 hours urinary cortisol excretion (mean and standard deviation) for both treatment 
groups at the begiwling of the study, at the end of the treatment period and at the end of the 2 
week follow up. 
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In anothcr double-blind study involving adults with atopic dennatitis, treatment with 0,005% 
FP ointment was compared with that using 0,05% Betamethasone-17,21-dipropionate 
ointment 13• After twice daily application for 4 weeks, no significant difference in investigators 
overall assessment, symptoms (erythema, pruritus, skin thickening, lichenification, 
vesiculation, crusting) and patients assessment was observed. Regarding systemic side-effects, 
tretment with FP was noted to be safe as measured by plasma C011isollevels12,13. 
In the present study, we measured 24 hours urinary cortisol excretion. TIlls turned out to be 
problematic due to incomplete urine collection. Therefore, creatinine excretion was detennined 
and used for estimating the completeness of the urine collection. It turned out that most of the 
differing urine runounts could be attributed to real differences in urine production, whereas 
correction for creatinine was necessary in two children. 
In agreement with other reports in adults 12,1J, no significant suppression of the HPA axis after 
treatment with 0.05% FP creant was detected. 
Besides systemic adverse effects, a number of local adverse effects have been associated with 
regular topical corticosteroid application. As far as clinical trials with Fluticasone propionate 
are concemed, buming (0-6%), folliculitis (1.7-4.3%), irritation (4%), hypertrichosis (1.7%) 
and pmritus «3%) are the most fi'equcntly rep0l1ed side-effects13 , Skin atrophy is the most 
serious local side-effect. Age may be important, with younger patients experiencing more skin 
atrophy than older patients15 . Data on the skin thinning effect of FP in children are not 
available. However, in a placebo-controlled volunteer study in adults, it was demonstrated that 
application of 0,05% FP cream once daily ovcr a period of 8 weeks did not significantly affect 
skin thickness as measured by pulsed ultrasound and histology'6, An explanation for the lack of 
atrophy obscrved in that study may be the unusual molecular steroid stmcture of FP based on 
the 19-carbon ruldrostane stmcture. This stmcturc is highly selective for the glucocorticoid 
receptor with little or no activity at progesteron, androgen, oestrogen, or mineralocorticoid 
receptors', The half-life of the FP-rcceptor complex is 10 hours" which exceeds all other cor-
ticosteroids, Although tltis indicates a high therapeutic potency, FP has been shown to have 
little effect on the HPA axis', TItis may be due to limited percutaneous absorption and once in 
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the circulation, rapid elimination by liver metabolism (first pass effect approximating 100%). 
These properties suggest that FP is of particular value for treating young children, in whom 
systemic absorption is a major concern. 
To date, data on the effect of fluticasone propionate in atopic dennatitis originate from studies 
in adults and cannot simply be extrapolated for use as guideline in children. TIle present study 
shows that 0.05% FP cream applied once daily is safe and at least as effective as 0.05% CB 
cream applied twice daily in the acute treatment of moderately severe atopic dennatitis in 
childhood. Further studies are imperative for evaluating the value of fluticasone propionate in 
the short- and long-tenn treatment of atopic dennatitis in young children. 
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Wet-wrap in atopic dermatitis 
Treatment of erythrodermic atopic dermatitis with "wet-wrap" jluticasone 
propionate 0.05% cream/emolliellt 1 " 1 dressings 
Oranje AI', Wolkerstorfer A, de Waard v d Spek FB. 
Topical corticosteroids are the mainstay of therapy in atopic dermatitis. Recently 
corticosteroids with an improved benefit/risk ratio have been developed. 1 These show potent 
local efficacy and relatively weak or no suppression of the hypothalamic-pituitary-
adrenocortical (HPA) axis. Fluticasonc propionate 0.05% cream or ointment is such a 
corticosteroid with an improved benefit/risk ratio.' Relatively few clinical studies on the 
efficacy and safety oftopical corticosteroids in children are available. 
In 1991, Goodyear et al described a method of treatment with dressings in children with 
erythrodenllic atopic demmtitis.3 Their method involves a wet-wrap technique using 
open·weaved cotton tubular dressings (Tubi[ast) impregnated with a I : 9 dilution (10%) of 
betamethasone valerate 0.01 % applied twice daily according to a standard protocol :,5 This 
is done for a few days until 90-100% clearance of dermatitis is obtained. They have observed 
that 9 a.m. cortisol levels at the time of the wet map application are suppressed after 2-5 
days, rctuming to nonnal 2 weeks post-therapy.4 An attempt at long-teon treatment with wet 
wraps in five patients at home was unsuccessful in all cases. Time-consuming application, 
decreasing effectiveness, secondary bacterial infection and prolonged HPA suppression were 
mentioned as reasons for failure. 
We developed a modified protocol using fluticasone propionate 0.05% cream/emollient I: I 
diluted in the wet-,wap method Cfable I). In contrast to the earlier reports we used a less 
diluted corticosteroid, applied only once daily. We also used the same in adult patients. We 
present the results in three children and four adults, all suffering from severe erythrodermic 
atopic demmtitis. The severity of atopic dennatitis was measured by evaluating the objective 
SCORAD.,,7 A significant improvement in atopic demlatitis was observed after 2 weeks 
(SCORAD 74-38 to 33-10). 
179 
Chapter 5.3 
Table I Wet~wrap method: treatment procedure with fluticasone propionate (adapted from 
Goodyear et al3 with modification) 
Cut out appropriate sized pieces ofTubifast for the anns, legs, and trunk to fonn three 
separate suits. 
2 Apply fluticasone propionate 0.05% cream I : I diluted with Vaseline 20% in cetomacrogol 
cream to the skin. In children older than 6 months and younger than 2 years the combination 
ratio is 1 : 3. 
3 Soak the individual pieces ofTubifast in water. 
4 Put on the first layer of , wet' Tubifast. Tie the ann and leg pieces to the trunk section. 
5 Applya second dry suit ofTubifast over the top of the wet layer. Again tie the arm and leg 
pieces to the trunk section. 
6 Make a mask for the face if involved. In patients younger than 2 years, apply hydrocortisone 
acetate I % or clobetasol butyrate cream (both diluted I : I with emollient) to the face, soak 
the mask in water and put it on. Then apply a second dry mask ofTuhifast over the top of 
the wet layer. 
7 Rc~wet the first layer every 2 h, and change daily after a bath (containing only oily bath 
additive). 
8 After 2 weeks, apply fluticasone propionate I: I (or I 3, depending upon age) diluted with 
emollient only on the active lesions 3~5 days a week and on the other days only emollient. 
Suppression of the HPA, as assessed by measurement of serum cortisol levels in all seven 
patients, occurred in one adult patient during a 2-week period. However it nonnalized during 
the follow-up when measured 2 weeks later, while continuing the treatment. It is noteworthy 
that this adult female patient used the lowest amount of fluticasone propionate of all the 
adults (175 g in 2 weeks). She also used clobctasol butyrate and desoxymethasone on the 
scalp, and these could have also influenced the cortisol values. No suppression was seen in 
the remaining patients, while large amounts of fluticasone propionate were used, ranging 
from 95 to 555 g fluticasone propionate 0.05%, Crable II). 
This therapy with a potent corticosteroid with minor systemic side~effects is an interesting 
and promising option in children and adult patients. In comparison with the earlier proposed 
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method, we used 50% corticosteroid versus 10% in the earlier studies, applied it only once 
daily versus twice daily and we used the same scheme with success also in adults. 
Using the wet-wrap technique with fluticasone propionate 0.05%, we observed a striking 
improvement in erythrodermic atopic dermatitis within 2 weeks of treatment. 
Of the seven patients (children and adults) treated, only one adult female had a temporary 
suppression of the HPA axis, but this patient also used other local corticosteroids. This 
method seems promising, especially with the use of local corticosteroids with only limited 
systemic side-effects. It is even more striking, because we used a dose of corticosteroid that 
was higher than used previously. Currently we are perfonuing a study with different 
concentrations. A long-term study should establish whether this therapy is safe for prolonged 
use, free of complications and whether the patients are able to use it at home. The long~teml 
follow-up in the patients described looks promising. 
Table2 Data of patients (3 children and 4 adults) with severe erythrodennic atopic 
dennatitis 
Day 0 Day 14 Amounl a/pure 
Palielll Age SeORAD COJ'tisaf SeORAD Corlisof j/ulicasone 
ro ionale use<t 
6 months 45 0.33 10 0.30 Unknown 
2 4 years 38 0.33 18 0.22 95 
3 6 years 47 0.40 10 0.23 130 
4 35 years 74 0.21 33 0.23 555 
5 36 years 64 0.37 30 0.37 300 
6 44 years 65 0.24 18 0.10' 175 
7 39 years 57 0.40 24 0.24 400 
a Serum cortisol levels in ~lTnolll (nonnal range: O.2~O.8 p.molll) 
b Amount of pure fluticasone propionate in g used in 14 days 
c Also used 30 g clobetasonc butyrate on face; after 6 weeks value returned to nonnal (0.24 P.IllOI/I) 
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Abstract 
The wet-wrap treatment involves corticosteroid dilutions under occlusive wet dressings, and 
has been reported to be highly effective in severe refractory atopic dermatitis (AD). We 
investigated the influence of duration of treatment and different corticosteroid dilutions on 
the efficacy and hypothalamic pituitary adrenal (HPA) axis suppression in children with 
severe refractory AD. Eighteen children were treated with a 50% fluticasone propionate (rp) 
cream dilution for two weeks. In another 5 children a side to side comparison was conducted 
with 10%,25% and 50% FP cream dilutions under wet-wrap, whereas a third group of 8 
children was treated with O%=emollient, 5%, 10% or 25% dilutions of fluticasone 
propionate cream applied on the whole body under wet-wrap. The systemic bioactivity was 
measured by the levels of 9 a.m. semm cortisol, 6 a.m. semm cortisol, and timed urinary 
cortisol/creatinine ratio. After one week, a major improvement was observed, without 
apparent differences between 5%, 10% or 25% dilutions of FP cream under wet-wrap. The 
improvement of AD amounted to 74% in the first and 8% in the second week of treatment. 
Furthennore, we noticed a significant dose response relationship for efficacy, with Illost 
cases being on the plateau of the curve, whereas the dose response curve for HPA axis 
suppression was without plateau. This indicated that less potent corticosteroid dilutions had 
comparable efficacy, but lower risk of HPA axis suppression as indicated by 6 a.m. se,um 
cortisol levels. In conclusion, wet-wrap treatment is highly effective in severe AD. Less 
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potent corticosteroid dilutions seem to have comparable efficacy but lower risk of HPA axis 
suppression. 
Introduction 
Severe atopic dermatitis (AD) remains difficult to treat. Although guidelines provide a good 
framework for managing AD,I,2 some of the patients will not improve with the conventional 
therapy, posing a major therapeutic problem for the physician, Cyclosporin A, the most 
extensively studied regimen for refractory AD, was reported to be effective in children with 
severe AD. 3-5 However, cyclosporin A may have potentially severe side effects, and should 
not be given for longer than 3 months. In children, therapies like UVA-I: PUV A,' 
recombinant interferon-y8 and systemic corticosteroids arc not indicated. Thus, there is still a 
need for an effective treatment in children with severe AD. 
In 1991, Goodyear et al described a highly effective method of treatment with dressings in 
children with severe erythrodermic atopic dermatitis.9 Their method involved a wet-wrap 
technique involving the use of open-weaved cotton tubular dressings (Tubifast) impregnated 
with a 10% dilution of betamethasone valerate 0.0 I % cream applied twice daily according to 
a standard protocol:'" They observed that 9 a.m. cortisol levels at the time of the wet-wrap 
application were suppressed after 2-5 days, but returned to normal 2 weeks post-therapy. 
We developed a modified protocol using fluticasone propionate (FP) 0.05% cream-emollient 
dilutions (50% on the body and 10% on the face) once daily under wet-wrap dressings. 12 
Fluticasone propionate is a potent corticosteroid, which seems to have an improved 
benefit/risk ratiou ,,,. In the first part of the study, involving 18 children, we observed a 
major improvement in all children and reversible 9 a.m. cortisol suppression in 3 children 
after 2 weeks of treatment. However, 9 a.m. serum cortisol is not a sensitive marker of the 
systemic bioactivity of topical corticosteroids, and other investigators used less potent 
corticosterod dilutions. Although the application of corticosteroids under occlusion was 
associated with a high rate of side effects in the past, the wet-wrap treatment is widely used, 
but the teclmique has not been satisfactorily evaluated. The purpose of this study was to 
investigate the efficacy and the safety of once daily wet-wrap dressings with different 
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fluticasone propionate dilutions and the duration of therapy in children with severe atopic 
dennatitis. 
Materials and Methods 
Patients and design 
Thirty-one children (15 males and 16 females) with AD according to the criteria of 
Sampson'5 and \Villiams et at,16 aged 5 months to 13 years were included. Disease severity 
was severe in 29 of the children according to an objective seORAD ;0, 4017• The wet-wrap 
protocol we used was described previously.12 Briefly, the patients were admitted to the 
hospital and took a bath for 5-10 minutes once daily, followed by the application of the 
diluted fluticasone propionate (FP) cream on the whole body. On top of this we applied first 
a wet and then a dry layer of tubular bandage made of cotton (tubifast®). This bandage was 
rewetted every two hours with water using a spray bottle. 
The first group consisted of 18 children who were treated with a 50% dilution of FP 
cream under wet-wrap dressings for 2 weeks. The objective SCORAD and 9 a.tn. semm 
cortisol were measured at the beginning and after 2 weeks of treatment. 
The second group of 5 children had symmetrically localised AD and was treated with 
different dilutions (10%, 25%, and 50%) of FP cream on the left and the right side of the 
body under wet-wrap dressings. After I week, the severity of AD was scored by objective 
SeORAD on both sides, and treatment was continued with a 10% dilution of FP crealll. The 
levels of 9 a.m. serum cortisol were measured at the beginning and after 2 weeks of 
treatment. 
The third group consisted of 8 children who were treated with different dilutions of 
FP cream (O%=emollient, 5%, 10%, and 25%) under wet-wrap dressings in each of 2 
children. Objective SeORAD and 6 a.lll. semm cortisol were measured daily during the first 
week, and after 2 weeks of treatment. Treatment with topical corticosteroids was stopped 3 
days before the baseline cortisol value was assessed, and the total amount of FP cream that 
was applied was recorded. 
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Clinical scaring system 
The severity of AD was scored using the objective SCORAD17,18 which includes the 
assessment of two items in a standardised manner: a) extent (applying the nIle of ninc) and 
b) intensity (erythema, odema/papulation, oozing/crust, excoriation, lichenification and 
dryness on a scale from 0 to 3), This scoring system reflects the modified consensus of the 
European Task Force on Atopic Dermatitis, Unlike the initial version called SCORAD 
index,19 subjective symptoms are not included in the scoring of AD in the objective 
SCORAD 17,18, 
Safety analysis 
To detennine the systemic load of the topical medication we assessed the HPA axis 
suppression. In the first 2 groups of 18 and 5 children respectively, 9 a.m. serum cortisol 
levels were measured at the beginning and after 2 weeks of treatment. In the third group of 8 
children serum cortisol at 6 a,m. and urinary timed morning cortisol/creatinine ratio were 
measured daily during the first week of treatment. Local side-effects were assessed by visual 
investigation. 
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Figure 1. Graph showing symptom score and systemic load of wct~wrap dressings using a 50% 
dilution of FP cream in 18 children. A) Objective SeDRAD before and after 2 weeks of treatment. 
B) 9 a.m. serum cortisol levels before and after 2 weeks of treatment. 
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Table I 
Mild AD 
Moderate AD 
Severe AD 
Wet~wrap in children with atopic dennatitis 
Number of children with mild, moderate, 
and severe AD before and after treatment. 
Before trealment 
1I~18 
o 
2 
16 
After h'ealmenl 
11=17 
II 
6 
o 
Statistical analysis 
Statistical analysis was perfomled with SPSS 7.5 using the Wilcoxon signed ranks test to 
assess differences in improvement of AD between the first and second week of treatment. 
The Spearman rank correlation was used to test monotonic relationships between 
improvement of AD, amount of FP cream I m2 body surface, number of days with decreased 
senlm cortisol level, and level of serum cortisol on day 7. Statistical significance was defined 
as p<O.05. 
Results 
In the first group of 18 children, a significant decrease in the objective SCORAD 
(p<O.OOO I) after 2 weeks of treatment was observed in 17 children (Fig. I A). One child was 
lost to follow-up after 4 days of treatment due to personal reasons. The severity of AD 
classified into mild, moderate, and severe according to the objective SCORAD decreased in 
all 17 children (Table I). For the evaluation of the safety we assessed the levels of 9 a.m. s 
erum cortisol at the beginning of the treatment and after 2 weeks (Fig. I B). Serum 
cortisol levels were temporarily below the normal range (0.2-0.8 Ilmolll) in 3 out of the 18 
children after 2 weeks indicating a suppression of the HPA axis. 
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Table 2 Objective SeORAD and extent of AD in 5 patients before and after one week of wet-
wrap with different dilutions offluticasone propionate on the left and the right side. 
Patient Left Righi 
Beginning =t>after 1 week Beginning =P after 1 week 
A 10%v5.50% 44 (65%) "'" 9 (10%) 44 (65%) ~ 9 (10%) 
B 25%V5.50% 50 (55%) ~ 16 (26%) 50 (55%) "'" 16 (26%) 
C 10%\'5.25% 55 (50%) "'" 13 (10%) 59 (30%) ~ 13 (10%) 
D 10% VS. 25% 43 (60%) "'" 14 (10%) 43 (66%) ~ 14 (10%) 
E 10% VS. 50% 40 (35%) ~ 12 (20%) 40 (35%) "'" 12 (20%) 
# The values in the table indicate objective seORAD and the affected body surface in percent. 
An objectivc SCORAD below 15 indicates mild AD, between 15 and 40 indicates moderate 
AD and above 40 indicates severe AD. 
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Figure 2. Graph of the relative improvement of AD in 8 children treated with different dilutions 
(O%=emollient, 5%, 10%,25%) of FP cream. The improvement of AD was measured by objective 
SeORAD. Lines represent the means of2 patients. 
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Figure 3. Graph showing the relative improvement of AD against the amount of FP cream / m2 body 
surface in 8 children treated with different dilutions (O%:=:emollient, 5%, 10%,25%) ofFP cream. 
To investigate the efficacy of different dilutions of FP cream under wet-wrap, a side 
to side comparison was performed in 5 children with different dilutions (10%, 25%, and 
50%) of FP cream on the left and the right side. After one week of treatment, the objective 
SeDRAD had decreased markedly in all 5 children, with no difference between the left and 
the right side in objective SeDRAD or affected body surface (Table 2). Furthennare, we 
noticed that already after one week of treatment major improvement in AD was achieved, 
while the second week of treatment resulted in only minor additional improvement. After 2 
weeks of treatment, we did not observe a decrease in 9 a.m. senun cortisol in any of the 5 
children (mean serum cortisol day 0: 0.42 ± 0.16; day 14: 0.45 ± 0.17). 
In the third group of 8 children, 3 different dilutions of FP cream (5%, 10%, 25%) 
were applied on the whole body in 6 children and emollient only in 2 children under wet-
wrap. After one week, the 2 children using only emollient under wet-wrap showed minor 
improvement, whereas in the 6 children in whom using 5%, 10% or 25% dilutions of FP 
cream were applied under wet-wrap showed a major improvement in AD (Fig. 2). 
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Apparently, there was no major difference in efficacy between 5%, 10% and 25% dilutions 
of FP cream (Fig. 2). However, a dose response relationship was obvious when the amount 
of FP cream/m2 body surface was considered (Speannan's correlation <=,0.97; p<0.0005) 
(Fig. 3). As seen in Fig. 3, there appears to be a plateau in the dose response relationship, 
indicating that amounts ofFP cream above 12 glm2 body surface did not increase efficacy. 
Furthennore, we observed major improvement after 1 week, with little improvement in the 
second week of treatment (Fig 4). The difference in improvement between the first and 
second week of treatment was statistically significant (z~-2.02; p<0.05). 
Adverse events, other than HPA axis suppression, in the first group were upper 
respiratory tract infection in 6, folliculitis in 6, herpes simplex infection in I, diarrhea in 1 
and itching in lout of the 18 children. In the second group of 5 children, we observed upper 
respiratory tract infection in 2, folliculitis in 2, abdominal pain in I and itching in I of the 
children. In the third group, we observed folliculitis in 5, balanitis in I and fumnculosis in I 
of the 8 children. A generalised folliculitis was observed in both of the children treated with 
only emollient during the first week. 
For a detailed analysis of the systemic load, 6 a.m. serum cortisol levels and timed moming 
urinary cortisol/creatinine ratio were measured daily in the third group of 8 children. A 
decrease in serum cortisol over the first week was observed and was the highest in the group 
treated with 25% FP cream, followed by the group treated with 10% FP cream and 5% FP 
cream (Fig. 5). 
Furthennore, we noted a significant relationship between the number of days with 
abnormally low semm cortisol levels «0.2 fllllOlll) and the cumulative amount of applied FP 
cream 1m2 body surface (<=,0.77; p<0.05). This indicated a dose response relationship for 
HPA axis suppression. The lowest levels of 6 a.m. serum cortisol were observed on day 4. 
However, no significant relationship was noted between the cumulative amount ofFP cream 
/m2 body surface and the 6 am cortisol level or urinary timed moming cortisol/creatinine 
ratio at day 7 (<=,-0.46; p~0.26). 
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Figure 4. Graph showing the relative improvement (mean ±SD) during the first and the second week 
of wet-wrap treatment. The difference was statistically significant (z=-2.02, p<0.05) 
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Figure 5. Systemic load as measured by 6 a.m. serum cortisol levels in 8 children treated with 
different dilutions (O%=emollient, 5%,10%,25%) ofFP cream. 
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Discussion 
The results of the present study show a dramatic improvement in AD irrespective of the 
dilution offluticasone propionate (5%, 10%,25%, and 50%) applied under wet-wrap. This is 
demonstrated both in a left to right side comparison in 5 children and by application of 
different dilutions in 8 children. The improvement of AD was significantly related to the 
amount of applied corticosteroid per m2 body surface. This relationship was apparent in a 
dose response curve in 8 children, which was characterised by a plateau. Most of the cases 
treated with FP cream under wet-wrap were located on this plateau indicating that less potent 
dilutions of the corticosteroid would result in a comparable improvement in AD. Taken 
together these results indicate that less potent dilutions of FP cream under wet-wrap may 
have efficacy similar to that with dilutions of higher potency. The improvement in AD 
occurred mainly during the first week of treatment. During the second week of treatment 
minor additional improvement was observed indicating that one week of treatment with wet-
wrap is sufficient. 
Most of the side-effects during the first 2 weeks of treatment were probably not related to the 
treatm.ent. Mild to moderate folliculitis, mainly on the legs, was observed in a large 
proportion of the children and appears to be related to the treatment. Interestingly, both 
children treated with only emollient under wet-wrap had generalised but mild folliculitis 
after 4 days. Thus, folliculitis under wet-wrap therapy may be related to the kind of 
occlusion constituted by the wet-wrap dressings. The addition of a corticosteroid may partly 
suppress the development of a folliculitis, but in some cases may aggravate the condition. 
The systemic load was measured by morning serum cortisol levels. In the first and the 
second group of children, 9 a.m. serum cortisol levels were below the nonnal range (0.2 
~mol/l) in 3 out of 18 in the first group and none out of 5 in the second group of children. 
However, 9 a.m. sennn cortisol has been reported to have large intra- and interindividual 
variability, which makes it a rather insensitive screening method for the systemic bioactivity 
of topical corticosteroids.20 Therefore, in the third group of8 children, we detemlined daily 6 
a.m. serum cortisol levels. The collection time is cmcial as a three-fold difference in the 
levels of serum cortisol between 8 a.m. and 10 a.m. has been documented". The early 
collection at 6 a.m. should minimize variations in cortisol levels. Additionally, urinary timed 
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morning cortisol/creatinine ratio was assessed, as this measure was reported to have 
excellent sensitivit/2,23. By using these detenninations we observed evidence of HPA axis 
suppression and we noticed a statistically significant dose response relationship between the 
amount of applied FP cream/m2 body sur~1ce and the number of days with low 6 a.m. senllll 
cortisol «0.2 flmolll). In contrast to the dose response curve for efficacy. the dose response 
relation for systemic bioactivity showed no plateau. This indicated that decreasing the 
amount of applied corticosteroid would improve the systemic safety without affecting the 
efficacy. Vice versa, increasing the amount of corticosteroid would increase systemic side-
effects without increasing efficacy. Such a dose response relationship with dissociation 
between efficacy and side-effects is a documented attribute of most drugs. However, as there 
are no reference values for 6 a.m. senllll cortisol or urinary timed morning senlln 
cortisol/creatinine values, the clinical relevance remains unknown. 
Remarkably. in the first and second group of children only 3 out of 23 children had evidence 
of HPA axis suppression, whereas in the third group of children all of the children had 
evidence of HPA axis suppression on at least one day. The discrepancy between these 
findings may be explained by the method that was used to measure the systemic load (9 a.m. 
serum cortisol versus 6 a.m. serum cortisol and urinary timed morning cortisol/creatinine 
ratio) and the timing of measurement (day 0 and day 14 versus daily assessment). Both 
measures are likely to increase the sensitivity of detecting the systemic bioactivity of a 
topical corticosteroid. 
Using wet dressings for the treatment of an acute deonatitis is an old principle in 
deollatology. However, new is the use of fluticasone propionate, which is a corticosteroid 
combining potent local efficacy with relatively limited suppression of the HPA axis. 13,14,24 
Tllis improved topicaVsystemic activity ratio25 is of particular benefit in children who have a 
high ratio of body surface to body weight and who may be at risk to develop systemic side-
effects." 
In an earlier report, Goodyear et al reported that cortisol levels were unifomlly low in all 30 
children after 2 to 5 days of wet-wrap treatment. This is remarkable as they also used 9 a.m. 
serum cortisol, as in our first group of 18 children. The difference with our results may be 
explained by a different wet-wrap protocol. In contrast with the fomler publications we 
applied the wet-wrap once daily instead of twice daily and we used dilutions of fluticasone 
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propionate instead of betamethasone valerate on the body. We expectcd that the choice of 
fluticasone propionate may increase the safety of the wet-wrap. Furthermore, a twice-daily 
application is likely to increase systemic side effects. A recent review on the efficacy of once 
daily vs. twice daily applications of corticosteroids reported no evidence to support an 
advantage of multiple daily applications.21 
No data are yet available on the efficacy and safety of long-term treatment with wet-wrap. 
We are currently investigating the wet-wrap for the long-term treatment in AD. Preliminary 
data reveal that a considerable number of patients failed to continue the treatment for a long 
time. Goodyear et al9 reported that an attempt at long-ternl treatment with wet-wraps in 5 
patients at home was unsuccessful in all cases. Time-consuming application, decreasing 
effectiveness, secondary bacterial infection and prolonged pituitary axis suppression were 
mentioned as reasons for failure. For the long-tenn treatment and guidance it is advisable to 
include regular nurse consultations in an out-patient setting. 
The mode of action of the wet-wrap method is probably a combination of I) protection of the 
skin from scratching 2) cooling of the skin and thereby reducing itching and inflammation 
and 3) enhanced penetration of emollients and corticosteroids. TIlls increased penetration of 
corticosteroids is a potential hazard with regards to systemic side-effects. Therefore, regular 
monitoring of the HPA axis with a sensitive method is mandatory, particularly if the wet-
wrap is used on the long tenn. 
The present study is limited by the small sample size in which HPA axis suppression was 
investigated by means other than 9 a.m. serum cortisol levels, and can therefore not claim to 
provide reliable information on the safety of the wet-wrap treatment because susceptibility 
for HPA axis suppression is highly variable. The scope of the study was rather to compare 
different dilutions of tluticasone propionate under wet-wrap with regards to efficacy and 
systemic bioactivity. 
We conclude that the wet-wrap therapy with f1uticasone propionate cream is highly effective 
in severe and refractory AD. Furthermore, we conclude that a 5% dilution of the 
corticosteroid seems to have comparable efficacy, but lower systemic bioactivity than 10% 
or 25% dilutions under wet-wrap, and that one week of treatment is sufficient to achieve 
major improvement. Further study in a larger number of children is necessary to establish the 
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efficacy and the safety of less potent corticosteroid dilutions under wet-wrap dressings for 
long-term treatment. 
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Atopic dennatitis (AD) is a chronically relapsing skin disease affecting about 10 to 20% of 
all children in western countries. Although, AD is often looked at as a minor skin disease, it 
has considerable impact on the child and its family even in mild disease. 
In the experimental studies described in this thesis we investigated selected aspects of AD in 
children with a focus on evaluation and therapy. In order to study a disease, an appropriately 
validated system to score the activity of disease is essential. The seDRAD index and the 
objective SeDRAD are widely accepted in Europe, but may be too complicated and time-
consuming for daily practice. Therefore, in the study described in chapter 3, we evaluated a 
simplified system, the Three Item Severity (TIS) score, which is based on the evaluation of 
some selected items of the SeDRAD, namely erythema, oedema/papulation and excoriation. 
\Ve noted a fair inter-observer agreement for investigators using the TIS and we 
demonstrated a high correlation between the TIS score and the objective seDRAD. We 
concluded that the TIS is a simple and quick system to score the severity of AD in daily 
practice and to screen patients for inclusion in clinical trials on AD. However, this study had 
the same limitation as all other studies on scoring systems in AD: We have no information 
whether and to which extent the TIS score reflects therapy-related variations of the severity 
of AD as there is no biological marker that could be used as gold standard. Therefore, the 
TIS could not be related to an objective biological marker but only to another clinical 
scoring system, which remains an arbitrary selection of items for scoring. 
In the studies described in chapter 4 we investigated whether biological markers reflect the 
severity of AD by comparing their serum levels with the objective SeDRAD. The levels of 
soluble adhesion molecules have been shown to reflect the expression of adhesion molecules 
on the endothelial cells and could potentially be used as an indicator of the inflammation in 
the skin. The correlation between objective SeDRAD and the levels of potential markers of 
inflammation (soluble adhesion molecules, eosinophil cationic protein) and markers of atopy 
(totallgE, specific [gEl were investigated in studies described in chapter 4.1. We observed a 
highly significant correlation between the levels of soluble E-selectin and the objective 
SeDRAD. This relationship was previously demonstrated in adults but has not yet been 
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described in children. We concluded that the levels of soluble E-selectin rellect the severity 
of AD both in adults and children and is a potential marker of inflammation in this disease. 
In another study, described in chapter 4.2, we investigated whether the levels of soluble E-
selectin, ICAM-l, and VCAM-I rellect therapeutic interventions. Patients with severe AD 
were treated with the wet-wrap therapy, which resulted in a marked improvement after two 
weeks. \Ve noted that the clinical improvement of AD was correlated with a significant 
decrease in the levels of sICAM-l but not sE-selectin. This was unexpected because sE-
selectin levels correlated with relatively small variations in SCORAD at the beginning, but it 
did not rellect the marked decrease in SCORAD after 2 weeks of treatment. These data 
indicated that the semm level of sE-selectin rellected the long-term (more than 2 weeks) 
severity of AD, but was not influenced by acute fluctuations in the severity of the disease. In 
conclusion, we advocate the use of both a clinical scoring system such as the objective 
SCORAD and additionally soluble E-selectin as an objective marker for the activity of AD. 
The differential expression of T lymphocyte subsets, in particular Thl I Th2 cells and their 
respective cytokines have been implicated in the pathogenesis of AD. Therefore, much of the 
basic research on AD concentrates on the T cell production of IL-4 and Interferon-y. In the 
investigations described in chapter 4.3, we evaluated the DynaMIX DIA kit which is a 
recently introduced method for measuring the production of IL-4 and Interferon-y in whole 
blood and we compared this method with the conventional ELISA technique. The DynaMIX 
DIA kit differs from the conventional ELISA in the options for running the assay using 
whole blood and for freezing material after stimulation. This results in time-saving and 
increased practical usc. Using the manufacturer's instructions the DynaMIX DIA kit did not 
perform as well as the conventional ELISA. However, after adapting the culture and 
stimulation conditions, as described in our study, this system showed production levels of 
IL-4 and interferon-gamma similar to those obtained by our conventional ELISA. Based on 
its better practical performance the adapted DynaMIX DIA kit can be used effectively for 
assessing cytokine production. 
Chapter 6 deals with the treatment of AD. An overview of the different aspects of therapy 
in children with AD is given in chapter 6.1. Guidelines have been established which provide 
a good framework for managing children with AD. In a recent consensus, emphasis was put 
on explanation and education of parents, use of emollients, the choice of the appropriate 
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corticosteroid and the avoiding provoking h1ctors. [n chapter 6.2 the efficacy and safety of a 
new, so~called 4th generation topical corticosteroid, fluticasone propionate 0.05% cream was 
investigated in children with moderate active AD. FJuticasone propionate 0.05% cream is a 
potent corticosteroid which seems to have an improved topical/systemic activity ratio. \Ve 
used c1obetasone butyrate 0.05% cream applied twice daily as an established reference 
therapy. We observed that once daily application of !luticasone propionate 0.05% cream was 
highly effective and comparable to twice daily clobetasol butyrate 0.05% cream application. 
Local side-effects (striae, teleangiectasiae, skin thinning, hair growth) were not noticed and 
systemic side effects (temporary hypothalamic pituitary adrenal axis suppression), as judged 
by 24 hours urinary cortisol excretion, were apparent in lout of 21 children. This child 
belonged to the clobetasone butyrate group. We concluded that !luticasone propionate 0.05% 
cream was effective and safe for the short-tenn treatment of AD in children. After the 
corticosteroid treatment was stopped, we noticed recurrence of AD within 2 weeks, 
indicating the need for long-term treatment. However, reliable data on the long-term use of 
potent topical corticosteroids in children with AD are not available. With the experience 
obtained from this pilot stndy, a larger multi-centre study was planned with the aim to 
investigate both short- and long-tern, efficacy and safety of topical treatment with 
corticosteroids in children with AD. 
However, in severe AD, which is refractory to conventional treatment as outlined in 
guidelines, other approaches are required. Severe AD remains difficult to treat. There is no 
consensus on the optimal regimen and the choice of treatment has to be individually 
determined. A modified protocol for the wet-wrap therapy in children with severe atopic 
dennatitis is presented in chapter 6.3. Basically, the wet-wrap therapy is an occlusive 
treatment using corticosteroids under tubifast dressings. Although, the wet-wrap therapy is 
widely used in some countries it has not been extensively studied. Safety considerations are 
cmcial because such a therapy may be related to potentially severe side-effects. The 
presented data were based on a slllall number of children. Therefore, we investigated the 
efficacy and safety of the wet-wrap treatment in 18 children with severe atopic dermatitis. 
As described in chapter 4.2, we noticed a marked efficacy after 2 weeks in all children, but 
we also noticed systemic side-effects (reversible suppression of morning sennn cortisol) in 3 
of the 18 children. We concluded that the wet-wrap therapy was a very effective and 
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relatively safe treatment which, however, needs to be accurately followed in order to prevent 
clinically relevant side effects. The value of the wet-wrap therapy for the treatment of AD 
has to be considered in the context of other regimens for refractory AD like cyclosporine A 
or interferon-gamma, which also harbour the risk of potentially severe side-effects. 
To increase the safety of the wet-wrap treatment, in chapler 6.4, we studied different 
dilutions of the applied corticosteroid with regard to daily serom cortisol levels and objective 
SCORAD. In this study, we observed a comparable improvement with different dilutions 
(I :3, I :9, I: 19) of the corticosteroid. Furthermore, we noticed that virtually all improvement 
occurred in the first week. This study extended our knowledge on the optimal corticosteroid 
concentration and the optimal duration of daily wet-wrap treatment. As a result we adapted 
our wet-wrap protocol and at present we use once daily wet-wrap and less potent dilutions of 
Iluticasone· propionate for only one week. The safety of the therapy would therefore be 
increased. 
In conclusion, the investigations described in this thesis deal with two aspects of AD in 
children: evaluation of the severity and therapy. For the evaluation of AD the TIS score may 
improve the way of recording in daily practice, whereas biological markers like soluble E-
selectin may be a useful addition to a clinically based scoring system. For the treatment, this 
thesis offers new therapeutic modalities in both moderate and severe AD in childhood. 
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Snmellvnttillg ell disclIssie 
Atopisch eczeem is een chronisch recidiverende huidziekte die 10 a 20% van aile kinderen in 
westerse landen betreft. Hoewel atopisch eczeem vaak als een milde ziekte beschouwd 
wordt, kan het grote invloed hebben op zowel kind als familie. 
De experimentele studies in dit proefschrift behandelen de evalnatie en de behandeling van 
atopisch eczeem. Om een ziekte te bestuderen is een gevalideerd systeem voor het bepalen 
van de activiteit van de ziekte noodzakelijk. De SeORAD index en de objectieve SeORAD 
zijll breed geaccepteerd in Europa maar zijn te ingewikkcld en tijdrovend voor de dagelijkse 
routine. Daarom onderzochten wij in hoofdstuk 3 ccn eenvoudig meetsysteem, de "Three 
Item Severity (TIS) score". De TIS score is gebaseerd op de evaluatie van enkele criteria uit 
de SeORAD index, namelijk erytheem, oedeem/papels en krabeffecten. Wij vanden een 
goede overeenstemming tussen artsen die de TIS score gebruikten. Verder vonden wij cen 
zeer goede correlatie tussen TIS score en objectieve SeORAD. Wij concludeerden dat de 
TIS score een eenvoudig en snel door te voeren systeem is om de ernst van atopisch eczeem 
in de dagelijkse routine te bepalen. 
Deze studie heeft echter dezelfde beperking als andere studies over een op klinische factoren 
gebaseerd systeem voor het bepalen van de ernst van de ziekte namelijk: wij weten niet in 
hoeverre therapie gerelateerdc variaties van de ernst van atopisch eczcem worden 
weergegeven door de TIS score omdat er geen biologische marker is die als gouden 
standaard toepasbaar is. Daarom werd de TIS score niet vergcleken met een objectieve 
biologische marker maar met cen ander klinisch systeem, wat eigenlijk ook op eell 
wilfekeurige selectie van symptomen bemst. 
In hoofdstuk 4 onderzochten wij de relatie tussell biologische parameters en de ernst van 
atopisch eczeem. Het is aangetoond dat de concentratie van "soluble" adhesie moleculen 
nauw gerelateerd is aan de expressie van adhesic moleculen op de celmembraan. Dit geeft 
aan dat de senlm concentraties van adhesie moleculen gebruikt zouden kWlllen worden als 
indicatie voor de uitgebreidheid en intensiteit van de ontsteking in de llUid. In hoofdstuk 4.1. 
werd de relatie tussen potentiele biologische markers (soluble adhesie moleculen, eosinophil 
cationic protein, totaal IgE, speciliek IgE) en de objectieve SeORAD onderzocht.We zagen 
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cell duidelijk verband tussen de serumspiegels van soluble E-sclectin en de objektieve 
SCORAD. Deze relatie was daarvoor al aangetoond bij volwassenen maar was nog niet 
beschreven bij kinderen. We concludeerdcn dat de serumspiegels van soluble E- selectin de 
ernst van atopisch eczeem wcerspiegelen bij zowel volwassenen ais kinderen en dat het cen 
mogclijkc marker is WUl de ontsteking bij de ziekte. In cen andere shldie, beschreven in 
hoofdstuk 4.2, onderzochten we of de semmspiegels van soluble E-selectin, ICAM-I en 
VCAM-I het effect van een behandeling reflecteren. Kinderen met ernstig atopisch eczeem 
werden met de "wet wrap" therapie behandeld. We zagen dat de klinische verbetering van 
atopisch eczeem geassocieerd was met cen duidelijke afname van de serumspiegels van 
sleAM 1 maar niet met de serumspiegel van sE-selectin. Dit was onverwacht orudat relatief 
kleine verschillen in SCORAD gemeten voor behandeling wei correleerde met de spiegels 
van sE-selectin, maar de grote verschillen in SeDRAD yoor Cl1na behandeling niet in cen 
vennindering van de spiegels van sE-selectin resulteerden. Deze gegevens toonden aan dat 
de senllnspiegcl van s E-selectin de ernst op lange terrnijn (meer dan twee weken) 
weerspiegclt maar dat deze niet beYnvloed wordt door acute fluciuaties van de ernst van de 
ziekte. Concluderend adviseren wij het gebmik van zowel een op klinische factoren 
gebaseerd meetsysteem, zoals de objectieve SCORAD als ook de spiegels van sE-selectin aIs 
cen objectieve marker voor de huidontsteking bij atopisch eczeem. 
De differentiele expressie van subgroepen van T Iymfocyten (T helper I / Thelper 2) en van 
de bijbehorende cytokinen worden in verband gebracht met het ontstaan van atopisch 
eczeem. 
Daarom is vee! van het basale onderzoek naar atopisch eczeem gericht op de T cellen en de 
productie van IL-4 en interferon-yo In de onderzoeken beschreven in hoofdstuk 4.3, 
onderzochten we een recent geintroduceerde methode (DynaMIX DlA kit) om de productie 
van IL-4 en Interferon-y in bloed te bepalen en we vergeleken deze methode met de 
conventioneele Elisa techniek. De DynaMIX DlA kit verschilt van de gebmikelijke ELISA 
methode door het gebmik van niet gecentrifugeerd bloed en de mogelijkheid materiaal 
tijdens de test te kunnen invriezen. Hierdoor is deze test eenvoudiger, praktischer en neemt 
de uitvoering minder tijd in beslag. Met de door de producent aanbevolen procedure 
presteert de DynaMIX DlA kit minder goed dan de conventionele ELISA. Echter, na 
aanpassing van de test wat betreft kweek en stimulatie vonden wij met de DynaMIX DlA kit 
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productie rates van IL-4 en interferon-y die vergelijkbaar waren met degene van de 
conventionele ELISA. Wij concludeerden dat mits de kweek- en stimulatie methode 
aangepast wordt, de DynaMIX D1A kit een effectieve methode is om de productie van IL-4 
en interferon-y te meten. 
Hoofdstuk 6 gaat over de behaudeling van atopisch eezeem. In hoofdstuk 6.1 wordt een 
overzicht gegeven van de verschillende aspecten van therapie voor kinderen met atopisch 
eezeem. Er zijll riehtlijnen opgesteld die een goed uitgaugspunt vormen om kinderen met 
atopiseh eczeem te begeleiden en te behandelen. Belangrijk is een goede uitleg aan de 
ouders, het gebmik van een emollient, de keuze van het juiste corticosteroi'd en het 
vennijden van uit/okkende factoren. In hoofdstuk 6.2. is de effectiviteit en veiligheid van een 
nieuw zogenoemd 4de generatie lokaal corticosteroi'd, fluticasone propionate 0,05% creme 
onderzocht bij kinderen met een matig actief atopisch exceem. Fluticasone propionate 0,05% 
creme is een sterk werkzaam corticosteroi'd met, naar het Iijkt, een verbeterde lokale versus 
systemische werking. Ter vergelijking gebruikten we een gangbare behandeling met 
c1obetasone butyrate 0,05% creme 2 keer per dag aangebracht. We zagen dat het I keer per 
dag aanbrengen van fluticasone propionate 0,05% creme zeer effectief was en vcrgelijkbaar 
met het 2 maal daags aanbrengen van c1obetasol butyrate 0.05% creme. Lokale bijwerkingen 
als striae,teleangiectasiae, verdikking van de huid en haargroei werden niet gezien. 
Systemische bijwerklngen die onderzocht werden in 24-uurs urine vonden wij bij I van de 
21 kinderen. Dit kind behoorde tot de c1obetasone butyrate groep. We concludeerden dat 
fluticasone propionate 0.05% creme effcctiefwas en veilig voor de korte temlijnbehandeling 
van kinderen met atopisch eczeem. Nadat de behandeling met corticosterol'den gestopt was, 
zagen we het exceem binnen twee weken weer terug komen. Oit is een aanwijzing dat een 
lange tennijnbehandeling nodig is. Betrouwbare gegevens over de lange termijnbehandeling 
met sterke lokaal werkende corticosteroi'den bij kinderen met atopisch eczeem zijn er eehter 
niet. 
Met de ervaring die uit deze pilot-studie verkregen is, werd een groter multicentre onderzoek 
gepland. Het doel ervan is om de effectiviteit en de veiligheid van lokale behandelingen met 
corticosteroiden bij kinderen met AD bij zowel lange- als korte termijnbehandeling te 
onderzoeken. 
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Echter, bij emstig atopisch exceem wat resistent is tegen conventionele behandeJing, is cen 
andere aanpak vereist. Emstig atopisch eczeem blijft moeilijk Ie behandelen. Er is geen 
consensus over de optimale benadering en de keuze van de behandeling moel individueel 
bepaald worden.Een aangepast protocol voor de wet wrap thcrapie bij kinderen met ernstig 
AD wordt beschreven in hoofdstuk 6.3. In fcite is de wet wrap therapie een occlusive 
behandeling waarbij corticosterolden gebmikl worden onder lubifasl (katoenen verband). 
Hoewel deze therapie in sommige landen veel gebmikl wordt, is er nooit uitgebreid 
onderzoek naar gedaan. Controle van de veiligheid is zeer belangrijk omdat corticosterolden 
onder occlusie ernstige bijwerkingen kunnen veroorzaken. De beschreven gegevens zijn 
gebaseerd op een klein aantal kinderen. Daarom onderzochten we de effecHviteit en de 
veiligheid van de wet wrap behandeling bij 18 kinderen met emstig atopisch eczeem . Zoals 
beschreven in hoofdstuk 4.2 zagen wij cen opmcrkelijk verbetering van het eczeem na twee 
weken bij aile kinderen maar we merkten oak systemische bijwerkingen in de vonn van een 
reversibele onderdmkking van ochtend semm cortisol bij 3 van de 18 kinderen. Wij 
concludeerden dat de wet wrap therapie eell zecr effective en rclatief veiligc therapie is die 
echter zeer goed gevolgd moet worden om klinisch relevante bijwcrkingen te voorkomen. 
De waarde van de wet wrap therapie voor de behandeling van atopisch eczeem moet gezien 
worden in een context van andere regimes voor thcrapieresistent atopisch eczeem zoals 
cyclosporine A of interferouMgamma die oak cell risico voor mogeUjk emstige bijwerkingen 
behelzen. 
Om de veiligheid van de wet wrap behandeling te vergroten (hoofdstuk 6.4) bestudeeerden 
we de invloed van verschillende verdunningen van het lokale corticosteroid op de objektieve 
SCORAD en de semm cortisol spiegels. In deze studie vonden we een aanzienlijke 
verbetering van de ernst van het eczeem die niet duidelijk gerelateerd bleek te zijn aan de 
verdunningen (1:3, 1:9, 1:19) van het corticosteroid. Verder observeerden wij dat de 
verbetering van het eczeem zich voomamelijk voordeed in de eerste week. Deze studie 
vergrootte onze kennis omtrent de optimale corticosteroid concentratie en de optimale duur 
van de dagelijkse wet wrap behandeling. Als resultaat hiervan hebben wij ons wet wrap 
protocol aangepast en gebmiken op dit moment I maal per dag wet wrap met een hogere 
verdmming van fluticasone propionate voor de duur van slechts 1 week. De veiligheid van 
de be han de ling is daardoor vergroot. 
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Concluderend kan gezegd worden dat de studies in dit proefschrift twee aspekten van 
atopisch eczeem bij kinderen behandelen: namelijk de evaluatie en de behandeling. Wat de 
evaluatie betreft kan de TIS score het begeleiden van een patient in de dagelijkse praktijk 
verbeteren, tenvijl biologische markers zoals soluble E-selectin een zinvolle aanvulling 
kunnen zijn op een klinisch gebaseerd scoring systeem. \Vat de behandeling van atopisch 
eczeem betreft worden nieuwe therapeutische mogelijkheden voor zowel matig tot emstig 
atopisch eczeem voorgesteld. 
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